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ABSTRACT 
 
Megan Elizabeth Fox: Adaptations in in vivo catecholamine signaling in models of stress 
and addiction 
(Under the direction of R. Mark Wightman) 
 
Catecholamine neurotransmission plays a key role in regulating a variety of 
behavioral and physiological processes, and its dysregulation is implicated in both 
neurodegenerative and neuropsychiatric disorders. Understanding how catecholamine 
signaling is regulated in vivo may provide insight into its role in disease states ranging 
from anxiety and drug addiction to Parkinson’s disease. This work combines rapid, 
selective, and spatially resolved voltammetric measurements with pharmacology and 
behavior.  We used this approach in divergent animal models to investigate the 
dynamics of in vivo norepinephrine and dopamine signaling.  Our initial investigations 
focused on norepinephrine release in the ventral bed nucleus of the stria terminalis 
(vBNST), where we found differential regulation in models of anxiety and depression. 
When animals were challenged with social-isolation stress and drug-dependence, 
adaptations in vBNST norepinephrine regulation varied with respect to both stressor 
and baseline stress-reactivity. We hypothesized that certain stressors elicited 
catecholamine efflux, and turned to real-time measurements in awake, freely moving 
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animals. To understand how release could produce plasticity in catecholamine 
regulation mechanisms after drug dependence, we focused on opiate exposure and 
withdrawal. We found opposing responses from dopamine and norepinephrine: whereas 
dopamine fluctuations in the nucleus accumbens (NAc) increased during morphine 
intoxication, they decreased during precipitated withdrawal. Conversely, increased 
norepinephrine overflow in the vBNST was found only during withdrawal, and was time 
locked to somatic withdrawal behaviors. While probing real-time catecholamine 
overflow, we also discovered hemispheric synchrony of NAc dopamine fluctuations, and 
revealed previously unappreciated cross-hemispheric projections in both the 
dopaminergic and noradrenergic systems. Our findings of opposing catecholamine 
responses, combined with genetic differences in response to stressors provide new 
insight into catecholamine regulation. Future work should continue to address how 
dopamine and norepinephrine signal in vivo and in real time and contribute to the 
development of a variety of neuropsychiatric conditions.  
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CHAPTER 1: CONTRASTING REGULATION OF CATECHOLAMINE 
NEUROTRANSMISSION IN THE BEHAVING BRAIN 
 
 Introduction 
The catecholamine neurotransmitters dopamine and norepinephrine modulate a 
variety of behavioral and physiological processes through their actions on post-synaptic 
receptors, and their dysregulation underlies the pathophysiology of many disease 
states. Deficits in dopamine and norepinephrine are a hallmark of neurodegenerative 
disorders such as Alzheimer’s (Weinshenker, 2008) and Parkinson’s disease (Schapira, 
2009), and maladaptive catecholamine signaling promotes the development of 
psychiatric disorders such as depression and drug addiction (Chaudhury et al, 2015; 
Koob and Volkow, 2010). Despite making up a relatively small proportion of synapses 
within the brain (Brady, 2005), catecholamine neurons can signal through volume 
transmission (Cragg et al, 2001; Garris et al, 1994a) to affect a wide variety of 
downstream targets and influence communication throughout the entire brain. Over 40 
years ago, Ralph Adams envisioned using electrochemistry in vivo to measure 
oxidizable neurotransmitters (Kissinger et al, 1973). This technique has enabled 
researchers to measure neurotransmitter release and uptake in brain slices, 
anesthetized and freely behaving animals to more precisely determine their actions on 
neural communication and behavior. Although several electrochemical techniques have 
been applied to the challenge, fast-scan cyclic voltammetry (FSCV) has been more 
widely applied due to its fast time resolution and chemical selectivity over other
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measurements.    
It is impossible to cover the last four decades of in vivo electrochemistry in a 
single review. Therefore this introduction has three goals. First, we will provide a 
general overview of fast-scan cyclic voltammetry and the pioneering work in brain slices 
that led to measurements in intact animals. Second, we will focus on the use of 
anesthetized animals combined with pharmacology to reveal differences in regulation of 
dopamine and norepinephrine. Third, we will highlight studies in freely moving animals 
that reveal contrasting roles for these catecholamines in modulating behavior.  
1. Building the foundation for in vivo recordings 
Fast-scan cyclic voltammetry 
In fast-scan cyclic voltammetry (FSCV), a potential sweep is applied to an 
electrode at a rapid scan rate (100-1000V/s) to oxidize and reduce electroactive 
species. The resultant current from this potential sweep can be converted into 
concentration estimates for the species of interest through the use of in vitro calibration 
factors and multivariate analysis techniques (Keithley et al, 2009; Rodeberg et al, 2015). 
FSCV measurements are typically conducted at glass-encased, carbon-fiber 
microelectrodes where the sensor is 5-10 microns in diameter, and with an active length 
of 50-150 microns. The small size of the sensor allows for minimal tissue damage, as 
well as excellent spatial selectivity (Peters et al, 2004). Voltammetric measurements are 
typically conducted at fast sampling frequencies by repeating the potential sweep every 
20-200 ms. A commonly used waveform for detection of catecholamines sweeps from -
0.4 to +1.3V at 400 V/s, applied every 100-ms (Figure 1.1). This rapid sampling allows 
for the detection of single release and uptake events.   
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Regulation of extracellular catecholamines in brain slices  
In brain slices, or “ex vivo” recordings, a carbon-fiber electrode is positioned 
~100 µm into the tissue near a stimulating electrode. The release and subsequent 
uptake of neurotransmitters is measured while directly depolarizing nearby terminals. 
Early studies focused on dopamine, and FSCV in brain slices allowed researchers to 
determine that extracellular concentrations were a balance of release and uptake, with 
metabolism operating on a slower time scale (Near et al, 1988). In contrast to striatal 
dopamine, norepinephrine release in slices containing the bed nucleus of the stria 
terminalis (BNST) requires delivery of longer pulse trains and follows different release 
kinetics (Miles et al, 2002) which may be due to the differences in vesicular release rate 
between norepinephrine and dopamine (Chiti and Teschemacher, 2007) or differential 
dependence on N-time calcium channel activity (Mitchell and Adams, 1993). 
Additionally, maximal norepinephrine efflux only weakly depends on stimulation current 
above 250 µA, unlike striatal dopamine, which does not approach saturation even with 
stimulation currents of 450 µA (Kennedy et al, 1992). Despite evidence that both 
catecholamines are released from similar sized vesicles (Bergquist and Ludwig, 2008; 
Papke et al, 2012), the mechanism underlying differential release kinetics is unknown.  
After catecholamines are released they are cleared from the extracellular space 
by neuronal transporters. The primary clearance mechanism for dopamine is the 
dopamine transporter (DAT) which obeys Michaelis-Menten kinetics (Wightman et al, 
1988) and genetic deletion of DAT prolongs the life of extracellular dopamine by three 
hundred-fold (Jones et al, 1998). Release and uptake rates are heterogeneous in sub-
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regions of the striatum (Salinas et al, 2016; Trout and Kruk, 1992) which might be 
attributed differences in striosome and matrix compartments (Salinas et al, 2016). The 
primary clearance mechanism for norepinephrine is the norepinephrine transporter 
(NET), but non-NET mechanisms may play a larger role in norepinephrine clearance, as 
the lifetime of vBNST clearance is only prolonged six-fold in NET knockout mice (Miles 
et al, 2002; Xu et al, 2000). DAT is also expressed in the vBNST, and there is some 
evidence that DAT may help clear norepinephrine from the extracellular space in mice 
lacking NET. Although DAT has a higher affinity for dopamine over norepinephrine, 
catecholamine transporters are notoriously promiscuous (Daws, 2009), and mice 
lacking DAT exhibit a slight reduction in norepinephrine clearance rate (Miles et al, 
2002). However, DAT is not likely a major contributor to norepinephrine clearance in 
animals with normal transporter function, because pharmacological blockade of DAT in 
rats does not affect norepinephrine clearance rate (Palij and Stamford, 1992). However, 
in cases of prolonged signaling, DAT may serve as an additional mechanism for 
norepinephrine clearance. 
Extracellular catecholamine concentrations are also governed by autoreceptor 
control of release. Circuitry is mostly severed in a slice preparation, which serves as an 
advantage when examining regulation of release at catecholamine terminals. Any 
effects on release exerted by receptor agonists/antagonists can thus be attributed to 
direct actions on terminals.  The principal autoreceptor for dopamine is the D2 (Beaulieu 
and Gainetdinov, 2011). D2 receptors maximally inhibit dopamine release within 500-
1000ms, and the time course varies between dorsal and ventral striatum (Phillips et al, 
2002). D2 receptors become markedly desensitized after knockout of DAT due to 
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persistent elevation of extracellular dopamine concentrations (Jones et al, 1999). The 
principle autoreceptor controlling norepinephrine efflux is the α2, and it operates on a 
similar time course as D2 receptors (Palij and Stamford, 1993; Trendelenburg et al, 
2001). Despite having similar mechanisms in place to control extracellular 
concentrations, the fundamental differences in dopamine and norepinephrine release 
and uptake position them to influence neuronal communication in diverse ways.  
Catecholaminergic Plasticity  
A number of studies have used brain slice preparations to investigate 
adaptations to release and uptake mechanisms. In animals trained to self-administer 
high levels of cocaine, both electrically stimulated and cocaine-potentiated dopamine 
release is attenuated (Calipari et al, 2014a; Ferris et al, 2012; Ferris et al, 2011; Mateo 
et al, 2005). This effect is reversed by a single amphetamine infusion in cocaine self-
administering animals (Ferris et al, 2015). Similar to the persistent elevated dopamine 
concentrations in DAT knock-outs, chronic amphetamine self-administration produces 
increases in evoked dopamine and attenuates D2 receptor function (Calipari et al, 
2014b). Catecholamine receptors are also regulated by G protein-coupled receptor 
kinases and deletion of G protein-coupled receptor kinase 2 (GRK2) from D1 or D2 
containing neurons produces contrasting effects on dopamine regulation. GRK2 
deletion in D2-containing neurons enhances D2 activity and depresses baseline 
dopamine release, whereas GRK2 deletion from D1-containing neurons enhances 
dopamine release and uptake. These adaptations are paralleled by bidirectional 
sensitivity to cocaine: in D1 containing neurons, GRK2 deletion increases cocaine 
sensitivity, whereas lack of GRK2 in D2 neurons reduces sensitivity (Daigle et al, 2014). 
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Dopamine regulation can also become dysregulated in rats reared in social isolation. 
These animals exhibit enhanced dopamine release and uptake as compared with 
group-reared rats. Interestingly, social isolation amplifies psychostimulant, but not 
cocaine inhibition of DAT (Yorgason et al, 2016). Because methamphetamine and 
cocaine both inhibit dopamine uptake, these findings suggest other adaptations outside 
of DAT play a role in the plasticity. The stress of social-isolation likely facilitates release 
of corticosterone, which has a profound impact on other transport mechanisms, such as 
organic cation transporters (Gasser et al, 2006).  
Although fewer studies have used slice voltammetry to assay changes in 
noradrenergic function, work from the Stamford lab demonstrated adaptations in 
somatodendritic norepinephrine release in the locus coeruleus (LC). Bath application of 
the analgesic tramadol reduces norepinephrine clearance (Halfpenny et al, 1999), but 
chronic treatment does not affect uptake mechanisms. Instead, chronic tramadol 
appears to sensitize α2 function (Hopwood et al, 2001). In mice lacking the metabolic 
enzyme monoamine oxidase A (MAO-A), presynaptic control mechanisms become 
dysregulated.  Peak LC norepinephrine efflux is higher, and accompanied by decreased 
clearance rates and α2 control over release (Owesson et al, 2002; Owesson et al, 
2003). Similar adaptations to vBNST norepinephrine were found in anesthetized rats 
following stressors as discussed below in section 2.  
Other modulators of catecholamine release 
Terminal catecholamine release can be modulated by other signaling molecules. 
For example, optogenetic activation of cholinergic interneurons is sufficient to elicit 
dopamine release in the striatum (Cachope et al, 2012; Threlfell et al, 2012). In the 
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striatum, insulin also activates cholinergic interneurons to enhance dopamine release 
(Stouffer et al, 2015), however in the ventral tegmental area (VTA), it suppresses 
somatodendritic release and enhances dopamine reuptake (Mebel et al, 2012).  Nitric 
oxide (NO) donors also modulate dopamine in a manner dependent on cholinergic 
activity. Under reduced acetylcholine, NO modulates dopamine release in a frequency-
independent manner and acts directly on dopamine terminals, in contrast to its 
frequency-dependent modulations in the presence of nicotinic receptor activity (Hartung 
et al, 2011). We could find no reports detailing how norepinephrine release is influenced 
by other signaling molecules in slices. Since infusion of NO donors into the BNST 
produces anxiety (Faria et al, 2016), and norepinephrine in the BNST regulates the 
stress axis (Forray and Gysling, 2004), NO donors may potentiate norepinephrine 
release in the BNST to produce elevated stress/anxiety, but this has not yet been 
shown. Additionally, a host of neuropeptides are known to regulate BNST activity (Kash 
et al, 2015) and may, in turn, regulate norepinephrine release.  By combining slice 
voltammetry with the diverse tool-box of genetic manipulations, specific cell-type 
activation, and selective pharmacology, new modulators of catecholamine release will 
be identified that will contribute to a better understanding of how these 
neurotransmitters are regulated, and aid in the development of more effective 
pharmacotherapies. 
2. In vivo recordings in anesthetized animals    
Voltammetric measurements in anesthetized animals allow for precise 
measurements of release and uptake in the intact brain. Since neural activity is 
suppressed in anesthetized animals, neurotransmitter release is typically elicited by 
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stimulating neurons or their axon bundles directly. Early studies used direct electrical 
stimulation, although recent optogenetic strategies provide an opportunity to excite or 
inhibit discrete cell-types (McCutcheon et al, 2014; Witten et al, 2011). Dopamine and 
norepinephrine differ structurally by only one hydroxyl group and their voltammograms 
in vivo are indistinguishable (Park et al, 2009). Thus, we have turned to a multi-step 
approach to validate the origin of the signal at the electrode.  First, we limit our 
measurements to regions containing predominately dopamine or norepinephrine.  
Tissue homogenate studies have confirmed that norepinephrine is the primary 
catecholamine in the ventral bed nucleus of the stria terminalis (vBNST) and the 
anteroventral thalamus (AV), thus our first in vivo norepinephrine measurements were 
restricted to those regions (Park et al, 2009).  Many dopamine rich regions lie adjacent 
to the vBNST and without the visual confirmation of electrode placement afforded by a 
slice preparation, we turned to a pharmacological approach to rule out contributions by 
dopamine (Figure 1.2). Voltammetric signals are only considered noradrenergic if they 
respond to norepinephrine drugs (e.g., α2 antagonist idazoxan) but not dopamine drugs 
(e.g., D2 antagonist raclopride). Finally, a constant current is applied to the carbon-fiber 
electrode to make a lesion in the brain for subsequent histological validation of 
electrode placement in the target region.  
 Differential release of catecholamines in anesthetized animals 
Dopamine release is typically evoked by stimulating neurons in the ventral 
tegmental area (VTA)/ substantia nigra (SN) or the medial forebrain bundle (MFB). By 
carefully lowering the carbon-fiber and stimulating electrodes, it is possible to generate 
a “functional map” of the neurons and terminals that support catecholamine release. 
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The excellent spatial selectivity afforded by microelectrodes enables the 
characterization of regulation mechanisms in discrete structures or microdomains of a 
given region.  Early studies used voltammetry in anesthetized rats to reveal an apparent 
heterogeneity of release and uptake in compartments of the striatum and basolateral 
amygdala (Garris and Wightman, 1994b; May and Wightman, 1989). Dopamine 
regulation also differs between the NAc and the olfactory tubercle (OT). Dopamine 
release reaches smaller concentrations in the OT as compared with the NAc, and DAT 
inhibition produces smaller increases in OT dopamine compared with NAc 
(Wakabayashi et al, 2016).    Recent work in our lab has used this classical mapping 
approach combined with multiple electrodes and pharmacology to reveal an unexpected 
population of dopamine neurons that release dopamine into the contralateral striatum. 
Whereas NAc dopamine release is ~20x higher as elicited by ipsilateral vs contralateral 
VTA stimulations, dopamine release in the contralateral dorsomedial striatum is 
hemispherically equivalent with SN or pendunculopontine tegmental nucleus (PPTg) 
stimulations. The contralaterally projecting dopamine neurons originating from the VTA 
are also differentially regulated by D2 receptors, as they are more sensitive to the D2 
antagonist raclopride than ipsilateral VTA projections (Fox et al, 2016a). The high 
spatial resolution afforded by microelectrodes combined with pharmacological 
approaches will continue to enable functional characterization of dopaminergic circuits 
in intact animals. 
In anesthetized animals, norepinephrine release is typically measured in the 
vBNST with stimulation of neurons in the nucleus of the solitary tract, or its axon 
bundles. Using a multi-electrode approach, Park and colleagues measured dopamine 
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and norepinephrine release simultaneously in the NAc and vBNST with a stimulation 
that targeted both noradrenergic axons and the VTA/SN. As previously demonstrated in 
slices, release and uptake of norepinephrine in the vBNST is slower as compared with 
dopamine in the NAc, even with identical stimulation location. The two catecholamines 
are also differentially regulated. Basal levels of dopamine increase when D2 receptors 
are antagonized and uptake is blocked with amphetamine (Park et al, 2011). In the 
vBNST, α2 autoreceptor antagonism with amphetamine does not elevate basal 
norepinephrine (Park et al, 2011). Additionally, tyrosine hydroxylase inhibition depletes 
dopamine release faster than norepinephrine (Park et al, 2011). This contrasting 
regulation is further corroborated in studies using more selective uptake inhibition. 
When dopamine regulating mechanisms are blocked in anesthetized animals (i.e., D2 
and DAT), dopamine concentrations fluctuate spontaneously in the striatum (Venton 
and Wightman, 2007). However, similar blockade of noradrenergic regulation (i.e., α2 
and NET) does not elicit spontaneous norepinephrine fluctuations in the vBNST (Park et 
al, 2015). Although norepinephrine and dopamine have similar regulation mechanisms, 
they signal in distinct ways when control mechanisms are blocked. These findings hint 
at uncovered mechanisms controlling norepinephrine release. Moreover, the larger 
stimulations required to elicit norepinephrine suggest that norepinephrine is only 
released endogenously under extreme physiological conditions.    
A few studies have made measurements in regions with mixed catecholamines, 
despite their indistinguishable voltammograms. The prefrontal cortex (PFC) receives 
both dopaminergic and noradrenergic innervation, and early work shows dopamine is 
the predominant catecholamine released in the medial PFC following VTA stimulations 
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(Garris et al, 1993). This finding was confirmed in a recent report; however, D2 receptor 
antagonism paradoxically attenuates dopamine release in this region (Shnitko and 
Robinson, 2014b). Pharmacology in cortical regions must thus be selected carefully for 
signal validation, particularly because NET takes up dopamine in the PFC (Moron et al, 
2002). Both the dorsal BNST and the NAc shell receive some norepinephrine 
innervation in addition to dopamine. Selective pharmacology indicates norepinephrine in 
the NAc is restricted to the more caudal portion of the shell, (Park et al, 2010) and 
norepinephrine in the dorsal BNST is contained to the medial portion. One study found 
dmBNST norepinephrine is ~50% of vBNST release and is accompanied by slower 
clearance and reduced α2 and NET function compared to vBNST regulation (Herr et al, 
2012). These studies highlight that voltammetry, combined with anatomical and 
pharmacological validation enables characterization of release and uptake mechanisms 
in an intact brain. Moreover, this basic understanding provides a basis for comparison 
following manipulations such as stress or drug exposure.  
Adaptations in catecholamine function  
Voltammetric measurements in anesthetized animals allow for researchers to 
identify how different manipulations interact with intact circuitry to produce functional 
adaptations in catecholamine release. For example, selective genetic inactivation of 
NMDA receptors in dopamine neurons disrupts evoked dopamine release in a 
stimulation-site dependent manner. Whereas dopamine release is unchanged in 
NMDAR knock-out mice following MFB stimulations, dopamine release elicited by the 
PPTg is blunted compared with controls (Zweifel et al, 2009). In mice overexpressing 
catechol-o-methyl transferase (COMT), striatal dopamine release capacity is increased 
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despite unchanged levels of tyrosine hydroxylase or DAT (Simpson et al, 2014). Without 
the intact circuitry afforded by an anesthetized preparation, these differences in release 
may not have been discovered.  Recent work in our lab has examined how baseline 
genetic differences impact catecholamine regulation mechanisms.  Norepinephrine in 
the vBNST of Sprague-Dawley (SD) rats was compared with Lewis and Wistar-Kyoto 
(WKY) rats. Whereas release and uptake were similar between SD and WKY rats (Fox 
et al, 2015), there were marked differences in release, uptake, and autoreceptor control 
in Lewis rats, without differential α2 or NET expression (McElligott et al, 2013).  
Additionally, depletion of LC norepinephrine with DSP-4 produced adaptations to α2 
receptors and uptake in SD, but not WKY rats without changing norepinephrine release 
magnitude (Fox et al, 2015). These findings underscore the importance of voltammetric 
catecholamine measurements in intact systems, because differential release and 
uptake likely contribute to the phenotypic variations observed in genetically diverse 
animal models.   
Dysregulations in catecholamine signaling are implicated in the development of 
addiction and numerous neuropsychiatric conditions (Koob et al, 2010). Several studies 
have used anesthetized preparations to uncover adaptations to catecholamine circuits 
following drugs of abuse, particularly cocaine. Chronic administration of cocaine, heroin, 
or a “speedball” cocktail of the two produces variable adaptations to NAc dopamine in 
rats. In animals with a history of chronic self-administration, evoked dopamine is 
reduced compared with animals receiving a single drug dose. Dopamine reuptake rate 
is also greater in speedball administering animals compared with animals administering 
cocaine or heroin alone. Furthermore, evoked dopamine is increased following an 
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injection of either cocaine or speedball in animals with self-administration history 
(Pattison et al, 2012). In another study, one day pre-treatment with cocaine does not 
alter dopamine response to a subsequent cocaine challenge. However, 7 days of 
cocaine exposure potentiates the effect of a cocaine challenge on dopamine signaling in 
the NAc and is accompanied by an increase in apparent Km of DAT (Addy et al, 2010). 
There is some evidence that kappa opioid receptors mediate cocaine-potentiated 
dopamine release in the NAc. The endogenous ligand for kappa opioid receptors is 
dynorphin, which is released during stress and promotes dysphoria (Chavkin, 2013). 
Kappa activation alone inhibits evoked dopamine in the NAc, and on a short-time scale, 
pre-treatment with a kappa agonist attenuates dopamine response to cocaine in the 
NAc. However, on a longer time-scale, pre-treatment with a kappa agonist increases the 
cocaine-induced increase in NAc dopamine (Ehrich et al, 2014).This is an interesting 
finding in the context of stress-induced cocaine use. It is possible that dynorphin 
released by stress promotes a dysphoric state that drives drug administration. On a 
short time-scale, this stress decreases cocaine’s actions on mesolimbic dopamine, 
resulting in escalation of drug-intake to compensate for cocaine’s attenuated effect. 
However, on a longer time-scale, kappa activation potentiates cocaine’s effects on 
dopamine, further driving its reinforcing properties. Although cocaine clearly increases 
extracellular dopamine concentrations, there are other signaling mechanisms outside of 
elevated dopamine that drive persistent drug use.   
Adaptations to dopamine signaling have also been studied after other drugs of 
abuse. Large doses of methamphetamine reduce evoked striatal dopamine and 
decrease DAT uptake rates (Howard et al, 2011). This effect is exacerbated when 
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methamphetamine is administered in the presence of reward-associated cues, but can 
be attenuated with cannabinoid receptor antagonism (Loewinger et al, 2012). This 
disruption in normal dopamine function likely drives increased methamphetamine use. 
Similar to methamphetamine in the striatum, a high dose of ethanol decreases evoked 
dopamine and slows clearance in the mPFC. However, when the same dose is given to 
adult animals with a history of intermittent alcohol exposure in adolescence, dopamine 
clearance is slowed, but ethanol does not suppress dopamine release (Shnitko et al, 
2014a; Shnitko et al, 2015b).  In the NAc, adolescent alcohol use reduces tonic levels of 
dopamine in adulthood. However PPTg, but not MFB evoked dopamine release is 
increased in these animals. The administration of an allosteric GABAA agonist 
attenuates increased dopamine release and decreases risk-taking behavior of animals 
with adolescent alcohol exposure (Schindler et al, 2016). These findings suggest that 
there is increased inhibitory tone after alcohol exposure that drives changes in 
dopaminergic signaling through a disinhibitory mechanism. Dopamine modulated 
learning signals are disrupted in humans with a long history of alcohol-intake (Deserno 
et al, 2015), which may increase craving and contribute to the increased risk-taking 
behavior found in both humans and animal models. Although ethanol does not exert 
direct actions on dopamine neurons, its disruption of normal dopamine signaling 
contributes to alcohol abuse. 
  Work investigating adaptations to norepinephrine signaling have been limited, 
but two recent studies from our lab examined the effects of stress and drug-exposure on 
norepinephrine release and regulation. Three days of morphine paired with naloxone 
precipitated withdrawal produces exacerbated norepinephrine in the vBNST.  In SD 
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rats, both α2 and uptake are blunted, whereas only α2 function is attenuated in WKY. 
The treatment did not impact regulation mechanisms in Lewis rats, highlighting the 
importance of genetic factors in susceptibility to catecholamine dysregulation after drug 
exposure (Fox et al, 2015; McElligott et al, 2013). Furthermore, when SD and WKY rats 
were exposed to 2-weeks of social isolation, SD rat noradrenergic function resembles 
that of a morphine-addict, whereas WKY norepinephrine is unchanged (Fox et al, 2015). 
Similar to drug exposure, Lewis rats also did not alter noradrenergic synaptic function 
following social isolation, suggesting their regulation mechanisms are maximally 
disrupted (Fox and Wightman, unpublished observations).  Researchers have also used 
anesthetized animals to investigate the mechanisms of non-abused drugs on 
catecholamine regulation. For example, the dopamine precursor, L-DOPA, enhances 
dopamine release in both dorsal and ventral striatum, but causes a delayed inhibition of 
dopamine release in the dorsal striatum.  L-DOPA also reduces uptake rates by 
decreasing Vmax of DAT (Harun et al, 2015). Since dopamine is the metabolic precursor 
to norepinephrine, L-DOPA may also affect norepinephrine concentrations, but this area 
is currently unexplored. Noradrenergic deficits are also a key component in the 
development of Alzheimer’s disease, and the way pharmacotherapies alter 
catecholaminergic function should be a topic of ongoing investigation. Electrochemical 
measurements in anesthetized animals allow researchers to examine discrete circuits 
and how they become functionally altered after a variety of treatments. Continued 
efforts should focus on changes in norepinephrine function in addition to dopamine due 
to their distinctly different patterns of release and uptake in vivo.  
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3. Catecholamines function in awake animals 
The first awake-animal FSCV dopamine measurements were conducted nearly 
20 years ago and the signals researchers found were closely associated with a novel 
stimulus or environment (Garris et al, 1997; Rebec et al, 1997; Robinson et al, 2001). 
However, dopamine concentrations were also found to fluctuate in the absence of any 
external stimuli in awake animals at rest (Robinson et al, 2002).  Spontaneous 
dopamine fluctuations, or “transients” have been measured in the dorsal striatum, 
nucleus accumbens, and olfactory tubercle (Robinson et al, 2002), and they display 
heterogeneity in their frequency, amplitude, and duration in subregions of the NAc 
(Wightman et al, 2007). Dopamine transients in the NAc originate from cell-firing in the 
VTA (Sombers et al, 2009), are increased by cannabinoid receptor activation (Cheer et 
al, 2004), and are the main source of average extracellular NAc dopamine levels 
(Owesson-White et al, 2012).  DAT blockade with nomifensine increases spontaneous 
and stimuli-related dopamine transients (Robinson and Wightman, 2004), and acute 
phenylalanine/tyrosine depletion reduces the frequency, but not amplitude of 
spontaneous transients (Shnitko et al., 2016). Recent work employing a dual-electrode 
approach has revealed that at rest, spontaneous dopamine transients in the NAc shell 
synchronize ~75% of the time (Fox et al, 2016a). Importantly, FSCV measurements of 
dopamine transients provide a clearer picture of dopaminergic activity, and the time 
course of dopamine transients as measured by FSCV is more closely linked with 
uptake-inhibition induced stereotypy than microdialysis measurements (Budygin et al, 
2000). In contrast to striatal dopamine, norepinephrine concentrations are not known to 
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fluctuate spontaneously in the vBNST of animals at rest, further illustrating the 
differences in endogenous catecholamine signaling.  
ICSS 
Intracranial self-stimulation (ICSS) was first described by Olds and Milner (Olds 
and Milner, 1954), and through extensive mapping studies, it was determined that sites 
that supported the best self-stimulation were centered around the medial forebrain 
bundle, implicating catecholamine signaling as a principle mediator of the behavior. In 
this paradigm, an animal is trained to respond instrumentally (e.g. lever-press) to deliver 
an electrical stimulation to its brain. The presentation of the lever is traditionally 
preceded by a cue that predicts reward availability. Dopamine is released following 
direct electrical stimulation of the VTA/SN or MFB, but as animals become well trained, 
the NAc dopamine release moves to the cue in a time-locked fashion and is 
accompanied by decreases in stimulation-evoked dopamine (Owesson-White et al, 
2008). To this end, the dopamine response elicited by a reward-predicting cue, but not 
the reward, provides strong support for dopamine’s involvement in reward prediction 
error (Schultz, 2013). Disruption of endocannabinoid signaling reduces cue-evoked 
dopamine, whereas increases in cannabinoid receptor 1 signaling increase cue-evoked 
dopamine and reward seeking (Oleson et al, 2012). Recent work employing a 
multimodal sensor has uncovered how dopamine interacts with specific post-synaptic 
receptors in the NAc to drive ICSS (Owesson-White et al, 2016). The combination of 
voltammetric dopamine  measurements with single unit activity allows for real-time 
measurement of dopaminergic modulation of cell firing in awake animals (Takmakov et 
al, 2011). As before in non-behaving animals, iontophoresis barrels lying adjacent to the 
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multimodal sensor enable localized drug delivery to chemotype nearby cells (Belle et al, 
2013); i.e., unit activity is selectively altered by either D1 or D2 drug delivery and the  
functional receptor activity of individual neurons is identified in real time.  In this recent 
report, rats were trained to press a lever for electrical stimulation of the VTA. As before, 
dopamine is elicited by the lever-predicting cue, but cue-associated dopamine acts 
directly on identified D2-containing neurons.  Dopamine responses associated with the 
lever press are instead mediated by both D1 and D2-containing neurons (Owesson-
White et al, 2016). In agreement with this, intra-NAC shell infusions of D1 antagonists 
block lever-press behavior and alter lever-press associated firing (Cheer et al, 2007a). 
The coupling of iontophoresis with electrochemical and electrophysiological recordings 
provide a technical advantage over previous drug delivery techniques, since large 
volumes of drugs can disrupt animal behavior. Future work employing this discrete drug 
delivery technique will allow for receptor-level mechanisms to be uncovered in real time, 
without necessitating the use of transgenic animals. Furthermore, this technique may be 
extended into regions containing mixed catecholamines for signal validation prior to 
making measurements during behavior.    
 Typical ICSS stimulations also target noradrenergic axons, and in one study, 
norepinephrine and dopamine responses were recorded in subterritories of the BNST 
during ICSS. Both norepinephrine and dopamine are evoked by the electrical 
stimulation delivered following the lever press. Similar to the NAc, cues that predict 
lever presentation elicit dopamine release in the dorsolateral BNST, however cues do 
not elicit norepinephrine in the vBNST even during NET inhibition. When animals 
undergo extinction, i.e. a lever-press no longer results in electrical stimulation, 
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norepinephrine and dopamine overflow switch. Whereas norepinephrine is released in 
the vBNST at the time of stimulation anticipation, dopamine concentrations in both NAc 
and dlBNST decrease (Park et al, 2013). It is tempting to speculate that vBNST 
norepinephrine is acting to suppress dopamine release through its actions on VTA 
projecting neurons in the BNST. Norepinephrine is not elicited by cues predicting ICSS, 
but its release during extinction may serve as a signal to guide action selection. When 
effort no longer results in reward or positive outcome, norepinephrine may shape 
dopamine’s response in order to facilitate learning about the negative outcome. Indeed, 
animals lacking LC norepinephrine lever-press longer and with more vigor during ICSS 
extinction (Mason and Iversen, 1979), and LC lesions impair attention (Selden et al, 
1990). Future work should address the involvement of norepinephrine in extinction from 
other reward paradigms, which may provide insight into how action selection is shaped 
in the context of negative or unanticipated outcomes.  
 Natural Rewards and Aversion 
A number of studies have measured dopamine release in response to natural 
rewards, such as food pellets or sucrose. Oral infusion of sucrose elicits dopamine in 
the NAc (Roitman et al, 2008) and is potentiated by infusions of ghrelin into the lateral 
ventricle or intra VTA orexin-A. Moreover, the magnitude of dopamine release is greater 
in animals previously food-restricted (Cone et al, 2014), and dopamine response to an 
unexpected food reward is blunted in mice lacking NMDARs in dopamine neurons 
(Parker et al, 2010).  Additionally, prolonged high-fat diet alters dopamine release by 
reducing uptake in the absence of DAT gene expression adaptations (Cone et al, 2013). 
“Food addiction” has been recently added to the DSM-5 (APA, 2013), thus uncovering 
20 
 
the effects of high calorie food and insulin on dopamine signaling is an important area of 
investigation (Stouffer et al, 2015). Stressful life experience dysregulates dopaminergic 
signaling (Yorgason et al, 2016), and may contribute to the development of eating 
disorders through its actions on the dopamine system. 
 In contrast to dopamine, little is known regarding norepinephrine signaling during 
caloric rewards or changes to diet, which is of particular interest given norepinephrine’s 
involvement in anorexia (Janhunen et al, 2013; Nedelescu et al, 2016).  One study 
showed unexpected sucrose delivery does not elicit release in the vBNST (Park et al, 
2012), however norepinephrine may be released during prolonged omission of food as it 
is during omission of ICSS reward. Moreover, norepinephrine influences the HPA axis 
(Forray et al, 2004) and by engaging the brain’s stress centers, it may suppress feeding 
behavior and promote anorexia. Recording norepinephrine overflow in awake animals 
after delivery/omission of high-calorie foods may reveal its modulation of dopamine 
signaling and contribute to dysregulated patterns of food consumption. 
Food-predictive cues also elicit dopamine in the NAc (Roitman et al, 2004), and 
sucrose-predictive cues evoke greater dopamine release than those that predict 
saccharin (McCutcheon et al, 2012). Inactivation of the basolateral amygdala with 
baclofen/muscimol attenuates NAc dopamine evoked by sucrose paired cues without 
blunting VTA-stimulated release in the NAc (Jones et al, 2010). Dopamine release can 
also time-lock to sucrose-predictive cues in the dorsolateral, but not dorsomedial 
striatum (Shnitko and Robinson, 2015a). NAc dopamine selectively modulates 
excitatory responses of NAc neurons during sucrose-seeking behavior, and cue-evoked 
dopamine is observed in both NAc core, and shell, although it is of greater magnitude 
21 
 
and duration in the shell as compared with the core (Cacciapaglia et al, 2012; 
Cacciapaglia et al, 2011).  When rats must press one lever to extend a second lever for 
sucrose delivery, dopamine responses vary between the NAc core and shell. In the 
core, dopamine release is greatest after presentation of the first lever, or the “seeking 
lever”, and less for subsequent presentation of the “taking lever” and reward delivery. In 
the shell, dopamine release is robust to both levers as well as reward delivery (Saddoris 
et al, 2015a). When animals are asked to choose between immediate and delayed 
reward, dopamine responses in the shell scale with the interval between cue and 
reward delivery (Day et al, 2010), and with an animals’ preferred reward  (Day et al, 
2010; Sugam et al, 2012). Enhancing dopamine release in the NAc during cues with 
optogenetics alters the decisions rats make regarding which lever to press to get which 
magnitude of reward, and they alter choice based on delay, but not magnitude of reward 
(Saddoris et al, 2015b). Norepinephrine may be released in the vBNST during 
presentation of a lesser-magnitude reward than anticipated by the animal, but no 
studies have investigated norepinephrine signaling in paradigms involving different food 
reward magnitude.  
Dopamine is also elicited during delivery of a non-caloric reward.  When animals 
are sodium-depleted, NAc dopamine signaling increases when animals are given a salt 
solution, and over time, dopamine responses move to the salt-predictive cue in sodium-
depleted rats (Cone et al, 2016).  Delivery of aversive stimuli suppress dopamine 
transmission in the NAc (Fortin et al, 2016)  and fear-cues decrease NAc core signaling 
but increase NAc shell signaling (Badrinarayan et al, 2012). Corticosterone treatment 
acutely decreases NAc dopamine uptake, possibly via uptake-2 inhibition, and the 
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suppression of NAc dopamine signaling after the aversive tastant quinine depends on 
corticotropin releasing factor-VTA interactions (Graf et al, 2013; Twining et al, 2015). 
During delivery of an aversive tastant, decreased dopamine in the NAc is accompanied 
by increased vBNST norepinephrine (Park et al, 2012; Roitman et al, 2008). The 
reciprocal signaling of dopamine and norepinephrine during rewarding and aversive 
stimuli is corroborated in studies investigating the response of these catecholamines 
during delivery of a noxious stimulus (Park et al, 2015). Dopamine responses vary after 
cessation of a tail pinch, although the predominant effect is suppression of dopamine 
overflow during the noxious stimulus. A tail pinch increases norepinephrine in the 
vBNST, and although these studies were conducted in anesthetized animals, one might 
suspect that norepinephrine in the vBNST would also increase in awake animals during 
a noxious stimulation, such as a foot-shock. Indeed, markers of noradrenergic activity 
increase following foot-shock (Passerin et al, 2000; Rassnick et al, 1998).  How 
norepinephrine is released during a variety of noxious stimuli should be investigated, as 
there may be an important role of norepinephrine to suppress dopamine responses to 
support learning about aversive or negative outcomes.  
Social interactions also elicit phasic dopamine responses, and presentation of a 
conspecific increases the frequency of dopamine transients, although habituation 
decreases this response (Robinson et al, 2002). Dopamine is also released in the NAc 
in response to prosocial ultrasonic vocalizations, and like conspecific presentation, 
decline rapidly upon subsequent playbacks (Willuhn et al, 2014). NAc dopamine is also 
modulated by reward delivery to a conspecific, as stronger dopamine release is 
measured during conspecific reward receipt vs. an empty box. Similar to other pro-
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social interactions, this response attenuates, and even becomes reversed in repeated 
trials, with reductions in dopamine during conspecific reward delivery (Kashtelyan et al, 
2014). Interaction with an aggressive, and unfamiliar rat also elicits dopamine release in 
the accumbens (Anstrom et al, 2009); however, how unconditioned aggression interacts 
with norepinephrine signaling has not been explored. Interestingly, aggressive Lewis 
rats have higher norepinephrine content in the amygdala (Patki et al, 2015), and social 
defeat stress increases norepinephrine synthesis and NET expression in the LC (Chen 
et al, 2012; Fan et al, 2013). Given that norepinephrine influences the HPA axis, it is 
tempting to hypothesize norepinephrine is released during an animal’s decision to fight 
or flee during aggressive social interactions, and this should be a topic of future 
investigation.   
Drugs of Abuse 
Drugs of abuse have variable actions on catecholamine neurons, and those that 
interfere with reuptake (e.g. cocaine, psychostimulants) have been recently reviewed 
(Covey et al, 2014).  Emerging evidence supports cannabinoid modulation of dopamine 
signaling and drug-reward (Cheer et al, 2007b; Hernandez et al, 2014) and has been 
reviewed in detail elsewhere (Covey et al, 2015). Despite reports that cannabinoids 
increase LC norepinephrine activity (Oropeza et al, 2005; Page et al, 2007), how 
cannabinoid receptor activation influences phasic norepinephrine release has not been 
investigated.  
Electrophysiological data show that ethanol stimulates dopaminergic 
transmission (Brodie et al, 1999), and tonic activation of VTA dopamine neurons 
suppresses voluntary alcohol drinking by elevating basal dopamine efflux (Bass et al, 
24 
 
2013). However, there is disparity in alcohol’s effects on neurochemistry. Microdialysis 
data support a biphasic dopaminergic response, where low doses produce increases in 
NAc dopamine (Yoshimoto et al, 1992)  and decreases at higher doses (Blanchard et al, 
1993). As measured by FSCV, acute ethanol dose-dependently decreases evoked 
dopamine in the dorsal striatum (Budygin et al, 2001), but there is an apparent 
heterogeneity of dopamine response in the NAc. In some recording locations, ethanol 
increases dopamine transient frequency, whereas in some the frequency is decreased 
or even unaffected (Robinson et al, 2009). Interestingly, cues that predict ethanol 
reward are time locked to dopamine release in the dorsolateral striatum and NAc, but 
not in the dorsomedial striatum (Shnitko et al, 2015a). This apparent heterogeneity in 
dopamine response to ethanol should be addressed, because alcohol exposure has 
circuit specific effects on dopaminergic transmission (Schindler et al, 2016). 
Furthermore, information regarding the effect of phasic norepinephrine signaling after 
alcohol is lacking, despite microdialysis work demonstrating a sensitization to 
norepinephrine response to alcohol after early life stress (Karkhanis et al, 2014). 
Polymorphisms in vesicular monoamine transporter 2 are associated with increased risk 
for alcoholism (Fehr et al, 2013), and how alcohol impacts catecholaminergic signaling 
in these individuals would be an interesting area of exploration.  
In addition to alcohol, recent work has examined the effect of an acute 
intravenous delivery of opiates on catecholamine release. In one study, researchers 
delivered the opiates oxycodone and morphine to freely moving rats. Intravenous 
oxycodone evokes a lasting effect on dopamine transient frequency and magnitude in 
the NAc; however, i.v. morphine produces a much shorter (~1 min)  increase in phasic 
25 
 
dopamine transmission (Vander Weele et al, 2014).  In our laboratory, we extended this 
work to determine the impact of drug withdrawal in addition to drug exposure on 
dopamine release. In contrast to the previous report, subcutaneous administration of 
morphine produces a persistent (>1 hr) increase in dopamine transient frequency, which 
may reflect the differential time course of drug delivery between the two studies. When 
animals underwent naloxone-precipitated withdrawal, dopaminergic transmission 
decreased in the NAc. Although naloxone decreased the frequency of dopamine 
transients regardless of prior drug-exposure, only in animals undergoing withdrawal 
were dopamine transient concentrations suppressed.  We also measured 
norepinephrine in the vBNST, and found that morphine-exposure did not elicit 
norepinephrine responses, but robust norepinephrine release events occurred during 
precipitated withdrawal that coincided with specific somatic withdrawal behaviors (Fox 
et al, 2016b). Similar the opposing responses highlighted above, contrasting dopamine 
and norepinephrine signaling under drug exposure and withdrawal confirm their 
reciprocal signaling during appetitive and aversive stimuli. These findings are interesting 
in the context of the allostasis model, which suggests that during the development of 
addiction, positively reinforced behaviors dominate early on, with negatively reinforced 
behaviors emerging later in the addiction cycle (Koob et al, 2010). It is tempting to 
speculate that the noradrenergic response during withdrawal acts to suppress transient 
dopamine concentrations through its actions on VTA projecting vBNST neurons. Since 
glutamatergic inputs from the vBNST exert an excitatory influence over VTA dopamine 
neurons (Georges and Aston-Jones, 2002), and norepinephrine’s actions through α2A 
receptors decrease excitatory transmission in the vBNST (Egli et al, 2004), 
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norepinephrine release during withdrawal/aversion may act through α2 receptors in the 
vBNST to suppress VTA activity and decrease dopaminergic output as a consequence. 
This hypothesis is corroborated by the suppression of NAc dopamine concentrations 
after α2 receptor activation with clonidine (Murai et al, 1998). Furthermore, 
norepinephrine causes GABAA inhibition of VTA-projecting BNST neurons (Dumont and 
Williams, 2004), which may serve as an additional source of reduced dopaminergic 
output via VTA inhibition. Thus noradrenergic suppression of dopamine may attenuate 
drug-potentiated dopamine signaling, causing escalation of intake per the allostasis 
model. Indeed noradrenergic signaling is exacerbated in Lewis rats, a model of 
increased drug consumption (McElligott et al, 2013), which may contribute to their 
increased drug self-administration (Picetti et al, 2012). Future work should address how 
this progresses longitudinally, as well as how exposure and withdrawal from other drugs 
of abuse might produce opposing responses from catecholamines to contribute to the 
addiction cycle.   
4. Clinical Implications   
Voltammetric catecholamine measurements in models of human disease have 
provided new insights into their pathogenesis. To model Parkinson’s disease, 
researchers have turned to animals that express the mutant proteins found in human 
patients to uncover how these mutations lead to catecholaminergic deficits. For 
example, researchers expressed mutant human leucine-rich repeat kinase 2 in rats, and 
found impaired striatal dopamine release. The adaptations to circuit function appear in 
the absence of neurodegeneration, and suggest that dopaminergic dysfunction might 
precede measureable markers of neurodegeneration and cell-death (Sloan et al, 2016). 
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In another study, expression of mutant α-synuclein in tyrosine-hydroxylase neurons 
produces differential catecholamine deficits that are regionally specific: evoked 
dopamine is reduced in the dorsal striatum, but not in the NAc, and vBNST 
norepinephrine release is unchanged (Taylor et al, 2014). These genetic manipulations 
afford ways to test early circuit function, and might become a useful preclinical model for 
testing Parkinson’s therapeutics. Researchers have also used voltammetry to 
investigate aberrant dopamine signaling in a model of the neurodevelopmental disorder, 
Angelman’s syndrome. Mice lacking maternal ubiquitin ligase E3A (UBE3A) exhibit 
increased mesolimbic dopamine and attenuated nigrostriatal dopamine in the absence 
of adaptations to the number of dopaminergic cells (Riday et al, 2012).  Although 
dopamine replacement therapies such as L-DOPA may have some therapeutic 
potential, due to the pathway-specific adaptations in these mice, such global elevation 
of extracellular dopamine may instead lead to more dysfunction. In apparent contrast to 
this, a recent report found optogenetically evoked NAc dopamine in brain slices did not 
differ between mice lacking UBE3A and their controls (Berrios et al, 2016). It is 
important to note that different cell populations are activated by electrical vs. optical 
stimulations which may contribute to the differences in dopamine release. However in 
both studies, animals lacking UBE3A were more sensitive to VTA self-stimulation; i.e., 
they delivered more optical stimulations, and also acquired robust self-stimulation 
behavior to lower electrical stimulation currents. This brings up two important points. 
First, direct depolarization of dopamine terminals in a brain slice is not necessarily 
indicative of the magnitude of dopamine release in an intact brain. Second, adaptations 
in non-catecholamine neurons may facilitate dysregulated signaling that are not readily 
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apparently in a slice preparation with selective terminal depolarization. Moving forward, 
we need to consider the evidence from both preparations to integrate how circuit 
function becomes disrupted in disease models.   
Recent advances have enabled researchers to also conduct electrochemical 
measurements in humans in parallel with deep brain stimulation (DBS) probes. Human 
recordings typically employ a fused-silica microelectrode assembly that house reference 
and recording electrodes and are positioned within or nearby DBS probes. In the first 
human recordings, striatal dopamine fluctuations were measured during a decision-
making task (Kishida et al, 2011). Separate work at the Mayo clinic has made 
voltammetric measurements of adenosine during implantation of DBS probes for 
treatment of essential tremor using a wireless system (Chang et al, 2012a; Kasasbeh et 
al, 2013). More recent work asked how dopamine encodes reward prediction errors in 
Parkinson’s patients (Kishida et al, 2016). Although this study found dopamine 
integrates reward prediction error with counterfactual prediction error, it is difficult to 
determine if this is a normal property of dopamine neurons, given the relatively low 
dopamine concentrations and possible adaptations following pharmacological 
intervention in Parkinson’s patients. Human measurements are further complicated by 
the calibration methodology often employed. Although standardized training sets for 
principle component analysis may predict the identity of a given analyte (e.g. 
dopamine), they are notoriously poor at concentration prediction, which may lead to 
inappropriate interpretation of the data (Johnson et al, 2016). Nevertheless, information 
gleaned from preclinical disease models with recordings in humans will provide new 
mechanistic insight for the progression and treatment of neurodegenerative diseases. 
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5. Summary 
Over the last four decades, electrochemical methods for measuring 
catecholamine dynamics and circuit function have been employed in brain slices, 
anesthetized, and freely behaving animals. Despite the progress in understanding the 
fundamentals of catecholamine release and uptake, and how they become dysregulated 
in disease models, lingering questions still remain. Contrasting signaling mechanisms 
between norepinephrine and dopamine have been described at the ex vivo level, and 
the two catecholamines are similarly divergent in anaesthetized and freely behaving 
animals. An ideal approach to correct the relative dearth in norepinephrine recordings, 
while maintaining the high spatiotemporal resolution of FSCV at microelectrodes, would 
be to employ a waveform that differentiates between the two catecholamines. This 
would further facilitate recordings in brain regions containing mixed catecholamines, 
such as the PFC. However, due to their structural similarity, the development of a 
waveform that differentiates the catecholamines electrochemically has proven difficult if 
not impossible. For the time being, future work should address norepinephrine signaling 
using selective pharmacology for signal validation. The seemingly opposing nature of 
these catecholamines during rewarding/aversive stimuli may not hold true in all 
behavioral paradigms, and should be a topic of future investigation.  
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Table 1.1: Opposing Catecholamine Responses 
Stimulus NAc Dopamine vBNST Norepinephrine 
At rest  - 
ICSS   
Stimulation   
ICSS-predictive cue  - 
ICSS-extinction   
Food reward   
Unexpected Food  - 
Food-predictive cue  ? 
Food-omission  ? 
Drugs of abuse   
Drug exposure  -, ? 
Drug Withdrawal  , ? 
Noxious/Aversive   
Quinine   
Fear cues  ? 
Tail pinch   
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Figure 1.1: Fast-scan cyclic voltammetry for the detection of catecholamines. The most 
commonly used waveform sweeps from -0.4 to +1.3 V at a scan rate of 400 V/s. The 
positive-going scan oxidizes dopamine and norepinephrine to their ortho-quinone form, 
and the negative going scan reduces them back to dopamine or norepinephrine. 
Plotting the resultant current vs potential results in identical characteristic cyclic 
voltammograms (CVs) for both dopamine and norepinephrine.  
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Figure 1.2: Spatially resolved measurements combined with pharmacology ensure 
selective dopamine or norepinephrine measurements. Brain slice, adapted from the 
atlas of Paxinos and Watson showing norepinephrine terminals (red) surrounded by 
dopamine terminals (yellow), highlighting the need for a small sensor. Boxes show 
mock electrically stimulated response types to different drugs. Red bar denotes 
stimulation.  In the green box, a pure dopamine signal increases with D2 antagonism, 
and remains elevated with α2 antagonism; a pure norepinephrine signal does not 
increase following D2 antagonism and only responds to α2 antagonism. In the red box, a 
mixed dopamine / norepinephrine signal responds to both D2 and α2 antagonists.  
Abbreviations: DS, dorsal striatum; ac, anterior commissure; dBNST, dorsal bed 
nucleus of the stria terminalis; vBNST, ventral bed nucleus of the stria terminalis; VP, 
ventral pallidum   
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CHAPTER 2: NORADRENERGIC SYNAPTIC FUNCTION IN THE BED NUCLEUS OF 
THE STRIA TERMINALIS VARIES IN ANIMAL MODELS OF ANXIETY AND 
ADDICTION1 
 
Introduction 
In drug-dependent individuals, researchers have highlighted the development of 
a persistent ‘negative emotional state’ when access to drugs is terminated (Koob, 
2009). Substance abuse is often co-morbid with anxiety disorders and impacted by 
stressful life experiences (Hyman et al, 2009; Sinha, 2008). The risk for developing an 
addiction, however, varies considerably between individuals, and different people can 
have very different responses to drug or stress exposure. One means for addressing 
this issue is examining animals with divergent behavioral phenotypes in appropriate 
neuronal structures. Akin to human addicts, inbred Lewis (L) rats self-administer opiates 
at high levels (George and Goldberg, 1989), and show escalation of drug-taking 
behavior (Picetti et al, 2012). Additionally, L rats display several anxiety-like phenotypes 
as compared with outbred Sprague-Dawley (SD) rats, as well as hypocortisolemia; thus, 
they have been suggested to be a good model of post-traumatic stress disorder (PTSD) 
                                                          
1 This chapter originally appeared as an article in Neuropsychopharmacology. The original 
citation is as follows :  McElligott ZA, Fox ME, Walsh PL, Urban DJ, Ferrel MS, Roth BL, 
Wightman RM (2013). “Noradrenergic Synaptic Function in the Bed Nucleus of the Stria 
Terminalis Varies in Animal Models of Anxiety and Addiction.” Neuropsychopharm 38(9): 1665-
1673. 
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(Cohen et al, 2006). The bed nucleus of the stria terminalis (BNST) is a forebrain 
nucleus in the extended amygdala positioned to relay between cortical, hippocampal 
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and amygdalar inputs, and stress and reward centers (Drolet, 2009). The BNST is 
densely innervated by noradrenergic fibers arising from the A1, A2 (via the ventral 
noradrenergic bundle or VNB), and A6 (via the dorsal noradrenergic bundle) cell bodies 
(Forray et al, 2004). Norepinephrine signaling within the BNST modulates anxiety-like 
behavior and influences induction of the hypothalamic–pituitary–adrenal (HPA) axis 
(Cecchi et al, 2002), affects expression of learned and physical opiate withdrawal 
behaviors (Delfs et al, 2000) and contributes to stress-induced reinstatement of drug 
seeking (Erb et al, 2000; Leri et al, 2002; Wang et al, 2001). Furthermore, 
norepinephrine impacts both excitatory (McElligott and Winder, 2009) and inhibitory 
synaptic transmission (Dumont et al, 2004), induces synaptic plasticity (McElligott and 
Winder, 2008), and releases corticotropin-releasing factor (CRF) in the BNST 
(McElligott et al, 2010; Nobis et al, 2011). The Morilak lab found that extracellular 
norepinephrine in the BNST was the same in non-manipulated L and SD rats; however, 
when restrained for 30 min, extracellular norepinephrine was elevated in L rats 
compared with SD rats (Pardon et al, 2002) . Furthermore, L rats exhibit fear 
generalization and anxiety-like behaviors that are BNST dependent (Duvarci et al, 
2009). 
Here, we hypothesized that the noradrenergic system projecting to the BNST 
may be differently regulated in these two rat strains. Furthermore, we tested whether 
the noradrenergic system is differentially modulated in a model of morphine addiction. 
Previously, we demonstrated that norepinephrine dynamics and their regulation can be 
examined in the BNST with fast-scan cyclic voltammetry (Herr et al, 2012; Park et al, 
2009). We used this technique in the ventral BNST (vBNST) to investigate the 
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mechanisms underlying differences in norepinephrine overflow in L rats as compared 
with SD rats, and to test the hypothesis that morphine dependence alters regulatory 
mechanisms at noradrenergic neurons. We found that non-manipulated L rats had a 
reduced rate of clearance and decreased sensitivity at their α2-adrenergic receptors 
(ARs) as compared with SD rats. Furthermore, using high-performance liquid 
chromatography (HPLC), we found that non-manipulated L rats had higher 
norepinephrine tissue content. When SD rats were made physically dependent on 
morphine (Schulteis et al, 1999), modeling the condition of a human addict, there was a 
significant reduction in their norepinephrine uptake rate and in their response to a 
challenge with an α2-AR antagonist as compared with controls. In contrast, neither 
clearance rate nor α2-AR sensitivity were different in morphine-dependent L rats as 
compared with control or non-manipulated animals. Correlated to these alterations at 
norepinephrine synapses in the BNST, morphine-dependent SD rats, but not L rats, 
showed heightened anxiety-like behavior as compared with controls. The changes that 
occurred in morphine-dependent SD rats were profound: they exhibited 
indistinguishable norepinephrine uptake rates and similar responses to an α2-AR 
antagonist as non-manipulated L rats. Thus, noradrenergic synapses underwent a 
remarkable adaptation when SD rats were made physically dependent on morphine. 
Furthermore, the data revealed that the vBNST norepinephrine system of the non-
manipulated L rat resembled a ‘morphine-dependent state’. 
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Materials and Methods 
Animal care 
All experiments were performed in accordance with the University of North 
Carolina at Chapel Hill (UNC) Institutional Animal Care and Use Committee’s 
guidelines. SD and L rats (males; 350–450 g; L rats total n=70, SD total n=85; Charles 
River, Wilmington, MA) were housed within UNC animal facilities and given food and 
water ad libitum. Electrochemical, biochemical, and behavioral experiments were 
performed as follows: voltammetry, SD n=34, L n=26; HPLC, SD n=22, L n=15; 
autoradiography, SD n=14, L n=13; elevated plus maze, SD n=15, L n=16. 
Evoked norepinephrine release 
Norepinephrine release in the vBNST was evoked from stimulation of the VNB as 
previously described (Park et al, 2009). Briefly, animals were anesthetized with 
urethane (1.5 g/kg i.p.) and placed in a stereotaxic frame (Kopf, Tujunga, CA).  Holes 
were drilled in the skull for the carbon-fiber and stimulating electrodes at coordinates 
from a rat brain atlas(Paxinos and Watson, 2007).  A Ag/AgCl reference electrode was 
placed in the contralateral hemisphere.  A carbon-fiber microelectrode was placed in the 
vBNST (+1.2 mm ML, 0 mm AP, 7.2–7.8 mm DV).  An untwisted bipolar stimulating 
electrode (Plastics One, Roanoke, VA) was placed in the VNB (+1.0 mm ML, −5.2 mm 
A-P, 8.0–8.5 mm DV from bregma).  Both the carbon-fiber and stimulating electrodes 
were adjusted in the dorsal-ventral axis to obtain optimum norepinephrine release. 
The electrical stimulation was delivered with a pair of constant-current stimulus 
isolators (model NL800, NeuroLog System, Digitimer).  The stimulations consisted of 
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biphasic pulses (±300 μA, 2 ms/phase) applied at 60 Hz and 60 pulses unless otherwise 
noted.  Stimulation pulses were computer generated and applied between cyclic 
voltammograms.  
To measure evoked norepinephrine release, a triangular scan (−0.4 to +1.3 V, 
400 V/sec) was repeated every 100 ms to generate cyclic voltammograms.  Data were 
digitized with a computer employing Tar Heel CV software written in LABVIEW (National 
Instruments, Austin, Texas).  Three-dimensional color plots were used to examine the 
voltammetric data with the abscissa as voltage, the ordinate as acquisition time, and the 
current in false color.  The average of 10 cyclic voltammograms collected before the 
electrical stimulation was used for background subtraction.  Digital smoothing was 
accomplished under software control after data collection. Data were evaluated with 
principal component analysis to resolve individual analytes as described previously 
(Keithley et al, 2010; Keithley et al, 2009).  An average calibration factor (6 nA/1 µM 
NE/100 µm carbon fiber) was used to convert current to concentration.  
Electrode placement was verified by making electrolytic lesions with the carbon-
fiber microelectrode as previously described (Park et al, 2009).  Animals were 
euthanized with urethane before a constant current (20 µA for 10 s) was applied to the 
electrode in the recording site.  Brains were subsequently removed from the skull, and 
stored for at least three days in 10% formaldehyde. Coronal sections (45 µm thick) were 
made with a cryostat (Leica, Germany), and slices were mounted on slides and 
coverslipped before viewing under a light microscope. 
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Determination of norepinephrine and dopamine content in tissue slices 
Brains were rapidly removed from anesthetized rats (urethane 1.5 mg/kg). 
Coronal sections (300 μm thick) were prepared using a Lancer Vibratome (World 
Precision Instruments, Sarasota, FL) in 4 °C artificial cerebral spinal fluid (aCSF). The 
aCSF (in mM: 126 NaCl, 25 NaHCO3, 2.45 KCl, 12 NaH2PO4, 1.2 MgCl2, 2.4 CaCl2, 20 
HEPES, and 11 glucose) was adjusted to pH 7.4 and oxygenated (95% O2/5% CO2). 
Tissue containing the vBNST or nucleus accumbens (NAc) was excised with a 1-mm 
punch, and homogenized in 0.1 N HClO4 containing 1 μM hydroquinone. Tissue 
processing and HPLC were performed as previously described (Park et al, 2009). The 
tissue was homogenized with a sonic dismembrator (Fisher Scientific, Model 60, 
Pittsburgh, PA), and the homogenate was spun down at 6000 rpm for 10 minutes.  The 
supernatant was removed and filtered using a 0.2 µm syringe filter (Millex-LG).  HPLC 
employed published procedures (Lahdesmaki et al, 2002; Mefford, 1981).  Briefly, 20 µL 
injections were made onto a reverse-phase column (5 µm, 4.6 x 5 mm, Waters Atlantis).  
The mobile phase consisted of 0.1 M citric acid, 1 mM sodium hexylsulfate, and 0.1 mM 
EDTA (pH = 3), with  5% or 10% methanol as an organic modifier.  The flow rate was 
1.0 mL/min.  Catecholamines were detected with a thin layer radial electrochemical cell 
(BASi, West Lafayette, IN) at constant potential vs Ag/AgCl.  Data were collected at 60 
Hz using a LabVIEW stripchart recorder program (Jorgenson Lab, UNC) and homebuilt 
electronics.  Standards were prepared fresh in 0.1 N HClO4 and the ratio of analyte 
peak area to hydroquinone peak area was used to calculate tissue concentrations. 
40 
 
Autoradiography 
Norepinephrine transporter (NET) and α2-adrenergic receptor (α2-AR) receptor 
autoradiography methods were adapted from autoradiography methods previously 
described (Allen et al, 2011).  Briefly, brains were quickly removed, frozen on dry ice, 
and stored at -80°C until processing. Coronal brain sections (16 µm) (Bregma: 0 mm to 
Bregma -0.1 mm) were cut on a cryostat and thaw-mounted onto slides (Fisher 
Scientific Tissue Path Superfrost Plus Gold Slides, #15-188-48) and vacuum desiccated 
at 4°C overnight.  For α2-AR receptor autoradiography, sections were incubated with 
125iodoclonidine (200 pM; α2-AR receptor agonist) for 1 hour at RT in binding buffer (170 
mM TrisHCl, pH 7.6; 20 mM MgCl2) to determine total binding.  Rauwolscine (10 µM; 
adrenergic antagonist) was added to the incubation mixture to determine non-specific 
binding.  Sections were washed (2X5 min) in ice-cold binding buffer (170 mM TrisHCl, 
pH 7.6; 20 mM MgCl2), rinsed in ice-cold water (to remove residual salts), then air-dried 
and exposed to hyperfilm (GE Healthscience) for 48 hours.  For NET autoradiography, 
sections were incubated with 125 Nisoxetine ((R)-N-methyl-(2-[(125)I]iodo-phenoxy)-3-
phenylpropylamine; 60 pM) for 90 minutes at RT in transporter buffer (50 mM TrisHCl, 
pH 7.4; 120 mM NaCl; 5 mM CaCl2) to determine total binding.  Nisoxetine (1 µM; 
adrenergic antagonist) was added to the incubation mixture to determine non-specific 
binding.  Sections were washed (2X5 min) in ice-cold buffer (50 mM TrisHCl, pH 7.4; 
120 mM NaCl; 5 mM CaCl2), rinsed in ice-cold water (to remove residual salts), then air-
dried and exposed to hyperfilm (GE Healthscience) for 48 hours.  
Films were developed and photographed with a digital camera system 
(Metaview).  Image analysis was performed using ImageJ software to define regions of 
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interest (ROI) in the ventral bed nucleus of the stria terminalis and this ROI was 
transposed onto the non-specific binding images.  Average pixel intensities of the 
nonspecific ROI was subtracted from the total ROI to obtain qualitative specific binding 
data.  
Acute morphine dependence 
The morphine-dependence protocol was modified from (Schulteis et al, 1999). 
Briefly, over the course of 3 days rats were injected once daily with 10 mg/kg morphine 
s.c., followed 4 h later by 1 mg/kg naloxone s.c. Behavioral, electrochemical, and 
autoradiography experiments were performed on the fourth day. 
Elevated plus maze 
The elevated plus maze (EPM) was used to assay anxiety-like behavior. Animals 
were isolated in a novel cage for 5 min before running the maze. Animals explored the 
maze for 5 min and their movement and time spent in each section (open arms, center, 
enclosed arms) was measured and recorded using Ethovision software (Noldus, 
Netherlands). 
Chemicals and drugs 
All chemicals and drugs were purchased from Sigma-Aldrich (St Louis, MO), with 
the exception of naloxone (Tocris Bioscience, Ellisville, MO), and used as received. 
Drugs were dissolved in sterile saline (0.9%). 
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Statistics 
Results are average values ± SEM. Mainly unpaired Student’s t-tests and 2-way 
analysis of variance (ANOVA) with post-hoc Bonferroni tests were used to determine 
statistical significance. Morphine withdrawal scores, pre-withdrawal weight, and fecal 
boli weight were compared using a 3-way ANOVA with a post-hoc Tukey's Honestly 
Significant Difference (HSD) Test. Linear regression analysis was used to examine the 
relationship between stimulation intensity and [NE]max. Differences were considered 
significant when *P<0.05, **P<0.01, ***P<0.0001. 
Results 
L rats had greater norepinephrine tissue content 
Owing to the phenotypes discussed above, we investigated the catecholamine 
tissue content in the nucleus accumbens (NAc) and the vBNST in L rats compared with 
SD rats. We did not see significant differences between the strains in the levels of 
dopamine in the NAc (SD: 5.25±0.96 μg/g n=5, L: 6.06±0.32 μg/g n=5); however, in the 
vBNST, L rats had significantly more dopamine and norepinephrine tissue content (SD 
NE: 4.55±0.84 μg/g n=5 vs L NE: 10.9±1.52 μg/g n=5; SD DA: 1.06±0.32 vs 3.15±0.46 
n=5; Figure 2.1 a–c). We presumed the dopamine in the vBNST was mainly localized in 
norepinephrine neurons because dopamine is the metabolic precursor to 
norepinephrine, and dopaminergic projections are mainly to the dorsal lateral BNST 
(Meloni et al, 2006; Park et al, 2012). 
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L rats had altered noradrenergic neurotransmission compared with SD rats 
Next, we examined regulation of noradrenergic synaptic function using 
electrically-evoked release measured with fast-scan cyclic voltammetry in anesthetized 
rats. This method has been used extensively to characterize regulation of dopamine 
and serotonin neurotransmission (John et al, 2006), and we recently demonstrated its 
use to measure norepinephrine dynamics in vivo in the vBNST(Herr et al, 2012; Park et 
al, 2009). With the carbon-fiber microelectrode positioned directly beneath the anterior 
commissure, norepinephrine release was evoked by electrical stimulation of the VNB 
(example electrode placement shown in Figure 2.1d). Norepinephrine release (shown in 
color plots encoding voltammetric recordings over a 15-s interval) occurred upon 
stimulation, and its concentration fell to its original value after stimulation. Consistent 
with our previous report (Park et al, 2009), norepinephrine evoked release was 
unaffected by raclopride (2 mg/kg), a D2 receptor antagonist. In contrast, idazoxan 
(5 mg/kg, IDA), an α2–AR antagonist, increased norepinephrine evoked release 
(examples in Figure 2.1f). 
We compared stimulated release of norepinephrine in the vBNST in L and SD 
rats. The maximal amplitude of stimulated release ([NE]max) was evaluated as a function 
of pulse number in the stimulus train (at 60 Hz) and fit with a linear regression. Both 
strains responded to stimulation linearly, although the slope of the line was greater in 
the L rats (L vs SD, respectively, r2=0.98 vs 0.99, slope: 4.93±0.11 vs 3.11±0.21, 
P<0.05; Figure 2.2b). The clearance half-life (t1/2 or time from the [NE]max to half the 
maximal concentration) following 60 Hz 60 pulse stimulations was significantly greater in 
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L rats than in SD rats (2.6±0.2 s, n=6 vs 1.9±0.1 s, n=11 respectively, P<0.05; Figure 
2.2c). Additionally, when a saturating dose of the α2-AR antagonist IDA (5 mg/kg i.p.; 
see Figure 2.3 for dose response curve) was administered under the same stimulation 
conditions to L rats, the increase in [NE]max was significantly reduced compared with SD 
rats (163±11% of pre-drug baseline, n=8 vs 217±14% of pre-drug baseline n=10, 
respectively, P<0.05; Figure 2.3c), further suggesting that norepinephrine dynamics are 
different in these strains. Autoradiography for α2-AR and the norepinephrine transporter 
(NET), however, showed no differences between the strains (SD n=4, L n=4, Figure 
2.4), suggesting total protein levels are the same. 
Following this characterization, we probed the effect of an acute morphine 
injection (5 mg/kg i.p.) on norepinephrine dynamics. Surprisingly, the acute morphine 
slightly but significantly increased [NE]max in L rats but not in SD rats (116±9% of pre-
drug baseline, n=5, P<0.05 vs 91±5% of pre-drug baseline, n=5; Figure 2.3e). There 
was no change in t1/2 in either strain following acute morphine (L rats: 118±15% of pre-
drug baseline, n=5; SD rats: 120±12% of pre-drug baseline, n=9; Figure 2.3f). 
Furthermore, when the response to IDA was compared in acutely treated and non-
manipulated animals, there was a main effect of strain (2-way ANOVA, F=9.41, P<0.01; 
SD rats: 191±12.8% vs 217±14% of pre-drug baseline, n=5 and 10, with and without 
morphine, respectively; L rats: 158.6±5.4% vs 163±11% of pre-drug baseline, n=5 and 
8, with and without morphine, respectively) but not of drug treatment. Therefore, acute 
morphine alone did not alter IDA response in either strain. 
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Morphine-dependent SD rats had increased anxiety-like behavior 
Next, we assayed animals that had experienced morphine withdrawal using a 
dependence paradigm that modeled the negative affect experienced by human addicts 
(Amitai et al, 2006; Koob, 2009; Schulteis et al, 1999). Once daily, we administered 
10 mg/kg morphine s.c., followed by 1 mg/kg naloxone s.c. 4 h later (denoted MN), for a 
total of 3 days (SD n=27, L n=22). Control animals received a saline injection s.c. 
followed by 1 mg/kg naloxone 4 h later (denoted SN) once daily for a total of 3 days (SD 
n=26, L n=23). For 10 min following the injection of naloxone, animals were assayed for 
withdrawal behaviors and assigned a global withdrawal score (Figure 2.5a). There was 
a significant effect of drug and day on the global withdrawal score, but not of strain (3-
way ANOVA, F=25.34, P<0.0001; Figure 2.5b). Thus, SD and L rats that received 
morphine had significantly greater withdrawal symptoms than their saline control 
counterparts. By the third day, both strains that received morphine showed withdrawal 
scores that were significantly different from the first day, while saline controls did not 
(Tukey’s HSD Test, P<0.0001). Furthermore, there was an effect of day and treatment, 
but not strain, with regard to pre-withdrawal body weight (F=15.99, P<0.001). Both 
strains that received morphine had significant decreases in pre-withdrawal body weight 
(day 3 vs day 1, Tukey’s HSD Test, P<0.01 SD, P<0.05 L; Figure 2.5c). As a 
quantitative measure of withdrawal-induced gut motility, we weighed the fecal boli 
produced during the 60 min following naloxone administration. Again, we found a 
significant effect of treatment but not strain (F=59.08, P<0.0001) and a significant 
increase in day 3 vs day 1 fecal boli weight (Tukey’s HSD Test, P<0.001 SD, P<0.01 L; 
Figure 2.5d). The similarity in responses to the morphine/naloxone challenge shows that 
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morphine dependence was induced in both strains. Owing to the short half-lives of 
morphine and naloxone (Trescot et al, 2008), both drugs were eliminated by 
experimentation time on day 4. 
We next examined MN and SN animals of both strains on the EPM. Both center 
and enclosed arm time showed an interaction (2-way ANOVA, center: F=5.78, P<0.05; 
enclosed: F=5.49, P<0.05) and a main effect of strain (2-way ANOVA, center: F=15.2, 
P<0.001; enclosed: F=14.0, P<0.001). Post-hoc analysis revealed significant 
differences between SD-MN and SD-SN time spent in the center (62±11 s vs 106±6 s, 
n=8 and 7, respectively, P<0.01) and the enclosed arms (222±15 s vs 175±9 s 
respectively, P<0.05). L-MN rats, however, failed to show any differences in time spent 
in the center or enclosed arms when compared with L-SN rats (center: 47±12 s vs 
44±8 s, enclosed: 239±13 s vs 250±11 s, respectively, n=8; Figure 2.5 e–g). No 
significant differences were noted in number of entries or open arm time between 
groups. 
Norepinephrine dynamics were altered in morphine-dependent SD rats but not L rats 
After establishing morphine dependence, animals were anesthetized on day 4 
and norepinephrine overflow was measured in the vBNST using fast-scan cyclic 
voltammetry. We found that the t1/2 in SD-MN rats was significantly longer than in SD-
SN rats (2.6±0.4 s vs 1.6±0.2 s, n=5 and 6, respectively, P<0.05; Figure 2.6a). 
Additionally the increase in [NE]max, following IDA was significantly blunted in the SD-
MN rats as compared with SD-SN rats (147±9% vs 186±8%, n=5 and 6, respectively, 
P<0.05; Figure 2.6b). Interestingly, neither t1/2 nor the response to IDA was altered by 
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morphine dependence in the L rats (t1/2: L-MN 2.3±0.3 s vs L-SN 2.6±0.3 s, IDA: L-MN 
163±25% of pre-drug baseline vs L-SN 157±10% of pre-drug baseline, n=5; Figure 2.6c 
and d). Neither SD-MN, L-MN, nor L-SN groups were significantly different from the 
non-manipulated L group with respect to either t1/2 or response to the IDA challenge. 
Similar to non-manipulated animals, we did not observe changes in α2-AR or NET 
binding in the vBNST of either strain or condition (SD-MN n=5, SD-SN n=5, L-MN n=4, 
L-SN n=5, Figure 2.4). 
Catecholamine tissue content in morphine-dependent and control Rats 
Finally, we compared the catecholamine tissue content in the BNST and NAc of 
MN animals and their controls (Table 2.1). Contrary to naïve animals, when 
norepinephrine tissue content was examined there was no significant interaction 
between MN and SN animals of each strain (2-way ANOVA, SD-MN: 1.97±0.49 μg/g, 
n=9; SD-SN 3.23±0.72 μg/g, n=8; L-MN: 4.36±0.70 μg/g, n=5; L-SN: 3.12±0.65 μg/g, 
n=5 P>0.05). When BNST dopamine levels were examined, however, there was a main 
effect of both strain and drug treatment (2-way ANOVA, SD-MN: 1.32±0.22 μg/g, n=9; 
SD-SN 0.71±0.17 μg/g n=8; L-MN: 2.69±1.02 μg/g, n=5; L-SN: 1.55±0.59 μg/g, n=5, 
P<0.05 for each factor). Interestingly, when dopamine levels in the NAc were measured, 
there was a significant interaction (2-way ANOVA, SD-MN: 5.21±0.91 μg/g, n=9; SD-SN 
4.85±0.75 μg/g n=8; L-MN: 7.25±1.31 μg/g, n=5; L-SN: 2.37+0.46 μg/g, n=5 P<0.05). 
Post-hoc analysis revealed that L-MN rats had significantly higher dopamine in the NAc 
than their L-SN controls (P<0.05), whereas SD animals showed no difference. 
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Discussion 
Previous studies have shown that L rats have anxiety and PTSD-like phenotypes 
(Cohen et al, 2006) and elevated extracellular norepinephrine in the BNST in response 
to a stressor (Pardon et al, 2002). They are also predisposed to substance abuse 
(Picetti et al, 2012; Sánchez-Cardoso et al, 2007). Here, we found that the tissue 
content of norepinephrine and dopamine in the vBNST, but not dopamine in the NAc, 
was elevated in L rats as compared with SD rats. Furthermore, using fast-scan cyclic 
voltammetry, we uncovered profound differences in the regulation of norepinephrine 
synaptic function in the vBNST in the two strains. Norepinephrine is less regulated in L 
rats when compared with SD rats because they have a reduced norepinephrine uptake 
rate and less sensitivity to an α2-AR antagonist. When SD rats were made dependent 
on morphine the two key regulators of norepinephrine overflow, uptake, and 
autoreceptor regulation, were both reduced such that norepinephrine neurotransmission 
resembled that of a non-manipulated L rat. In L rats, however, norepinephrine clearance 
and autoreceptor regulation were unaffected by morphine dependence. This 
physiological phenomenon correlated to an increase in anxiety-like behavior in SD-MN 
rats but not L-MN rats, as compared with their controls. The results demonstrate a 
robust plasticity within an organism’s noradrenergic system that may be influenced by 
genetic factors as well as environmental insults. 
L rats exhibited poor control over norepinephrine release and clearance 
Neurotransmitter levels in the extracellular space are determined by the balance 
between release and uptake (Wightman et al, 1988). Release is a function of the rate of 
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impulse flow (action potentials), the relative amount of norepinephrine in the releasable 
pool, and regulation by autoreceptors. The principal inhibitory autoreceptor in 
noradrenergic neurons is the α2 -AR (Trendelenburg et al, 2001). NET is primarily 
responsible for norepinephrine clearance by uptake (Xu et al, 2000), and it follows 
Michaelis–Menten kinetics (Park et al, 2009). Electrical stimulation of norepinephrine 
neurons provides a convenient way to monitor release and uptake. Stimulation at 
supraphysiological frequencies allows release to predominate over uptake, enabling its 
nature to be examined. The maximum concentration achieved ([NE]max), measured at 
the end of the stimulation, is thus predominantly a function of release. Recently the 
Jones lab has shown that the t1/2 after the stimulation provides a measure of the rate of 
uptake that agrees with more complex Michaelis–Menten modeling (Yorgason et al, 
2011). Thus, the electrical stimulations used here allowed quantification of several basic 
parameters that control extracellular norepinephrine. 
Our studies showed that [NE]max is similar in the two strains with shorter 
stimulation trains. This is surprising because the vBNST norepinephrine content is twice 
as large in naïve L rats compared with SD rats. While release is linear in both strains, 
the slope of the regression line in the SD rats was significantly less than L rats, 
indicating that L rats have a larger releasable pool (Montague et al, 2004). Microdialysis 
studies have shown that extracellular norepinephrine increases during restraint stress in 
L rats relative to SD rats (Pardon et al, 2002), possibly arising from the larger releasable 
pool revealed in this work. Additionally, our experiments that probed the efficacy of the 
autoreceptor revealed that it exerts greater inhibition of release in SD rats. Although 
urethane anesthesia has been shown to stimulate α2-ARs in the periphery (Armstrong et 
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al, 1982), our results in anesthetized animals mimicked the IDA effects observed in 
awake rats (Park et al, 2012). Taken together, our results suggest that L rats appear 
optimized for maximal norepinephrine neurotransmission. The combination of high 
content, low uptake rate, and low autoreceptor regulation ensures enhanced 
norepinephrine tone. 
Norepinephrine signaling in the BNST has been implicated in mediating control 
over the HPA axis and in anxiety-like behavior (Cecchi et al, 2002) and can release 
CRF within the BNST (McElligott et al, 2010; Nobis et al, 2011). Furthermore, prolonged 
norepinephrine signaling in the BNST induces synaptic plasticity that is modulated by 
stress (McElligott et al, 2010; McElligott et al, 2008). The altered mechanisms in L rats 
that allow enhanced norepineprhine signaling may result in their anxiety-like phenotypes 
observed by others (Cohen et al, 2006), and could translate to anxiety-susceptible 
human populations. Indeed, recent data show that targeting noradrenergic signaling 
mechanisms may alleviate symptoms of substance abuse and PTSD (Raskind et al, 
2000; Simpson et al, 2009). 
Morphine dependence enhanced anxiety-like behavior, increased norepinephrine 
clearance half-life and reduced autoreceptor function in SD but not L rats 
It is hypothesized in the allostasis model that the progression to addiction 
requires the engagement of neuronal stress/anxiety systems, including the release of 
norepinephrine in the BNST (Delfs et al, 2000; Koob, 2009). Therefore, a predisposition 
to the negative emotional state associated with engagement of these neuronal 
substrates might explain the co-morbidity that is associated with anxiety disorders and 
addiction. L rats have a high anxiety/PTSD phenotype that is at least partially due to 
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BNST function (Cohen et al, 2006; Duvarci et al, 2009) and a propensity to self-
administer and escalate opiate intake (Picetti et al, 2012; Sánchez-Cardoso et al, 2007). 
Interestingly, following withdrawal from morphine, but not acute morphine, SD rats 
showed profound plasticity in both autoreceptor regulation and uptake rates, as well as 
enhanced anxiety-like behavior. Moreover, the SD-MN rats had uptake rates and 
autoreceptor profiles indistinguishable from non-manipulated L rats. Surprisingly, L-MN 
rats exhibited neither this plasticity nor further increases in anxiety-like behavior, 
suggesting that autoreceptors and uptake rates in the L rats may be in a maximally 
depressed state. The correlation between vBNST norepinephrine and increased anxiety 
revealed in this work implicate plasticity at noradrenergic synapses as one mechanism 
for the development of anxiety and addiction phenotypes. 
Interestingly, our autoradiography experiments demonstrated that neither naïve, 
MN, nor SN rats of either strain showed alterations in α2-AR or NET levels in the 
vBNST. This may be due to several reasons. First, this technique probes targets that 
are on the cell surface and in internal pools; therefore, it does not exclusively examine 
functional receptors and transporters. Second, it is possible that the functional changes 
we observed are not due to alterations in protein level, but due to a post-translational 
modification. Finally, the BNST has strong expression of nonspecific organic cation 
transporters, which also may have a role in the clearance of NE (Gasser et al, 2009) 
and could be manipulated by the gene–environment interactions we probed here. 
Nevertheless, the functional results clearly showed that the synaptic dynamics are 
dramatically different between SD and L rats, and that they were greatly altered in SD-
MN rats. 
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Examining catecholamine tissue content in MN and control rats showed 
interesting changes in our treatment groups. Our data demonstrated that naloxone 
treatment lowered norepinephrine levels in the BNST in both strains regardless of 
pretreatment with morphine, and the effect was long lasting. These data are intriguing 
because naloxone and other μ-opioid antagonists are prescribed to humans for opiate 
and alcohol dependence (Heilig and Egli, 2006). Further, we found that L-MN rats had 
elevated dopamine in their NAc as compared with their controls, which may also 
contribute to their self-administration escalation phenotype (Picetti et al, 2012). 
We have shown that norepinephrine synapses in a genetic model of anxiety and 
addiction (L rats) permit exacerbated noradrenergic signaling due to reduced uptake 
and autoreceptor function. Furthermore, we showed that vBNST norepinephrine 
synapses in a relatively non-anxious SD rat resemble L rat norepinephrine synapses 
when SD rats are made morphine dependent. These data suggest that noradrenergic 
synapses undergo a plasticity event where increased norepinephrine signaling (here 
stemming from precipitated withdrawal) results in a biophysical/biochemical change 
within the presynaptic cell to permit prolongation of future norepinephrine signaling on 
post synaptic cells. Furthermore, these alterations correlated to enhanced anxiety-like 
behavior in the SD rats. Additionally, the data support the allostasis model (Koob et al, 
2010) and the idea that genetic factors contributing to negative affect could in turn 
increase susceptibility to developing substance abuse issues. 
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Figure 2.1:  Fast-Scan Cyclic Voltammetry of norepinephrine (NE) in the bed nucleus of 
the stria terminalis (BNST). (a–c) Tissue content analysis of catecholamines in the 
BNST and nucleus accumbens (NAc). (d) Representative histology of recording 
electrode placement in the ventral BNST (vBNST) (black dashed circle) and area 
excised for tissue content analysis (red dashed line; LV, lateral ventricle; AC, anterior 
commissure). (e) Representative cyclic voltammogram of NE at [NE]max. (f) 
Representative color plots demonstrating NE release and uptake in baseline conditions, 
following 2 mg/kg raclopride, or 5 mg/kg idazoxan. 
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Figure 2.2: Comparison of norepinephrine (NE) dynamics in naïve Lewis (L) and 
Sprague-Dawley (SD) rats. (a) Representative concentration traces demonstrating NE 
release and uptake in the ventral bed nucleus of the stria terminalis (vBNST) of both SD 
and L rats (scale bar, 100 nM; gray box =stimulation, 60 pulses, 60 Hz). (b) Input–output 
curve of [NE]max at 20, 40, 60, 80, 100 and 120 pulses in SD and L rats. (c) Histogram 
of mean clearance half-life of NE following 60 Hz, 60 pulse stimulation in both SD and L 
rats. 
56 
 
 
Figure 2.3: Effect of idazoxan (IDA) and morphine on norepinephrine release in the 
ventral bed nucleus of the stria terminalis (vBNST). (a and b) Representative 
concentration traces of Sprague-Dawley (SD) and Lewis (L) rats, respectively. Solid 
line—evoked norepinephrine (NE) concentration with 60 Hz, 60 pulses stimulation; 
dashed line—evoked NE concentration following 5 mg/kg IDA with the same electrical 
stimulus. (c) Average [NE]max following 5 mg/kg IDA relative to pre-drug stimulated 
release. (d) Change in [NE]max as percent of pre-drug baseline in both Sprague-
Dawley (closed squares) and Lewis (open circles) rats, plotted vs log concentration of 
IDA (n=3 each strain). (e) Average [NE]max to acute 5 mg/kg morphine relative to pre-
drug stimulated release. (f) Average clearance half-life following acute 5 mg/kg 
morphine relative to pre-drug stimulated release. 
57 
 
 
Figure 2.4: Autoradiography for α2AR and NET in naïve, MN, and SN animals. 
Representative non-specific, total binding, and autoradiography totals for A. α2-AR with 
125iodoclonidine and B. NET with 125 Nisoxetine in SD-MN, SD-SN, L-MN and L-SN 
rats.  
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Figure 2.5: Morphine dependence in Sprague-Dawley (SD) and Lewis (L) rats. (a) 
Model of drug administration paradigm. (b) Global withdrawal scores, (c) pre-withdrawal 
body weight (as % of day 1), and (d) fecal boli weight in SD morphine/naloxone (SD-
MN) and L-MN rats following withdrawal, compared with control SD saline/naloxone 
(SD-SN) and L-SN rats. Time spent in (e) open arms (f), center or (g) closed arms of the 
elevated plus maze as a fraction of total time in the maze in SD-MN, SD-SN, L-MN, and 
L-SN rats. 
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Figure 2.6: Clearance half-life and change in response following idazoxan (IDA) 
administration in morphine/naloxone (MN) animals vs saline controls. (a) t1/2 and (b) 
change in [NE]max as percent of pre-drug baseline in MN Sprague-Dawley (SD) rats vs 
saline controls (P<0.05). (c) t1/2 and (d) change in [NE]max as percent of pre-drug 
baseline in MN Lewis (L) rats vs saline controls (n.s.). SN, saline/naloxone. 
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Table 2.1 Catecholamine Tissue Content Analysis (μg/g) in the Nucleus Accumbens 
and Ventral Bed Nucleus of the Stria Terminalis of Control (Saline/Naloxone) and 
Morphine-Dependent (Morphine/Naloxone) Rats by HPLC. 
 
 
  DA NAc 
(μg/g) 
NE vBNST 
(μg/g) 
DA vBNST 
(μg/g) 
Sprague-Dawley    
 Saline/naloxone (n=8) 4.85±0.75 3.23±0.72 0.71±0.17 
Morphine/naloxone (n=9) 5.21±0.91 1.97±0.49 1.32±0.22 
Lewis    
 Saline/naloxone (n=5) 2.37±0.46* 3.12±0.65 1.23±0.37 
 Morphine/naloxone (n=5) 7.25±1.31* 4.36±0.70 2.69±1.02 
                  *P<0.05. 
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CHAPTER 3: STRESS AND DRUG DEPENDENCE DIFFERENTIALLY MODULATE 
NOREPINEPHRINE SIGNALING IN ANIMALS WITH VARIED HPA AXIS FUNCTION 2 
 
Introduction 
Researchers have demonstrated the importance of central noradrenergic 
activation in regulating behavioral and physiological responses to stress (Cecchi et al, 
2002; Fendt et al, 2005). In part, this is because norepinephrine can engage the 
hypothalamic-pituitary-adrenal (HPA) axis. Through such actions, norepinephrine has 
been identified as an important neural substrate associated with the aversive 
components of morphine withdrawal (Delfs et al, 2000). Such evidence has given 
support to the view that the negative affect experienced during drug withdrawal is 
mediated in part by norepinephrine, and can contribute to the addiction cycle (Koob et 
al, 2010). Interestingly, a number of psychological disorders and addictions are 
comorbid with stress and involve noradrenergic dysregulation (eg, post-traumatic stress 
disorder) (Hyman et al, 2006; Sinha, 2008). For example, exposing rats to intruder 
stress evokes an opiate-dependent like state and alters firing of norepinephrine neurons 
(Chaijale et al, 2013). Therefore, investigation of noradrenergic systems and their role in 
the initiation/termination of stress is important for understanding the pathophysiology of 
diseases that co-express with addiction. 
                                                          
2 This chapter originally appeared as an article in Neuropsychopharmacology. The original 
citation is as follows:  Fox ME, Studebaker RI, Swofford NJ, Wightman RM (2015) “Stress and 
drug dependence differentially modulate norepinephrine signaling in animals with varied HPA 
axis function.” Neuropsychopharm 40(7):1752-61 
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The ventral bed nucleus of the stria terminalis (vBNST) is a major target of 
norepinephrine innervation within the brain (Kilts and Anderson, 1986). Here, forebrain, 
limbic, and brainstem inputs converge to relay information about both physical and 
psychological stressors. The BNST receives small noradrenergic input from the locus 
coeruleus (LC), and major noradrenergic innervation from the A1 and A2 (via the ventral 
noradrenergic bundle) cell groups, and projects to stress and reward centers (Drolet, 
2009; Forray et al, 2004). The BNST has neurons containing corticotropin-releasing 
factor (McElligott et al, 2010), excitatory and inhibitory projections to the paraventricular 
nucleus of the hypothalamus (Choi et al, 2007), and activates the HPA axis (Forray et 
al, 2004). Norepinephrine is released in the BNST during restraint stress, oral 
administration of an aversive tastant, and during morphine withdrawal (Fuentealba et al, 
2000; Pardon et al, 2002; Park et al, 2012). Thus, norepinephrine release in the BNST 
can integrate stressful and aversive stimuli to generate an appropriate physiological 
response. 
Previously, we showed that two different rat strains, Sprague-Dawley and Lewis, 
markedly differed in the response of their noradrenergic system to morphine withdrawal 
(McElligott et al, 2013). Sprague-Dawley rats demonstrated profound plasticity of uptake 
and autoreceptor function, whereas control mechanisms were unchanged in Lewis rats. 
To better understand how genetic differences interact with drug withdrawal and 
stressors, we chose to compare the stress responses of Sprague-Dawley (SD) and 
Wistar-Kyoto (WKY) rats. WKY rats exhibit increased depressive phenotypes and HPA 
axis function relative to Sprague-Dawley rats (Carr and Lucki, 2010; Cohen et al, 2006), 
and under restraint-stress, extracellular norepinephrine varies between the two (Pardon 
63 
 
et al, 2002). Here, we used fast-scan cyclic voltammetry to evaluate differences in 
norepinephrine overflow and regulation between SD and WKY rats in response to 
stress. We subjected animals to acute morphine-dependence, 2 weeks of social-
isolation, and DSP-4 lesioning. In response to these stressors, we found robust 
neurochemical changes that differed between strains and corresponded with anxiety-
like behavior. 
Materials and Methods 
Animal Care 
Experiments were performed in accordance with University of North Carolina at 
Chapel Hill (UNC) Institutional Animal Care and Use Committee’s guidelines. Subjects 
were Sprague-Dawley and Wistar-Kyoto rats (males, 250–350 g on arrival from Charles 
River, Wilmington, MA) pair-housed in UNC animal facilities on a 12-hour day/light 
cycle. Animals were given ad libitum access to food and water, and their health was 
monitored daily during treatments. For social isolation, after 1-week of acclimation, 
subjects were randomly split into single or pair-housing for 2 weeks. Care was taken to 
reduce the number of animals used. For anesthetized voltammetry experiments, 108 
Sprague-Dawley and 103 Wistar-Kyoto rats were used. A separate group of 32 
Sprague-Dawley and 48 Wistar-Kyoto rats was used for anxiety measures on the 
Elevated Plus Maze (EPM). 
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Chemicals and Drugs 
Drugs were purchased from Sigma-Aldrich (St Louis, MO), with the exception of 
α2C antagonist JP-1302 dihydrochloride (Tocris Bioscience, Ellisville, MO), dissolved in 
sterile saline (0.9%), and used as received. JP-1302 and α2A antagonist BRL-44408 
maleate were administered to naïve animals in a range from 0.2 to 5 mg/kg i.p. to build 
a dose–response curve. Treated and control animals were given either 2 mg/kg BRL-
44408 i.p. or 2 mg/kg α2A agonist Guanfacine HCl i.p. to assay α2A function. At the end 
of the experiment, animals were given 2 mg/kg dopamine D2 antagonist raclopride 
tartrate i.p., followed by 5 mg/kg α2 antagonist idazoxan i.p. to validate signal per (Park 
et al, 2009). 
Measurement of Norepinephrine Release 
Norepinephrine release in the vBNST was measured in anesthetized animals as 
described previously (Park et al, 2009) Briefly, rats were anesthetized with urethane 
(1.5 g/kg), affixed in a stereotaxic instrument (Kopf instruments) and the scalp removed.  
Holes were drilled for the BNST (0.0 A-P, +1.2 M-L) and VNB (-5.2 A-P, +1.0 M-L) 
referenced from bregma and based on the atlas of Paxinos and Watson(Paxinos et al, 
2007). A Ag/AgCl reference electrode was placed contralaterally and secured with a 
screw.  A carbon-fiber microelectrode (~100 um long) was lowered into the vBNST (7.0-
7.6 mm D-V), and a bipolar stimulating electrode into the VNB (8-8.5 mm D-V).  Dorsal-
Ventral coordinates were optimized to achieve maximal measured norepinephrine 
release.  The maximum amplitude of evoked release ([NE]max) was taken as a 
measure of the combined processes of release and uptake (Yorgason et al, 2011).  The 
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half-life (t1/2) for norepinephrine to return to baseline after stimulation was taken as a 
quantitative measure of uptake rate(McElligott et al, 2013; Yorgason et al, 2011).  Drug 
effects were measured as a percentage of pre-drug stimulated release.   
Electrical stimulations were delivered with two constant-current stimulus isolators 
(model NL800, NeuroLog System, Digitimer).  The stimulations consisted of biphasic 
pulses (±300 μA, 2 ms/phase) applied at 60 Hz and 60 pulses unless otherwise noted.  
Stimulation pulses were computer generated and applied between cyclic 
voltammograms.  
For norepinephrine measurements, a triangular scan (−0.4 to +1.3 V, 400 V/sec) 
was repeated every 100 msec to generate cyclic voltammograms.  Data were digitized 
with a computer employing HDCV software(Bucher et al, 2013).  Color plots were used 
to examine the voltammetric data with the y-axis as voltage, the x-axis as acquisition 
time, and the current in false color.  The average of 10 cyclic voltammograms collected 
before the electrical stimulation was used for background subtraction.  Digital smoothing 
was accomplished under software control after data collection. Data were evaluated 
with principal component analysis to resolve individual analytes as described previously 
(Keithley et al, 2009).  An average calibration factor (6 nA/1 µM NE/100 µm carbon 
fiber) was used to convert current to concentration. 
Elevated Plus Maze 
Anxiety-like behavior was measured as described previously (McElligott et al, 
2013). Briefly, the number of entries and time spent in each section of the maze was 
measured over 5 min. Preference for the open arms was determined in each animal and 
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was expressed as a ratio of open-arm time over closed-arm time. The maze consisted 
of a cross-shaped platform elevated 1 m from the floor with two open and two closed 
arms. Each arm was 50 cm long and 10 cm wide and the closed arms were surrounded 
on three sides by 40 cm tall opaque walls. Arms of the same type were located across 
from each other. Rats were isolated in a novel chamber for 5 minutes prior to maze 
exposure, then placed in the center of the maze facing an open arm, and allowed to 
explore for 5 minutes. Time and entries spent in each section was recorded using 
Ethovision software (Noldus, Netherlands).   
Morphine Dependence 
For 3 days, rats were administered 10 mg/kg morphine sulfate s.c. once daily, 
followed 4 h later by 1 mg/kg naloxone HCl to induce withdrawal. Somatic indices of 
withdrawal (eg, teeth chattering) were scored each day per (Schulteis et al, 1999). 
Control animals received 3 days of 0.5 ml saline s.c., followed 4 h later by 1 mg/kg 
naloxone. On day 4, drug-free rats were assayed on the EPM or underwent surgery for 
norepinephrine measurements. 
DSP-4 Lesioning 
Wistar-Kyoto and Sprague-Dawley rats (150–200 g on arrival) were pair-housed, 
and administered two i.p., 50 mg/kg N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine 
(DSP-4) injections in 1 ml/kg saline 3 days apart. Control animals were given two 
1 ml/kg i.p. saline injections 3 days apart. Animals were allowed to recover for >10 days 
after the last injection. 
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Statistics 
Results are presented as average values ± SEM. Two-way analysis of variance 
(ANOVA) with post hoc Bonferroni tests were used to determine statistical significance. 
An unpaired t-test was used to determine differences in anxiety between morphine-
dependent and control WKY rats. Differences were considered significant when 
*P<0.05, **P<0.01, ***P<0.005. 
Results 
First, we chose to extend prior work demonstrating strain-dependent differences 
in norepinephrine regulation during stress (McElligott et al, 2013; Pardon et al, 2002). 
We characterized vBNST norepinephrine synaptic function in anesthetized WKY rats 
with electrical stimulations of the ventral noradrenergic bundle, and measured 
subsequent norepinephrine overflow with fast-scan cyclic voltammetry (Herr et al, 2012; 
Park et al, 2009). This technique allows characterization of release and uptake of 
biogenic amines (John et al, 2006). We measured norepinephrine by placing the 
carbon-fiber microelectrode directly beneath the anterior commissure (electrode 
placement shown in Figure 3.1a, sample color plot encoding voltammetric recordings in 
Figure 3.1b). Release increased linearly with increasing stimulation duration in WKY 
rats (60 Hz stimulations, r2=0.99, slope: 3.71±0.24; Figure 3.1c) similar to our findings in 
SD rats (slope: 3.11±0.21, (McElligott et al, 2013). Despite known phenotypic variations 
(Carr et al, 2010), we found no differences in norepinephrine clearance (t1/2) between 
WKY and SD rats in a baseline state (1.6±0.12 s vs 1.7±0.10 s, n=22 and 26, 
respectively). 
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The adrenergic α2 receptor serves as the inhibitory autoreceptor for 
norepinephrine, and two differentially regulated subtypes are present in the BNST 
(Scheinin et al, 1994). We assayed autoreceptor influence on release with α2 antagonist 
idazoxan in WKY and SD rats. After drug administration (5 mg/kg), the amplitude in 
evoked norepinephrine ([NE]max) was increased similarly in both strains (WKY: 
205±10.3% vs SD: 216±21.1%, n=6 and 5, respectively). To examine α2 subtype-
specific effects, we employed α2A and α2C selective antagonists BRL-44408 and JP-
1302, respectively. We found increased evoked norepinephrine in WKY rats following 
2 mg/kg BRL-44408, but not 2 mg/kg JP-1302 (examples in Figure 3.1e and f, BRL: 
140±6.9% vs JP: 95±4.5%, n=5). Similar effects were found in SD rats: (BRL: 
157±15.4%. vs JP: 102±7.3%, n=5 and 6, respectively). The selected doses (2 mg/kg) 
approach saturation (Figure 3.2) and are sufficient to produce robust behavioral effects 
in vivo (Sallinen et al, 2007). Thus, our findings indicate the α2A subtype is the principle 
noradrenergic autoreceptor in the vBNST of both WKY and SD rats, and it exerts similar 
control over norepinephrine release in both strains. 
Norepinephrine Dynamics were Differentially Altered in Morphine-Dependent SD and 
WKY Rats 
We hypothesized that SD and WKY rats would not differ in their response to 
morphine-dependence, owing to their noradrenergic similarity in a baseline state. To 
compare noradrenergic plasticity, we established morphine-dependence in SD and 
WKY rats as before (McElligott et al, 2013; Schulteis et al, 1999). Briefly, rats received 
10 mg/kg morphine followed 4 h later by 1 mg/kg naloxone once daily for 3 days. 
Consistent with our prior work, withdrawal was behaviorally evident in both strains by 
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day 3 (Figure 3.3). On day 4, rats were anesthetized and electrically evoked 
norepinephrine was recorded. First, we examined the effects on norepinephrine 
clearance and found clearance half-life showed a main effect of strain (F=5.8, P<0.05) 
and treatment (F=5.8, P<0.05). There was also a significant treatment × strain 
interaction (two-way ANOVA, F=10.35, P<0.01). In agreement with our previous work, 
morphine-dependent SD rats showed impaired uptake relative to controls (2.2±0.16 s vs 
1.5±0.06 s, n=12 and 11, respectively, P<0.001). To our surprise, uptake was unaltered 
in WKY rats (1.5±0.14 s vs 1.6±0.10 s, n=9 and 10, respectively, P>0.05, Figure 3.4a). 
As before, the protocol we employed allows time for clearance of morphine and 
naloxone (Trescot et al, 2008), thus altered uptake in SD rats is a consequence of 
morphine withdrawal. 
To assay the effects of morphine withdrawal on α2A function in these two strains, 
we administered 2 mg/kg of selective antagonist BRL-44408, or agonist guanfacine 
(2 mg/kg, GFC) and determined the effects on release. The doses were selected based 
on dose–response analysis in Figure 3.2 and 3.5. Response to autoreceptor drugs 
showed a main effect of morphine treatment (two-way ANOVA, BRL: F=26, P<0.0005; 
GFC: F=18.2, P<0.005) and strain (two-way ANOVA, GFC: F=4.7 P<0.05). Post hoc 
analysis revealed a significant decrease in response to BRL between morphine-
dependent animals and their saline-naloxone controls (SD: 102±3.5% for morphine 
withdrawal vs 167±9.1% for control, n=7, respectively, P<0.001; WKY: 104±6.5% for 
morphine withdrawal vs 147±6.4% for control, n=7, respectively, P<0.001, Figure 3.4b). 
Additionally, the α2A agonist, GFC, was less effective at inhibiting evoked 
norepinephrine release in both strains (SD: 87±3.6% for morphine withdrawal vs 
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65±4.9% for control, n=7, respectively, P<0.05; WKY: 102±8.9% for morphine 
withdrawal vs 75±3.8% for control, n=7, respectively, P<0.01, Figure 3.4c). Thus, 
following morphine withdrawal, α2A function is desensitized in both SD and WKY rats. 
WKY and SD Rats Exhibited Increased Anxiety-Like Behavior following Morphine-
Dependence 
We previously showed that morphine withdrawal increases anxiety-like behavior 
in SD rats (McElligott et al, 2013). To examine its impact on WKY rats, we assayed their 
behavior on the EPM. Withdrawal caused WKY rats to become more anxious, as they 
had reduced preference for the open arms compared with their saline-naloxone controls 
(unpaired t-test, Open/Closed time: 0.05±0.03 vs 0.39±0.12, n=8, respectively, P<0.01, 
Table 3.1). WKY rats treated with saline-naloxone did not demonstrate a change in 
open-arm preference relative to naïve animals (Table 3.2, pair-housed). 
Social-Isolation Altered Norepinephrine Signaling in SD, but not WKY Rats 
To further investigate differences between SD and WKY norepinephrine 
responses, we treated rats with chronic social isolation. This is a passive stressor that 
removes injection/handling stress, and is suggested to generate depression in rodents 
(Butler et al, 2014; Nestler and Hyman, 2010). Following 2 weeks of single-housing, rats 
were anesthetized and evoked norepinephrine was recorded. When comparing 
norepinephrine uptake between single (S) and pair (P)-housed animals, we found 
significantly slower uptake in SD-S rats compared with SD-P (2.3±0.09 s vs 1.7±0.10 s, 
n=20 and 26, respectively, P<0.001). However, WKY-S did not slow uptake relative to 
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pair-housed controls (1.6±0.06 s vs 1.6±0.12 s, n=21 and 22, respectively, P>0.05, 
Figure 3.6a). 
We next compared α2A drug effects between single and pair-housed animals, and 
found a main effect of housing (two-way ANOVA, BRL: F=24.12, P<0.0001; GFC: 
F=7.2, P<0.05) and a housing × strain interaction (BRL: F=8.2, P<0.01; GFC: F=5.4, 
P<0.05). Post hoc analysis revealed that BRL was less effective in increasing 
norepinephrine in SD-S animals as compared with SD-P (97±1.4% vs 158±11.9%, n=7, 
respectively, P<0.001, Figure 3.6b). Similarly, the decrease in release following GFC 
was attenuated in single-housed animals (91±3.2% vs 64±7.9%, n=7, respectively, 
P<0.01, Figure 3.3c). WKY-S failed to decrease drug response when compared with 
WKY-P rats (BRL: 124±8.9% vs 140±4.8%, n=7 respectively, P>0.05; GFC: 78±6.4% vs 
76±2.2%, n=7, respectively, P>0.05). 
Social Isolation Induces Anxiety-Like Behavior in SD Rats 
We assayed anxiety-like behavior in singly housed animals on the EPM. 
Enclosed arm time showed a main effect of strain (two-way ANOVA, F=8.24, P<0.01) 
and a housing × strain interaction (F=4.89, P<0.05). Open arm time showed a main 
effect of housing (F=4.83, P<0.05). Total number of entries showed a main effect of 
strain (F=6.11, P<0.05), and the reduced number of WKY entries agrees with previous 
studies (Carr et al, 2010; Cohen et al, 2006). Post hoc analysis revealed a significant 
reduction in open arm preference in single-housed animals (Open time/Closed time: 
0.33±0.09 vs 0.12±0.05, SD-S vs SD-P, n=8 and 7, respectively, P<0.05). WKY-S did 
not increase anxiety-like behavior relative to WKY-P rats (Table 3.2). 
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Coerulean Lesion Induced Noradrenergic Plasticity in SD Rats, but not WKY 
As both morphine dependence and social stress can alter the firing rate of the LC 
(Chaijale et al, 2013; Van Bockstaele and Valentino, 2013), we wanted to mimic the 
effects of long-term LC inhibition on BNST norepinephrine and behavior. We lesioned 
coerulean norepinephrine terminals using the neurotoxin DSP-4, which reduces 
norepinephrine from LC but not medullary cells (Fritschy and Grzanna, 1989). The 
vBNST receives little LC input, and stimulation electrode placement in the ventral 
noradrenergic bundle targets axons primarily from A1/A2 cell groups. Not surprisingly, 
[NE]max was unchanged by DSP-4 treatment (SD: 219±37 nM vs 322±87 nM, n=7, and 
6, respectively, P>0.05; WKY: 230±23 nM vs 239±19 nM, n=7 and 5, respectively, 
P>0.05). However, differences in synaptic function were found between vehicle and 
DSP-4-treated SD rats. Clearance half-life showed a strain × treatment interaction 
(F=9.5, P<0.01) and main effect of strain (F=13.2, P<0.005). DSP-4-treated SD rats had 
slower uptake than their controls (2.6±0.27 s vs1.6±0.15 s, n=7 and 8, respectively, 
P<0.01). WKY rats were unchanged (1.1±0.23 s vs 1.5±0.22 s, n=5 and 8, respectively, 
P>0.05, Figure 3.7a). Response to both BRL and GFC showed a strain × treatment 
interaction (two-way ANOVA, BRL: F=6.7, P<0.05; GFC: F=4.5, P<0.05), and main 
effect of treatment (BRL: F=11.9, P<0.01; GFC: F=5.8, P<0.05). Post hoc analysis 
revealed the response to BRL and GFC was blunted in DSP-4 treated SD rats (BRL: 
100±5.3% vs 155±14.7%, n=5, respectively, P<0.05; GFC: 90±2.8% vs 64±7.9%, n=5 
and 7, respectively, P<0.01) but not WKY rats (BRL: 130±6.4% vs 138±7.2% n=5, 
respectively, P>0.05; GFC: 80±3.8% vs 78±1.3% n=5, respectively, P>0.05, Figure 
3.7c). 
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Coerulean Lesion Increased Anxiety-Like Behavior in SD Rats 
The impact of DSP-4 lesioning on anxiety is dependent on dosage, recovery, and 
housing (Harro et al, 1995; Itoi et al, 2011; Lapiz et al, 2001). Our treatment increased 
anxiety-like behavior in SD rats, but not WKY rats as measured on the EPM. DSP-4-
treated SD rats spent less time in the open arms, and more time in the enclosed arms 
(Open time/Closed time: 0.12±0.03 vs 0.26±0.01, n=8, DSP-4 vs saline, respectively, 
P<0.05. The number of entries was also reduced (6±2 vs 15±2, n=8, respectively, 
P<0.05). DSP-4-treated WKY rats did not show increased anxiety compared with 
controls (Table 3.2). 
Discussion 
Extracellular neurotransmitter concentrations are balanced by release and 
uptake processes (Wightman et al, 1988). Norepinephrine release is controlled by both 
cell firing and autoreceptor modulation, and the norepinephrine transporter is the 
primary clearance mechanism (Xu et al, 2000) with metabolism operating on a slower 
time scale (Near et al, 1988). Previously, we showed Lewis rats have hindered uptake, 
blunted autoreceptor function, and increased anxiety compared with SD rats (McElligott 
et al, 2013). When stressed with morphine withdrawal, Lewis rats showed no change in 
the regulation of BNST norepinephrine. This was in contrast to the dramatic alterations 
in norepinephrine clearance rate and autoreceptor function found in drug-dependent SD 
rats (McElligott et al, 2013). Here, we show that naïve SD and WKY rats are 
indistinguishable from each other with respect to evoked norepinephrine overflow, 
however, each strain diverges in their adaptations to stress. We found that following 
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morphine withdrawal, WKY rats were similar to SD rats with increased anxiety and 
attenuated autoreceptor function, however, norepinephrine uptake rate in WKY rats was 
unaltered. Additionally, BNST norepinephrine control mechanisms were unchanged in 
socially isolated WKY rats, whereas SD rats challenged with social isolation became 
more anxious and exhibited exacerbated norepinephrine signaling. Following lesions of 
norepinephrine in the LC, SD rats showed reduced norepinephrine control and 
increased anxiety, surprisingly similar to acute morphine dependence, but WKY rats 
were unaffected. Overall, we find WKY rats respond only to select stressors and that 
anxiety correlates with the degree of regulation of extracellular norepinephrine in the 
BNST. 
The α2 receptors are the primary adrenergic autoreceptors, and they show 
subtype-specific desensitization and phosphorylation by G-protein receptor kinases 
(Jewell-Motz and Liggett, 1996). As two subtypes of α2 receptors are expressed in the 
BNST (Scheinin et al, 1994), we paired fast-scan cyclic voltammetry measurements 
with receptor-subtype-specific pharmacology to assay control over norepinephrine 
release by each subtype. Knock-out mice were used to determine that α2A acts as the 
principle autoreceptor (Trendelenburg et al, 2001). In agreement with this, we found the 
inhibition of α2A increased norepinephrine overflow in the vBNST to a similar extent in 
both rat strains. Although blockade of α2C receptors did not increase norepinephrine 
overflow, α2C inhibition generated a large alkaline flux following stimulated 
norepinephrine release, seen in Figure 3.1f as blue current just below norepinephrine 
peak oxidation potential. The α2C receptors in the vBNST may therefore be positioned to 
regulate blood flow/metabolism in the vBNST (Bucher et al, 2014). 
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WKY rats exhibit reduced locomotion in an open field, limited exploration in the 
EPM, low baseline startle, and limited stress responsivity as compared with SD rats 
(Cohen et al, 2006; Pardon et al, 2002). Correspondingly, increases in extracellular 
norepinephrine in the BNST, evaluated by microdialysis, were greater in SD during 
restraint stress than WKY rats (Pardon et al, 2002). Following the stresses of both 
social isolation and morphine withdrawal, we found in SD rats that uptake and 
autoreceptor regulation are downregulated. The decreased noradrenergic control in SD 
rats could generate the comparatively larger increase in extracellular norepinephrine 
found with microdialysis. In WKY rats, morphine withdrawal produced only attenuated 
autoreceptor function, whereas social stress had no effect on norepinephrine control 
mechanisms. These limited adaptations would result in the smaller alteration in the level 
of extracellular norepinephrine induced by stress (Pardon et al, 2002). Importantly, 
cellular activation in the BNST during stress is similar between the two strains (Ma and 
Morilak, 2004). Thus, the greater norepinephrine overflow others have measured in 
stressed SD likely reflect the changes in uptake rate and desensitized autoreceptors 
revealed in this work. 
Non-specific organic cation transporters (OCTs) are expressed throughout the 
BNST (Gasser et al, 2009). The high-capacity, low-affinity OCT3 is thought to act as a 
secondary means of norepinephrine clearance, and is inhibited by physiological levels 
of corticosterone (Gasser et al, 2006). The extent to which BNST norepinephrine is 
taken up by OCTs in vivo is not currently known, however, NET knockout mice still 
demonstrate catecholamine clearance in brain slices (Xu et al, 2000) relative to 
dopamine transporter knockouts (Giros et al, 1996), indicating this may be a significant 
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clearance mechanism for norepinephrine. Previously, we showed the altered 
norepinephrine clearance in SD rats following withdrawal was not due to decreased 
NET binding sites (McElligott et al, 2013). Instead, stress-induced corticosterone 
release may inhibit OCT3 and reduce clearance rate. WKY rats have elevated peak 
diurnal levels of corticosterone relative to SD rats (Rittenhouse et al, 2002), which may 
eliminate any OCT3 component of norepinephrine uptake because of chronic inhibition. 
In addition, WKY rats exhibit behavioral sensitivity to the NET inhibitor desipramine 
(López-Rubalcava and Lucki, 2000), highlighting the importance of NET in WKY rats. 
The unaltered norepinephrine uptake in WKY rats corresponds with their low stress 
responsivity, and is likely the result of HPA axis dysfunction. 
Social stressors promote drug self-administration and escalation, generate a 
long-lasting tolerance to opiate analgesia, and are as efficacious as physical stress at 
reinstating morphine place preference (Butler et al, 2014; Miczek et al, 2004; Ribeiro Do 
Couto et al, 2006). Exposure to stressful life events and HPA axis dysfunction have 
been implicated in the development of several psychiatric disorders that are comorbid 
with addiction, however, stress alone is not sufficient for their development (Faravelli et 
al, 2012). It has been suggested that stress can interact with genetic vulnerabilities in 
predisposed individuals to create the psychopathology. Valentino and coworkers 
(Chaijale et al, 2013)  found stress activation of the endogenous opioid system sufficient 
to generate a cellular opiate dependence in SD rats. Here, we used chronic social 
isolation, a passive stressor suggested to induce depression and anxiety in rodents 
(Butler et al, 2014; Nestler et al, 2010). Remarkably, after SD rats were socially isolated 
for 2 weeks, they resembled morphine-dependent SD rats, with increased anxiety and 
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enhanced noradrenergic signaling in the vBNST. Moreover, following social isolation, 
SD rats anxiety and norepinephrine regulation resembled that of our previous work in 
Lewis rats (McElligott et al, 2013) , a model of increased drug-intake and PTSD (Cohen 
et al, 2006; Picetti et al, 2012; Sánchez-Cardoso et al, 2007). In stark contrast, we 
found that WKY rats were unresponsive to social isolation, exhibiting no changes in 
anxiety-like behavior or norepinephrine signaling relative to their controls. These results 
support the idea that genetic differences can predispose individuals to psychological 
disorders or addictions, as their noradrenergic system may already resemble a drug-
dependent or anxious state. Additionally, individuals with anxiety or depression may not 
be able to appropriately adapt to stress because of low responsivity of the 
noradrenergic system. 
During stress, LC activity is tuned by a balance of CRF excitation, and 
endogenous opioid inhibition (Van Bockstaele et al, 2013), and chronic stress can 
decrease LC discharge rates (Chaijale et al, 2013). The BNST receives a small input 
from the LC (Forray et al, 2004), and its activation may be influenced by altered 
coerulean discharge rates following stress. Thus, we chose to mimic stress-induced LC 
inhibition by lesioning it with the potent and selective neurotoxin DSP-4. DSP-4 induces 
degradation of norepinephrine axons arising from the LC, while leaving brainstem 
norepinephrine innervation intact (Fritschy et al, 1989). The behavioral effects of DSP-4 
treatment are variable (Harro et al, 1995; Itoi et al, 2011; Lapiz et al, 2001), and in our 
study, we found an anxiogenic effect in SD rats with no change in WKY rats relative to 
their respective controls. This LC inhibition also lowered the number of maze entries SD 
rats made to that of WKY. Surprisingly, the DSP-4 treatment produced a robust, 
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dependence-like phenotype in the BNST norepinephrine regulation of SD rats. Such a 
response was not expected owing to the limited LC innervation of the BNST. These 
results may reflect feedback between the two main sources of central noradrenergic 
innervation through a common afferent (Van Bockstaele et al, 2013) and should be a 
point of future study. Cross-talk between noradrenergic inputs is supported by work 
demonstrating the importance of both medullary and coerulean norepinephrine in 
mediating the aversiveness (Delfs et al, 2000) and somatic withdrawal signs of 
withdrawal (Maldonado, 1997). Importantly, LC activation during opiate withdrawal is 
partly a result of excitatory input from the nucleus paragigantocellularis, a structure that 
innervates the nucleus of the solitary tract (A2). Following DSP-4 treatment, we found 
no change in norepinephrine regulation in WKY rats, similar to WKY rats exposed to 
social isolation stress. However, WKY rats were responsive to morphine withdrawal, the 
aversiveness of which is due to medullary norepinephrine (Delfs et al, 2000). WKY rats 
overexpress kappa opioid receptors in the LC, leaving the LC in a chronically inhibited 
state (Carr et al, 2010), a possible explanation for the low number of maze entries and 
lack of DSP-4 response. This persistent inhibition may attenuate any excitatory 
influence of CRF and partially explain the lack of noradrenergic facilitation to social 
isolation. Overall, these results suggest a plasticity of medullary inputs but not LC inputs 
in the BNST of WKY rats. 
We have shown that certain stressors permit exacerbated BNST signaling that is 
accompanied by increased anxiety. Furthermore, we showed the signaling changes 
coincide with α2A receptor function and are dependent on rat strain. Social isolation and 
persistent coerulean inhibition caused dramatic changes in the SD rat, and generated a 
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morphine-dependence-like phenotype. WKY rats were unresponsive to both social 
isolation and DSP-4 treatment. Following morphine withdrawal, they demonstrated 
increased anxiety and an intermediate change in norepinephrine signaling: decreased 
α2A function without a change in norepinephrine clearance. Taken together, this 
differential responsivity may reflect separate noradrenergic mechanisms for adaptation 
that depend on the stressor or its intensity. Moreover, our data support the idea that 
genetic factors contribute to stress response, which may in turn generate cellular 
conditions that favor drug use and future substance abuse issues. 
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Figure 3.1: Fast-Scan Cyclic Voltammetry of norepinephrine in the vBNST. (a) 
Electrode tract (dashed line) and representative histology of carbon-fiber electrode 
placement in the vBNST (dashed circle; DS, dorsal striatum; AC, anterior commissure). 
(b) Norepinephrine measured in the vBNST after electrical stimulation (white bar). The 
cyclic voltammogram (current vs potential) is obtained from the white dashed line, and 
the concentration vs time trace from the black dashed line. (c) Input-output curve of 
[NE]max at 20, 40, 60, 80, and 120 stimulation pulses in WKY rats. (d) Representative 
concentration traces comparing norepinephrine release and uptake in SD and WKY 
rats. (e and f) Representative color plots of electrically evoked norepinephrine in the 
vBNST with α2A (BRL), α2C (JP), and non-selective α2 (IDA) antagonists on board in 
WKY rats. 
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Figure 3.2: Norepinephrine release as a percent of baseline after 0.2 – 5 mg/kg (A) 
BRL-44408 and (B) JP-1302 in SD (black squares) and WKY (open circles) rats.  
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Figure 3.3: Global 
withdrawal score in 
(A) SD and (B) 
WKY rats based 
on the method of 
Schulteis et al., 
1999. Data are 
presented as mean 
± SEM. Two-way 
ANOVA with 
bonferroni post-
hoc analysis: ***, 
P<0.005 
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Figure 3.4: The effects of morphine dependence in Sprague-Dawley and Wistar-Kyoto 
rats. (a) Average norepinephrine clearance as measured by t1/2. (b and c) Average 
evoked norepinephrine ([NE]max) following administration of 2 mg/kg BRL-44408 (b), or 
guanfacine (GFC) (c) relative to pre-drug stimulated release. Data are presented as 
mean ± SEM. Bonferroni post hoc analysis: *P<0.05, **P<0.01, ***P<0.005.  
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Figure 3.5: Norepinephrine response as a percent of pre-drug baseline to 2 and 5 
mg/kg GFC in SD and WKY rats.  
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Figure 3.6: The effects of social isolation in Sprague-Dawley and Wistar-Kyoto rats. (a) 
Average norepinephrine clearance as measured by t1/2. (b and c) Average evoked 
norepinephrine ([NE]max) following administration of 2 mg/kg BRL-44408 (b), or 
guanfacine (GFC) (c) relative to pre-drug stimulated release. Data are presented as 
mean ± SEM. Bonferroni post hoc analysis: *P<0.05, **P<0.01, ***P<0.005. 
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Figure 3.7: The effects of coerulean lesioning in Sprague-Dawley and Wistar-Kyoto 
rats. (a) Average norepinephrine clearance as measured by t1/2. (b and c) Average 
evoked norepinephrine ([NE]max) following administration of 2 mg/kg BRL-44408 (b) or 
guanfacine (GFC) (c) relative to pre-drug stimulated release. Data are presented as 
mean ± SEM. Bonferroni post hoc analysis: **P<0.01. 
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Morphine dependence Open/Closed time Entries Open 
time 
Closed 
time 
Wistar-Kyoto     
   Saline-Naloxone (n=8) 0.39±0.12 6±1 22±4 s 76±14 s 
   Morphine-Naloxone 
(n=8) 
0.05±0.03* 6±1 6±3 s* 126±24 s 
Table 3.1. Anxiety-like Behavior Following Morphine Withdrawal in WKY Rats.  Total 
number of entries and time spent in the open and enclosed arms of the elevated plus 
maze was evaluated. An animal's preference for open arms was expressed as a ratio of 
open-arm time over closed-arm time. Data are presented as mean ± SEM. Treated 
WKY were compared with their controls using an unpaired t-test. Starred values denote 
significance between the treated group and the control directly above it. *P<0.05. 
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 Open/Closed 
time 
Entries Open time Closed time 
Social isolation 
 Sprague-Dawley 
 Pair-housed (n=7) 0.33±0.09 14±1 49±11 s 163±10 s 
 Single-housed (n=8) 0.12±0.05* 12±2 20±7 s* 201±12 s* 
 Wistar-Kyoto 
 Pair-housed (n=8) 0.26±0.06 9±2 38±8 s 156±10 s 
 Single-housed (n=8) 0.23±0.04 9±1 32±6 s 148±9 s 
Coerulean Lesioning 
 Sprague-Dawley 
   Saline (n=8) 0.26±0.01 15±2 47±6 s 165±8 s 
   DSP-4 lesioned (n=8) 0.12±0.03* 6±2* 25±6 s* 207±15 s* 
 Wistar-Kyoto 
   Saline (n=8) 0.17±0.05 6±1 25±8 s 162±8 s 
   DSP-4 lesioned (n=7) 0.13±0.03 7±3 24±4 s 193±14 s 
 
Table 3.2: Anxiety-like Behavior Following Differing Stressors.Total number of entries 
and time spent in the open and enclosed arms of the elevated plus maze was 
evaluated. An animal's preference for open arms was expressed as a ratio of open-arm 
time over closed-arm time. Data are presented as mean ± SEM. Treated animals were 
compared with their controls using a two-way ANOVA with Bonferroni post hoc analysis. 
Differences in anxiety following stress were determined for each strain by comparing 
treated animals with their respective controls. Starred values denote significance 
between the treated group and the control directly above it. *P<0.05. 
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CHAPTER 4: RECIPROCAL CATECHOLAMINE CHANGES DURING OPIATE 
EXPOSURE AND WITHDRAWAL 
 
Introduction  
Considerable evidence indicates forebrain catecholamine circuits become 
dysregulated during the development of addiction (Koob et al, 2010). The risk for 
addiction varies greatly following drug exposure, and repeated use causes lasting 
neural adaptations which converge with stress to increase the risk for relapse long after 
drug cessation (Hyman et al, 2009; Nestler, 2001; Sinha, 2008). The allostasis model 
describes the transition from drug use to drug-abuse as a switch from impulsive to 
compulsive drug taking, where positively reinforced behavior dominates early in the 
addiction cycle, and over time, emergence of withdrawal-induced dysphoria drives 
negatively reinforced drug use (Koob et al, 2010). 
Mesolimbic dopamine modulates motivation and reward, and is implicated in the 
positively reinforced components of addiction. Drugs of abuse have diverse actions on 
dopaminergic signaling, particularly in the ventral tegmental area (VTA) and its afferents 
(Juarez and Han, 2016). Increased VTA dopamine transmission is thought to aid 
associative memory formation and drive cue-induced drug seeking (Berke and Hyman, 
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2000; Everitt and Robbins, 2005; Hyman et al, 2006). Action potentials from  the VTA 
drive transient dopamine concentration fluctuations in the nucleus accumbens (NAc) 
(Sombers et al, 2009) that increase following drug of abuse and potentiate a drug’s 
reinforcing properties (Covey et al, 2014).  NAc dopamine also encodes information 
about negative events, as overflow is suppressed during tail-pinch delivery (Park et al, 
2015) and aversive tastants decrease NAc dopamine transients (Roitman et al, 2008; 
Twining et al, 2015). Drug withdrawal is aversive, and although basal dopamine levels 
decrease during withdrawal (Pothos et al, 1991; Weiss et al, 1996), previous work does 
not address its effect on transient dopamine concentrations. Since increased and 
decreased dopamine signaling contribute to the addiction cycle (Koob et al, 2010), it is 
important to investigate adaptations in real-time.  
Although dopamine has been the main catecholamine studied in addiction, 
norepinephrine also mediates drug reward (Olson et al, 2006) and withdrawal-aversion 
(Delfs et al, 2000). Suppression of noradrenergic signaling blocks stress-induced 
reinstatement (Erb et al, 2000; Leri et al, 2002; Shaham et al, 2000), and clonidine 
treatment promotes heroin-abstinence in human addicts (Kowalczyk et al, 2015). In the 
allostasis model, drug withdrawal engages the extended amygdala to produce 
dysphoria and advance the addiction cycle (Koob et al, 2010). The bed nucleus of the 
stria terminalis (BNST) is an important relay in the extended amygdala and a target of 
norepinephrine’s actions in opiate intoxication/withdrawal (Aston-Jones et al, 1999). The 
ventral BNST receives dense innervation from the nucleus of the solitary tract (NTS) 
(Forray et al, 2004), the source of norepinephrine critical for morphine-reward (Olson et 
al, 2006) and withdrawal-aversion (Delfs et al, 2000). Chronic morphine increases basal 
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norepinephrine in the BNST (Fuentealba et al, 2000), however no work addresses 
phasic release. Moreover, stress-dependent adaptations in vBNST noradrenergic 
signaling arise following morphine-dependence (Fox et al, 2015; McElligott et al, 2013), 
yet the source of this plasticity is unknown.  
Many studies focus on chronic drug administration (Harris and Aston-Jones, 
1994; Hemby et al, 1995; Kaufling and Aston-Jones, 2015; Mazei-Robison and Nestler, 
2012), however it is unknown  how a single drug exposure paired with withdrawal 
influences catecholamine signaling to advance the addiction cycle. Since appetitive and 
aversive stimuli elicit opposing responses from catecholamines (Park et al, 2012; 
Roitman et al, 2008; Twining et al, 2015), we hypothesized dopamine and 
norepinephrine signal reciprocally during drug intoxication/withdrawal to prime the 
system for addiction. We used voltammetry to measure catecholamine release in freely 
moving animals exposed to morphine and naloxone-precipitated withdrawal. During 
drug exposure, dopamine signaling increased in the NAc but morphine did not elicit 
norepinephrine in the vBNST. Conversely, drug withdrawal produced vBNST 
norepinephrine release that coincided with specific withdrawal symptoms and 
suppressed NAc dopamine transients. Finally, vBNST norepinephrine, but not NAc 
dopamine, was attenuated after morphine/naloxone treatment. These data provide a 
real-time view of catecholamine signaling during exposure/withdrawal and lend insight 
to how catecholamine circuits become dysregulated during the development of 
addiction.  
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Materials and Methods 
Animal Care 
All experiments were performed in accordance with the Institutional Animal Care 
and Use Committee guidelines of the University of North Carolina at Chapel Hill (UNC). 
Sprague-Dawley rats (males, 270-350 g; Charles River, Wilmington, MA) were given 
food and water ad libitum and pair-housed in UNC animal facilities on a 12:12-hour 
light:dark cycle until surgery. We selected 6-7 animals per group, which is typical of 
voltammetric studies.  Animals with misplaced electrodes were excluded from the study, 
as well as animals that exhibited mixed pharmacological response (See Fig 4.7). A total 
of 14 animals were included for dopamine measurements (7 Morphine, 7 Vehicle), and 
26 for norepinephrine measurements (7 Morphine, 7 Vehicle, 6 Morphine +Idazoxan, 6 
Vehicle + Idazoxan). All measurements took place during the light cycle.  
Sterotaxic Surgery 
Animals were anesthetized with isofluorane (4% induction, 1.5% maintenance) 
and affixed in a stereotaxic frame (Kopf Instruments). The scalp was removed and holes 
were drilled to implant guide cannulas in the right hemisphere (BASi, West Lafayette, 
IN) above the NAc shell (AP: +1.7 mm, ML: 0.8 mm) or vBNST (AP: 0 mm, ML: 1.2 
mm), referenced from bregma and based on the atlas of Paxinos and Watson. An 
additional guide cannula was implanted in the left hemisphere for insertion of a Ag/AgCl 
reference electrode on the day of recording. A bipolar stimulating electrode (Plastics 
One, Roanoke, VA) was targeted to the right VTA/ventral noradrenergic bundle (VNB; 
AP -5.2mm, ML +1.0, DV 8.2 mm), and a dental cement skull-cap was secured with 
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jeweler’s screws. Animals were subsequently singly housed and allowed to recover for 
3-days before making measurements.  
Voltammetric Catecholamine Measurements 
Fast scan cyclic voltammetry (FSCV) measurements of dopamine and 
norepinephrine were performed in awake animals as described previously (Park et al, 
2013). Briefly, a fresh carbon-fiber electrode (~100 µm active length) was lowered into 
the NAc shell or vBNST through the guide cannula with a custom-built 
micromanipulator. A triangular waveform (-0.4 to +1.3V, 400V/s) was applied to the 
electrode every 100 ms to oxidize and reduce catecholamines using HDCV for data 
acquisition and analysis (Bucher et al, 2013). After electrode placement, we recorded 
baseline signaling for ~10 min before giving 10 mg/kg morphine sulfate s.c. (Sigma-
Aldrich, St. Louis, MO) or 1 mL/kg  vehicle (saline 0.9%). 4h later, we administered 1 
mg/kg naloxone HCl s.c. (Sigma-Aldrich) and scored animals for somatic indices of 
withdrawal (Schulteis et al, 1999) over 20 min. In a subset of animals, 5 mg/kg idazoxan 
was given with naloxone to enhance norepinephrine overflow. 1h after naloxone 
administration, animals were anesthetized with urethane (1.5 g/kg), and the VTA/VNB 
was electrically stimulated using constant current isolators (Neurologs, model NL800) to 
obtain voltammograms for principal component analysis (PCA)(Rodeberg et al, 2015). 
We extracted dopamine currents using PCA and converted current to concentration 
using an averaged in vitro calibration factor (10 nA/µM). Only dopamine transients >3 
times the noise in the traces obtained by PCA were considered to be dopamine 
transients, and we measured increased dopamine transient frequency during the first 
hour of morphine administration. In awake animals, voltammetric peaks for 
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norepinephrine release in the vBNST were broader than expected.  We suspect 
contribution from a noradrenergic metabolite during withdrawal because these features 
were mimicked in anesthetized rats with long stimulations and were eliminated following 
clorgyline.  For this reason, we do not report norepinephrine concentrations but rather 
report voltammetric currents. When applicable, an averaged in vitro calibration factor (6 
nA/µM) was used to convert norepinephrine current to concentration in anesthetized 
animals.  
vBNST Pharmacology 
At the end of awake-animal recordings, we confirmed that the signal in the 
vBNST was due to norepinephrine and not dopamine by measuring electrically-evoked 
release after 2 mg/kg s-(-)-raclopride tartrate (D2 antagonist, Sigma-Aldrich) and 5 
mg/kg idaxoxan HCl (α2 antagonist, Sigma Aldrich). Only signals that responded to 
idazoxan but not raclopride were classified as norepinephrine release. Signals with 
mixed pharmacological response were excluded as in Figure 4.7. In three separate 
anesthetized animals, we delivered long, lower frequency stimulations (30 Hz, 120 
pulses) to the VNB to mimic the signals recorded in awake animals undergoing 
withdrawal. After collecting baseline release, we administered the monoamine oxidase 
inhibitor, clorgyline (Sigma-Aldrich, 75 mg/kg i.p.) and measured narrowed oxidative 
peaks at +0.6V.      
Somatic Withdrawal Signs 
Behavioral correlates of opiate withdrawal were measured during the first 20 min 
of precipitated withdrawal and assigned a global withdrawal score as described 
previously (McElligott et al, 2013; Schulteis et al, 1999).  We manually assigned time-
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stamps to each behavior and looked for presence or absence of dopamine transients or 
norepinephrine overflow during the withdrawal signs. Somatic withdrawal signs were 
either considered absent, present, or present with catecholamine signaling.   
Statistics  
All statistical tests were performed in Graph Pad Prism. 2-way, repeated 
measures analysis of variance (RM-ANOVA) with Bonferroni post-hoc were used to 
assess differences in dopamine transient frequency and concentration under varying 
drug conditions. Unpaired, Welch’s corrected t-tests were used to determine significant 
differences between the number and magnitude of norepinephrine release events, due 
to significant differences in the variance between morphine- and vehicle-treated groups.  
Results 
Morphine-intoxication increases dopaminergic transmission in the nucleus accumbens 
Drugs of abuse increase dopaminergic transmission in the NAc (Bossong et al, 
2009; Cheer et al, 2007b; Di Chiara and Imperato, 1988; Phillips et al, 2003; Volkow et 
al, 2007), which contributes to their acutely reinforcing properties. We used a dose of 
morphine that, when paired with precipitated withdrawal, generates rapid dependence in 
rats (Schulteis et al, 1999). To confirm morphine’s effect on dopamine in the NAc of 
freely moving rats (Vander Weele et al, 2014), we used voltammetry to record 
dopamine transients in locations exhibiting spontaneous activity ( ~2 transients min-1; 
schematic of placement and time line in Fig 4.1A). We found that morphine increased 
spontaneous dopamine transient frequency in the NAc (MRP, 10 mg/kg s.c.) relative to 
saline (VEH, 1 mL/kg s.c.) (9.9 ± 1.5 vs. 2.1 ± 0.5 transients min-1, MRP vs. VEH, n=7, 
respectively, t=4.976, P=.0016, Fig 1D), but the average concentration per transient 
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was similar under both conditions (MRP: 77.3 ± 7 vs. VEH: 72.1 ± 7 nM, N=7, 
respectively, Fig 1E). 
Naloxone-precipitated withdrawal decreases dopaminergic transmission in the nucleus 
accumbens 
 
 We next examined the impact of drug withdrawal by administering naloxone 
(NAL, 1 mg/kg s.c.) 4h after initial morphine (Fox et al, 2015; McElligott et al, 2013; 
Schulteis et al, 1999). We recorded dopamine transients during the peak of somatic 
withdrawal signs and found decreased dopamine transient frequency in animals 
undergoing withdrawal relative to the initial treatment (MRP-NAL: 2.3 ± 0.5, VEH-NAL: 
1.1 ± 0.1 transients min-1, respectively, N=7, respectively, 2-way RM ANOVA; 
Treatment group x NAL Interaction F(1,12)= 22.60, P=0.0005; MRP treatment 
F(1,12)=23.06, P=0.0004, NAL treatment F(1,12)= 40.30, P<0.0001. Bonferroni post-
hoc, P<0.001). Moreover, dopamine transient concentrations decreased during 
withdrawal (MRP-NAL: 57.6± 4 vs. VEH-NAL: 71.9 ± 8 nM, N=7, respectively. 2-way 
RM ANOVA; Treatment group x NAL interaction F(1,12)= 9.667, P= 0.0090, NAL 
F(1,12)=10.3, P=0.0075, Bonferonni post-hoc, P<0.01), reflecting decreased 
dopaminergic output. To test for adaptations after precipitated withdrawal, we 
anesthetized the animals and electrically stimulated the VTA. We found equivalent 
evoked dopamine in MRP-NAL and VEH-NAL-treated animals (1.28 ± .37 vs. 0.96 ± 
0.31 µM  N=7, respectively,  t=0.6634, P= 0.5196), in agreement with previous findings 
of unchanged tissue content (McElligott et al, 2013). Similar to rewarding and aversive 
stimuli (Roitman et al, 2008), NAc dopamine signaling increased during morphine 
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intoxication and decreased during withdrawal; however, acute exposure/withdrawal was 
insufficient to elicit persistent adaptations. 
Morphine-withdrawal, but not intoxication, elicits norepinephrine in the ventral bed 
nucleus of the stria terminalis 
 
Norepinephrine’s role in drug addiction is often overshadowed by dopamine, 
despite evidence that morphine reward is contingent on brainstem norepinephrine 
synthesis (Olson et al, 2006). Moreover, opiate-withdrawal aversion requires forebrain 
norepinephrine (Delfs et al, 2000), and morphine-dependence alters noradrenergic 
synaptic function (Fox et al, 2015; McElligott et al, 2013). We thus measured 
norepinephrine release in the vBNST during morphine exposure and withdrawal 
(schematic in Fig 4.2A). Unlike dopamine, norepinephrine concentrations in the vBNST 
do not fluctuate spontaneously in animals at rest, and morphine did not elicit 
norepinephrine overflow in the vBNST despite receiving dense projections from the NTS 
(Fig 4.2B). However, we observed broad norepinephrine release events during 
naloxone-precipitated withdrawal (Fig 4.2B). Norepinephrine release persisted for tens 
of seconds, in contrast to brief (~1 sec) dopamine transients recorded in the NAc.  
Voltammetric peaks for norepinephrine were also broader than expected, and we 
suspect contribution from a noradrenergic metabolite during withdrawal (Fig 4.3). 
Naloxone elicited norepinephrine release in some vehicle-treated animals, and release 
amplitudes did not differ between groups (MRP-NAL: 1.1 ± 0.1 nA, N=21 events vs 
VEH-NAL: 1.7 ± 0.5 nA N=3 events, t=1.669, P=0.1093, Fig 4.4E). However, the 
occurrence of norepinephrine release events was greater in animals undergoing 
morphine withdrawal relative to vehicle (MRP-NAL: 3.0 ± 0.5 vs VEH-NAL: 0.4 ± 0.2 
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events per animal, N=7, respectively; t=4.5, P=0.0028, Fig 4.4D). We next assayed 
norepinephrine release evoked by electrical stimulation of the VNB  and found 
significant attenuation in animals following  withdrawal (0.047 ± 0.011 vs. 0.218 ± 0.053 
µM, N=7; t=3.115, P=0.0207, Fig 4.4F), aligning with tissue content findings (McElligott 
et al, 2013).  
Catecholamine signaling differs during expression of withdrawal-related behaviors 
Somatic withdrawal signs like teeth-chattering and eye-twitches are a hallmark of 
opiate withdrawal in rats (Schulteis et al, 1999). To determine if catecholamine overflow 
was associated with withdrawal symptoms, we recorded the timing of somatic indices 
and looked for concurrent dopamine or norepinephrine release.  Morphine withdrawal 
decreased the frequency of dopamine transients, and transients ‘paused’ during certain 
behaviors (e.g. swallowing-movements, Fig 4.5A) before resuming after termination of 
the withdrawal sign. Dopamine release did not pause during spontaneous 
erection/ejaculation/penile grooming (EEP) in animals exhibiting the behavior (Fig 4.4B, 
4.5C). Norepinephrine release occurred with swallowing movements (SM) and teeth-
chattering (TC) in all morphine-withdrawn animals (Example in Fig 4.4C, Fig 4.5B), and 
in one VEH-NAL animal. Importantly, naloxone treatment produced global withdrawal 
scores similar to our previous reports (Fox et al, 2015; McElligott et al, 2013), and 
scores were significantly higher in morphine-withdrawn animals (Fig 4.5A, 2-way 
ANOVA, Bonferroni Post-hoc: Main effect of MRP F(1,12) =57.65, P<0.0001. DA: MRP-
NAL, 5.7± 1.0 vs. VEH-NAL, 2.0 ±0.5; NE: MRP-NAL, 7.2 ± 0.5 vs. VEH-NAL, 1.0 ± 0.4 
N=7, respectively).  To further investigate the link between norepinephrine release and 
somatic withdrawal signs, we administered the α2 antagonist idazoxan with naloxone to 
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elicit additional norepinephrine overflow. Systemic α2 antagonism elicited 
norepinephrine in VEH-NAL animals, resembling MRP-NAL, and was accompanied by 
withdrawal-associated behaviors in the absence of morphine (Fig 4.6).  
Discussion 
These findings establish that a single exposure to morphine, followed by 
precipitated withdrawal, elicits distinct signaling in brain regions associated with the 
addiction cycle. Dopaminergic signaling increased in the NAc during intoxication and 
decreased during withdrawal, but the single exposure did not alter evoked dopamine. 
Conversely, only morphine withdrawal elicited norepinephrine release in the vBNST, but 
acute exposure and withdrawal attenuated stimulated release. Norepinephrine release 
tracked two withdrawal-associated behaviors and was induced without morphine by α2 
antagonism. The combination of decreased dopamine output and recruitment of 
noradrenergic signaling revealed in this work suggests the negative reinforcement 
model of addiction begins working after a single exposure.  
Drugs of abuse increase dopamine overflow in the NAc (Cheer et al, 2007b; 
Daberkow et al, 2013; Phillips et al, 2003), which helps drive their acutely reinforcing 
properties, and a recent study showed intravenous morphine administration produces 
similar efflux (Vander Weele et al, 2014). We gave morphine s.c. since i.v. catheters 
require rats to be singly housed and social-isolation produces a stress profile similar to 
morphine-addicted rats (Fox et al, 2015). We found dopamine transients increased in 
frequency for a much longer duration (>60 min) than in (Vander Weele et al, 2014). This 
could be due to differences in baseline stress, or might arise from the slower time-
course of drugs delivered s.c. compared with i.v. Regardless, both methods of morphine 
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administration increased dopamine overflow in the NAc, confirming its actions on the 
mesolimbic dopamine system. When animals underwent naloxone-precipitated 
withdrawal, dopamine transients appeared to ‘pause’ during somatic withdrawal signs, 
and decreased in both frequency and magnitude in the MRP/NAL treated group. This 
effect was not solely due to naloxone, because transient concentrations only decreased 
in animals exposed to morphine. Withdrawal symptoms were most apparent during 
pauses in dopamine transients. Consistent with this, activation of D2 receptors in the 
NAc attenuates withdrawal symptoms (Harris et al, 1994).   Additionally, the decrease in 
dopamine transients during naloxone aligns with studies on reduced basal dopamine 
concentrations during withdrawal (Pothos et al, 1991; Weiss et al, 1996). Decreased 
dopaminergic output supports the allostasis model (Koob et al, 2010)  and likely 
contributes to the withdrawal-induced negative affect.  
The role of norepinephrine in drug addiction is often overshadowed by that of 
dopamine (Weinshenker and Schroeder, 2006), despite evidence that brainstem 
norepinephrine synthesis is crucial for establishing morphine self-administration (Davis 
et al, 1975) and conditioned place preference (Olson et al, 2006). The vBNST receives 
dense noradrenergic projections from the nucleus of the solitary tract (NTS) (Forray et 
al, 2004), and thus is a likely downstream target for norepinephrine’s actions in 
morphine reward. Surprisingly, we did not detect norepinephrine release in the vBNST 
during morphine, although it is possible elevated norepinephrine in the BNST develops 
after chronic drug exposure (Fuentealba et al, 2000). Alternatively, the NTS projects to 
a number of brain regions, including the VTA and NAcsh, where it may regulate 
dopaminergic activity (Moore and Bloom, 1979) to drive reinforcement and reward. 
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BNST norepinephrine is traditionally implicated in the aversive aspects of opiate-
withdrawal (Aston-Jones et al, 1999), and its regulation of the hypothalamic-pituitary-
adrenal axis (Forray et al, 2004) positions it to integrate the stressful and negative 
aspects of drug addiction. Indeed, direct infusion of adrenergic antagonists into the 
BNST suppresses stress-induced reinstatement of drug seeking and conditioned place 
preference (Leri et al, 2002; Wang et al, 2001), and three days of morphine paired with 
withdrawal produces noradrenergic plasticity in the vBNST (McElligott et al, 2013). 
When we induced withdrawal with naloxone, we found robust norepinephrine release in 
the vBNST that coincided with somatic withdrawal behaviors. In particular, 
norepinephrine was linked with swallowing movements and the neurons responsible for 
this reflex are located in the NTS (Kessler and Jean, 1985).  In some vehicle-treated 
animals, norepinephrine was released after administration of naloxone. We believe this 
to be a result of removing endogenous opiate tone, as some withdrawal signs were also 
noted in VEH-NAL animals. Norepinephrine release in the VEH-NAL group could also 
arise due to injection stress, and the split population in control animal response could 
reflect differences in baseline stress-reactivity. Regardless, the occurrence of release 
events was much greater in animals undergoing withdrawal relative to control. 
Additionally, when the α2 antagonist idazoxan was given with naloxone, both 
norepinephrine overflow and withdrawal behaviors were elicited in the absence of 
morphine, highlighting its role in withdrawal-aversion. Interestingly, releasable 
norepinephrine concentrations were depleted after withdrawal, reflecting signaling 
adaptations after the first withdrawal episode. This effect is consistent with previous 
work showing reduced norepinephrine tissue content in the vBNST after repeated 
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morphine-withdrawal (McElligott et al, 2013). Overall, these data support links between 
norepinephrine overflow and withdrawal symptoms, and provide mechanistic insight for 
adrenergic receptor therapy in treating human addicts (Kowalczyk et al, 2015). 
Moreover, the norepinephrine release during withdrawal uncovered here is the likely 
source of adrenergic receptor plasticity in the vBNST (McElligott et al, 2013).  
Dopamine and norepinephrine exhibit opposing responses to rewarding and 
aversive stimuli. Oral infusion of an appetitive tastant produces enhanced dopamine 
(Park et al, 2012; Roitman et al, 2008), whereas aversive tastants attenuate dopamine 
release and increase norepinephrine signaling. This effect is also seen in animals 
undergoing reward learning and its extinction (Park et al, 2013), and during presentation 
of a painful stimulus (Park et al, 2015). Reciprocal catecholamine signaling has 
interesting implications in the context of the aversive stimulus of drug withdrawal, due to 
norepinephrine’s potential influence on dopaminergic signaling. Glutamatergic inputs 
from the vBNST exert strong excitatory influence over VTA dopamine neurons (Georges 
et al, 2002), and norepinephrine’s actions through α2A receptors decrease excitatory 
transmission in the vBNST (Egli et al, 2004). Thus, norepinephrine release during 
withdrawal may act through α2 receptors in the vBNST to suppress VTA activity and 
decrease dopaminergic output as a consequence. Indeed, activation of α2 receptors with 
clonidine suppresses dopamine concentrations in the NAc (Murai et al, 1998). In 
addition, norepinephrine causes GABAA inhibition of VTA-projecting BNST neurons 
(Dumont et al, 2004), which may serve as an additional source of reduced dopaminergic 
output via VTA inhibition. This is further supported by the decreased dopamine 
concentrations we found during withdrawal, but not after morphine treatment. When 
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animals underwent withdrawal, elevated norepinephrine concentrations in the vBNST 
may have suppressed VTA activity thereby reducing dopamine transient concentrations. 
This effect was relieved at the end of the treatment, and direct electrical stimulation of 
the VTA resulted in equivalent dopamine release regardless of an animal’s exposure to 
withdrawal, in agreement with tissue-content findings (McElligott et al, 2013). The 
reciprocal actions of dopamine and norepinephrine seen here during intoxication and 
withdrawal reflect important feedback between catecholamine circuits during rewarding 
and aversive stimuli. 
Overall, the increased dopaminergic signaling we observed during intoxication 
supports a rich literature on dopamine’s role in the rewarding properties of drugs. 
Additionally, the enhanced noradrenergic overflow concurrent with withdrawal signs 
underscores norepinephrine’s importance in mediating opiate-withdrawal aversion. The 
combination of decreased dopaminergic output and enhanced noradrenergic overflow 
revealed in this work supports the allostasis model, and suggest negative reinforcement 
may emerge after the first exposure. Taken together, this real-time view of reciprocal 
catecholamine signaling provides insight as to how catecholamine circuits in the ventral 
forebrain become dysregulated after drug exposure and withdrawal. These adaptations 
may converge with stress or other risk factors to drive the development of addiction in 
susceptible individuals, and how they progress longitudinally should be a topic of future 
investigations.   
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Figure 4.1. Dopamine efflux in the nucleus accumbens (NAc) varies with morphine 
intoxication and withdrawal. (A) Schematic of electrode placement and experimental 
timeline. (B) Representative dopamine (DA) transients at baseline, after morphine 
(MRP), and after naloxone (NAL). Principal component analysis identified 
concentrations marked with asterisks as DA transients. (C) Representative DA 
transients at baseline, after saline (VEH), and after NAL. (D) Transient frequency and 
(E) average DA transient concentration under MRP or VEH and subsequent NAL. 
Average frequency and concentration of dopamine transients at baseline are indicated 
by the gray dashed lines (F) Representative evoked [DA] in MRP or VEH-treated 
animals. Inset shows data from all subjects. Bar graphs show average ±SEM with 
individual subjects overlaid. **, P<0.01,   ***, P<0.001, 2-way RM ANOVA, Bonferroni 
post-hoc.   
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Figure 4.3: MAO-inhibitor clorgyline suppresses oxidative current accompanying 
norepinephrine release. (a) A 30 Hz, 120 pulse electrical stimulation (red bar) elicits 
norepinephrine release accompanied by positive current at ~+0.4V (asterisk). (b) 
Inhibition of monoamine oxidase with clorgyline (75 mg/kg i.p.) attenuates the current at 
~+0.4V, suggesting oxidative current at this potential is due to a catecholamine 
metabolite. 
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Figure 4.2: Naloxone-precipitated withdrawal produces norepinephrine overflow in 
the ventral bed nucleus of the stria terminalis (vBNST). (A) Schematic of electrode 
placement. (B-C) Representative norepinephrine (NE) response under morphine 
(MRP)/saline (VEH) then naloxone (NAL). NE current is isolated from 
corresponding color plots using principal component analysis. Asterisk suggests 
oxidation of metabolite. (D) Total NE release events during MRP/VEH and 
subsequent NAL.  (E) Release amplitude during withdrawal in MRP/VEH-treated 
animals. (F) Representative evoked NE after withdrawal in MRP/VEH-NAL treated 
animals. Data from all subjects inset. (G) NE release amplitude following idazoxan 
(+IDA) treatment in MRP/VEH-NAL treated animals. Bars are average ±SEM with 
individual events overlaid. *, P<0.05, **, P<0.01, Welch’s corrected unpaired t-test.  
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Figure 4.4: Somatic withdrawal signs produce variable catecholamine release in the 
nucleus accumbens and ventral bed nucleus of the stria terminalis. (A-B) Dopamine 
transients pause during swallowing movements (SM) and occur during spontaneous 
erection/ejaculation/penile grooming (EEP). Asterisks denote dopamine transients 
extracted with PCA from the corresponding color plot. (C-D) Norepinephrine release 
occurs during SM and teeth chattering (TC) and is absent during EEP as extracted from 
the corresponding color plot. Red bars beneath color plots denote duration of 
withdrawal behaviors. 
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Figure 4.5: Catecholamine signaling coincides with specific withdrawal behaviors. (A) 
Global withdrawal score in morphine-naloxone (MRP, blue/green) or vehicle-naloxone 
(VEH, white) treated animals. Average ±SEM with individual subjects overlaid. ***, 
P<0.0001. (B) Heat map illustrating withdrawal signs coinciding with norepinephrine 
signaling in individual subjects. Light blue, sign present; dark blue, sign occurs with 
norepinephrine overflow; white, sign absent.  (C) Heat map illustrating withdrawal signs 
coinciding with dopamine signaling. Yellow, sign present; green, sign occurs with 
dopamine transients; white, sign absent. Abbreviations: EB, excessive eye blinks; PT, 
ptosis; SM, swallowing movements; TC, teeth-chattering; DIA, diarrhea; WDS, wet dog 
shakes; EEP, spontaneous erection/ejaculation/penile grooming.  
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Figure 4.6: Idazoxan enhances naloxone-precipitated withdrawal signs. (A) Heat map 
illustrating withdrawal signs in individual subjects that coincide with norepinephrine 
signaling. Light blue indicates presence of sign, dark blue indicates presence occurring 
simultaneously with norepinephrine overflow, white indicates absence of sign. 
Abbreviations: EB, excessive eye blinks; PT, ptosis; SM, swallowing movements; TC, 
teeth-chattering; DIA, diarrhea; WDS, wet dog shakes; EEP, spontaneous 
erection/ejaculation and penile grooming. (B) Global withdrawal score in morphine or 
vehicle-treated animals given 5 mg/kg idazoxan in conjunction with naloxone.  
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Figure 4.7: Mixed catecholamine recording locations respond to dopamine and 
norepinephrine drugs. Representative location of electrically evoked catecholamine 
release under baseline, 2 mg/kg raclopride, and 5 mg/kg idazoxan. Signals that 
responded in this way were excluded from analysis.  
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CHAPTER 5: CROSS HEMISPHERIC DOPAMINE PROJECTIONS HAVE 
FUNCTIONAL SIGNIFICANCE3 
 
Introduction  
Dopamine neurotransmission modulates arousal and motivation, and is important 
in expressing reward-seeking behavior. Dopamine is released on a subsecond 
timescale during unexpected reward (Sugam et al, 2012; Wassum et al, 2012), and 
becomes time-locked to cues that predict reward (Day et al, 2007; Owesson-White et al, 
2008; Phillips et al, 2003; Roitman et al, 2004; Saddoris et al, 2015a). Dopamine 
transients in the nucleus accumbens (NAc) occur as a result of cell-firing in the ventral 
tegmental area (VTA) (Cacciapaglia et al, 2011; Sombers et al, 2009), and reach 
concentrations of 50-200 nM in rats before returning to baseline (Robinson et al, 2002; 
Wightman et al, 2007). Striatal dopamine transients also occur spontaneously during 
periods of rest (Robinson et al, 2002; Wightman et al, 2007), reflecting endogenous 
dopamine modulation. The magnitude and frequency of dopamine transients increases 
following drugs of abuse (Cheer et al, 2007b; Stuber et al, 2005), which is thought to 
contribute to their reinforcing properties (Covey et al, 2014). Although numerous studies 
                                                          
3 This chapter originally appeared as an article in Proceedings of the National Academy of 
Sciences of the United States of America. The original citation is as follows: Fox, ME; 
Mikhailova, MA; Bass, CE; Takmakov, P; Gainetdinov, RR; Budygin, EA; Wightman, RM. 
(2016). “Cross-hemispheric dopamine projections have functional significance.” Proc Natl Acad 
Sci U S A: In press  
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have summarized the function of dopamine circuits in reward-based behaviors (Berridge 
and Robinson, 1998; Schultz, 2015) and motor control (Baik et al, 1995; Costa et al, 
2006; Crocker, 1997), anatomical descriptions of dopamine projections are conflicting 
(Andén NE, 1966; Geisler and Zahm, 2005; Jaeger et al, 1983; Nauta et al, 1978). 
Recent evidence suggests some dopamine neurons project contralateral to their origin 
(Geisler et al, 2005; Jaeger et al, 1983), contradictory to the uncrossed dopamine 
system described previously (Andén NE, 1966; Nauta et al, 1978). To date, the 
significance of contralaterally projecting dopamine neurons has not been established, 
nor how they may contribute to cross-hemispheric signaling. 
A potential role for contralateral dopamine projections emerged in a recent study 
on brain stimulation reward (Steinberg et al, 2014). When rats were trained to self-
stimulate the VTA, infusion of dopamine receptor antagonists in the NAc suppressed 
stimulation. This effect was seen whether the infusion was contralateral or ipsilateral to 
the stimulation site, reflecting cross-hemispheric modulation of the behavior. 
Furthermore, following unilateral stimulation, c-Fos was elevated in both hemispheres. 
Since this study did not examine dopamine release from VTA stimulations, the 
functional influence of contralateral projections could not be confirmed. Contralateral 
projections may also play a role in the neural adaptations in Parkinson’s disease, which 
is characterized by a loss of midbrain dopamine. A hemiparkinsonian state can be 
modeled with unilateral 6-hydroxydopamine (6-OHDA) lesions, and recent studies 
describe alteration of synaptic signaling following dopamine depletion (Capper-Loup 
and Kaelin-Lang, 2013; Day et al, 2006; Fieblinger et al, 2014; Gerfen, 2000; Thiele et 
al, 2014). If contralateral dopamine projections have functional significance, dopamine 
113 
 
arising from these intact projections may influence signaling in the lesioned hemisphere 
(Nieoullon et al, 1977). Understanding the influence of contralateral projections may 
afford new ways to implement therapies such as deep brain stimulation for Parkinson’s 
disease. 
In this study, we demonstrate that contralaterally projecting dopamine neurons 
are functional and influence cross-hemispheric striatal signaling. We measured 
spontaneous and stimulated dopamine release in rats with fast-scan cyclic voltammetry 
(FSCV). In freely moving rats, we found spontaneous synchronous dopamine release in 
both hemispheres that further synchronized following amphetamine. We show that 
electrical or optogenetic stimulation of dopamine neurons elicits physiologically relevant 
dopamine release in the contralateral NAc and dorsomedial striatum (DMS). Using 
pharmacology, we discovered dopamine projections are differentially regulated by D2 
receptors. We also extend these findings into 6-OHDA lesioned animals and 
characterize functional adaptations following unilateral depletion.  
Materials and Methods 
Animal Care 
Experiments were performed in accordance with the Institutional Animal Care 
and Use Committee guidelines of the University of North Carolina at Chapel Hill (UNC) 
and Wake Forest School of Medicine. Sprague-Dawley rats (males, 270-400 g; Charles 
River, Wilmington, MA) were given food and water ad libitum and pair-housed in UNC or 
Wake Forest animal facilities on a 12:12-hour light:dark cycle. All experiments took 
place during the light cycle. To reduce number of animals and suffering, we limited 
awake measurements to 3 per treatment group, sufficient to demonstrate the effect in 
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every animal. For anesthetized experiments, we selected 5-10 animals, typical of 
voltammetric studies. In total, 3 animals were used for bilateral transient measurements, 
20 for 6-OHDA studies, 53 for mapping/pharmacology, and 10 for optogenetic 
experiments.  
Spontaneous dopamine measurements 
Rats were anesthetized with isofluorane (4% induction, 1.5% maintenance) and 
affixed in a stereotaxic frame. The scalp was removed and holes were drilled to implant 
guide cannulas (BASi, West Lafayette, IN) bilaterally in the NAc (AP +1.3 mm, ML ±2.1 
mm, ±10º to the perpendicular).  A bipolar stimulating electrode (Plastics One, Roanoke, 
VA) was implanted in the right ventral tegmental area (AP -5.2mm, ML +1.0 mm, DV -
8.5 mm). A third cannula was implanted in the left hemisphere for inserting a Ag/AgCl 
reference electrode on the day of recording. Cannulas were secured with dental cement 
and jewelers screws. Rats were subsequently singly housed and allowed to recover. 
After 3 days of recovery, carbon-fiber microelectrodes were lowered bilaterally into the 
NAc of awake animals through microdrives. Voltammetric measurements of 
spontaneous dopamine transients were as described previously (Bass et al, 2013; 
Saddoris et al, 2015a) using HDCV. A triangular scan (-0.4 to +1.3V, 400 V/s) was 
applied to the working electrode every 100 ms to detect changes in dopamine 
concentration. Spontaneous dopamine efflux was measured for 30 min after saline 
(VEH, 1 mL/kg, i.p.), and 30 min after d-amphetamine (AMPH, 2.5mg/kg, i.p., Sigma-
Aldrich, St Louis, MO). Animals were then anesthetized (urethane,1.5 g/kg) and VTA 
stimulations were delivered to construct voltammograms for principle component 
analysis using an in vitro calibration factor (10 nA/µM) (Rodeberg et al, 2015). Only 
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transients >3 times the standard deviation of the noise in dopamine traces obtained by 
principle component regression were considered spontaneous dopamine.  
Spontaneous dopamine measurements-hemispheric synchrony 
Dopamine concentrations were extracted from color plots using principle 
component analysis as described above. We used a headstage that allows for 
simultaneous measurements at two electrodes, and thus aligned dopamine transient 
concentrations with respect to recording time at both electrodes. Dopamine transients 
were considered synchronous if their peaks occurred at the same time (e.g., t=127 s) 
and asynchronous if they did not occur at the same time (e.g., t=97 s, t=100 s).   
Lidocaine infusions 
Treatment-naïve rats were anesthetized with urethane (1.5g/kg), affixed in a 
stereotaxic frame, and holes were drilled in the NAc, DMS, VTA, and SN as above. A 
carbon-fiber electrode was lowered into the right DMS or NAc. A cannulated stimulating 
electrode (Plastics-One) was lowered into either the right SN (-7.8mm DV) or right VTA 
(-8.4 mm) and secured with dental cement. A second stimulating electrode was lowered 
into the left SN or VTA. Electrical stimulations were delivered every 2 min with 
Neurologs, alternating between contralateral and ipsilateral SN/VTA to establish 
baseline release.  Lidocaine was subsequently delivered to the ipsilateral SN/VTA (350 
nmol/0.5µL) and evoked dopamine was compared with baseline release over 40 min.  
Stereotaxic virus infusion  
Briefly, male Sprague-Dawley rats were anesthetized with ketamine HCl (100 
mg/kg, i.p. and xylazine HCl, 20 mg/kg, i.p.) and affixed in a stereotaxic frame. The 
scalp was removed and a small hole was drilled above the right SN (from bregma, AP -
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5.8 mm, ML, 2.0 mm) or right VTA (AP -5.8 mm, ML 0.7 mm) and an optic-fluid cannula 
(Doric Lenses, Canada) was implanted (DV -7.3 mm). 1.3 μL of pseudotyped AAV2/10 
virus was slowly injected over 3 min via a Hamilton syringe connected to the optic-fluid 
cannula. We used a previously characterized combinatorial targeting system, in which a 
Cre dependent ChR2 (EF1α-DIO-ChR2-EYFP) is co-infused with a tyrosine hydroxylase 
(TH) promoter-Cre-AAV, resulting in ChR2 expression only in TH+ neurons. A dental-
cement skull cap was secured over the exposed skull using jeweler’s screws.  
Optogenetic stimulations  
Optical stimulations (60Hz, 60 p, 4ms width) were delivered to transduced cells 
from a 473 nm laser (Beijing Viasho Technology Co., Ltd, Beijing, China), controlled 
using TTL pulses generated by a programmable function generator (Hewlett-Packard 
model 8116A). Average laser power output delivered by the optical fiber was 2.3 mW, 
measured using a commercial power meter (Newport Model 1815C).  
Immunohistochemistry  
Animals were deeply anesthetized with isoflurane and then transcardially 
perfused with 50 ml saline followed by 500 ml of 10% formalin. The brains were 
removed, postfixed for 2 h in 10% formalin, and then cryoprotected in 20% sucrose in 
PBS containing azide overnight. The brains were sectioned on a sliding microtome at 40 
μm. Tissue sections were incubated with a 1% H2O2 phosphate buffered saline-
Tween20 (PBST) solution for 30 min, rinsed three times with PBS, and incubated with a 
rabbit anti-GFP antibody (1:20,000, Invitrogen, catalog no. A6455) overnight at room 
temperature. Sections were rinsed three times with PBS and incubated with biotin-SP-
conjugated AffiniPure Donkey anti-Rabbit IgG (H+L) (1:1000, Jackson 
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ImmunoResearch Labs, cat. no. 711-065-152) for 1 hr. After three more rinses the 
sections were incubated with ABC reagent (Vectorlabs cat. no. PK-6100) and stained 
with diaminobenzidine (DAB, Sigma). Sections were then mounted and coverslipped 
with Permount. Images were collected on an Apiero slide scanner. 
Mapping contralateral dopamine release 
Treatment-naive rats were anesthetized with urethane (1.5 g/kg), affixed in a 
stereotaxic frame, and the scalp removed. Holes were drilled for working (NAc: AP + 1.3 
mm, ML +1.3 mm; DMS: AP +1.2 mm, ML +2.0 mm) and stimulating (VTA: AP -5.2, 
ML±1.0 mm; SN: AP -5.8 mm, ML ±2.0 mm; PPTg: AP-7.8mm, ML ± 2.0mm) 
electrodes. A bipolar stimulating electrode (Plastics One) was placed at a constant 
depth contralateral to the working electrode (VTA: -8.4 mm DV, SN: -7.8 mm DV) while 
a carbon-fiber microelectrode was lowered ventrally through the striatum in 200 μm 
increments to map release.  
300 µA electrical stimulations (60Hz, 1s) were applied with Neurologs (NL800). 
Once maximal dopamine release was attained at the working electrode, the stimulating 
electrode was adjusted ventrally by 200 µm intervals to map the effect of stimulation 
location on release. The stimulating electrode was removed from the contralateral and 
lowered ventrally through the ipsilateral hemisphere. In a subset of animals (5 DMS, 5 
NAc), 10 Hz stimulations were delivered to the contralateral SN/VTA. We also examined 
dopamine release in the dorsolateral striatum (AP +0.5 mm, ML +3.5 mm, N=5), and as 
evoked by PPTg stimulations (AP -7.8, ML ± 2.0mm, N=5).  
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6-hydroxydopamine lesions 
Rats were anesthetized with isofluorane and affixed in a stereotaxic frame. The 
scalp was removed and a hole for a bipolar, cannulated stimulating electrode (Plastics-
One) was lowered into the right SN (AP -5.8 mm, ML +2.0 mm, DV -7.8 mm) and 
secured with dental cement. 3 μL of 10 mM 6-hydroxydopamine hydrobromide/ 0.01% 
w/v ascorbic acid (Sigma-Aldrich) in sterile saline (0.9%), or saline (sham-lesioned) was 
administered through the cannula at a rate of 1 μL/min. The infusion needle (33 ga, 10 
mm long) was left in place for 10 min to minimize spread up the tract   Rats recovered 
from 6-OHDA lesions for 2-weeks before being placed in a clear plastic bowl (30 cm 
diameter, 20 cm high) and videotaped for spontaneous rotational behavior after 2.5 
mg/kg AMPH. 3-days after scoring rotations, rats were anesthetized (urethane, 1.5 g/kg) 
and a second stimulating electrode was placed in the left SN (AP -5.8, ML -2.0, DV -7.8 
mm). A carbon-fiber electrode was lowered into the right DMS (AP +1.2, ML +2.0, DV -
4.0 to -6.2 mm) in 200 µm intervals. A Ag/AgCl reference electrode was placed 
contralateral to the working electrode. Dopamine release was evoked using 1s, 300 µA 
stimulation pulses applied at 60 Hz using constant current isolators (Neurolog, NL800) 
and compared between hemispheres. In a subset of animals, a carbon-fiber electrode 
was lowered in the DMS of freely moving animals (DV -6.0 mm). Spontaneous 
dopamine transients were recorded after vehicle (1mL/kg saline) and AMPH (2.5 
mg/kg). Animals were then anesthetized (urethane, 1.5 mg/kg) and electrical 
stimulations were delivered to treated and contralateral SN to confirm lesion efficacy. 
Spontaneous Rotational Behavior  
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Rats were habituated to the chamber for 10 min before given 1 mL/kg saline i.p.  
A rotation was defined as four consecutive 90º turns in the same direction and summed 
over a 60 min trial. Subsequently, 2.5 mg/kg d-amphetamine (Sigma-Aldrich) was 
administered i.p. and rotations were measured for an additional 60 min.  The number of 
rotations contralateral to the lesion (i.e., counter-clockwise) was subtracted from the 
number of rotations ipsilateral to the lesion (i.e., clock-wise) and plotted as net-rotations 
over the 1 hr recording period. Videos were scored after the trials by an experimenter 
blind to the treatment.    
Pharmacology 
Baseline release was recorded for 20 min by repeating 1 s electrical stimulations 
every 2 min. Release was monitored for 30 min after D2 receptor antagonisism (s-(-)-
raclopride HCl, 2 mg/kg i.p., Sigma-Aldrich), and 30 min after subsequent dopamine 
transporter inhibition (GBR-12909, 15 mg/kg i.p.,Sigma-Aldrich).  
Histology 
At the end of FSCV experiments, a constant current (20 μA,10 s) was applied to 
the carbon fiber to mark the electrode recording location. In most 6-OHDA animals, 3 μL 
of 2% Chicago sky blue was infused through the cannulated stimulating electrode to 
mark the lesion boundaries. Brains were removed and fixed in 10% formalin for >24 hr. 
50 μm sections were taken on a cryostat (Leica, Germany) and viewed under a light 
microscope to identify electrode placements. In two 6-OHDA lesioned animals, we 
stained for tyrosine hydroxylase in 40µm sections using Rabbit anti TH (1:500, Fisher) 
and Goat anti rabbit IgG-Alexa 514 (1:500, Invitrogen). Sections were incubated with 
anti-TH for 18hr at 4º after 2 hr incubation in 10% normal goat serum/ 0.3% triton x-100 
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blocking solution. Sections were washed in PBS, and then incubated in anti-rabbit IgG-
Alexa 514 for 2 hr in 2% bovine serum albumin at room temperature. Sections were 
rinsed with PBS before being mounted, dried, and coverslipped, then imaged with an 
Olympus FV1000 microscope.   
Statistics 
Statistical analysis was performed using Graph Pad Prism and no data were 
removed. Mainly one-way ANOVAs with Bonferroni post-hoc determined significant 
differences between groups. A two-way repeated-measures ANOVA determined 
significant increases in dopamine transients and ipsilateral rotations after amphetamine. 
A two-tailed, unpaired T-test determined differences in raclopride response between 6-
OHDA and sham lesioned animals.  
Results  
Spontaneous dopamine transients synchronize in the NAc. 
FSCV has been used to measure dopamine fluctuations in a number of studies; 
however, all awake-animal measurements have been restricted to a single hemisphere 
(Cacciapaglia et al, 2011; Cheer et al, 2007b; Daberkow et al, 2013; Day et al, 2007; 
Hamid et al, 2016; Howe et al, 2013; Owesson-White et al, 2008; Phillips et al, 2003; 
Robinson et al, 2002; Roitman et al, 2004; Saddoris et al, 2015a; Sombers et al, 2009; 
Stuber et al, 2005; Sugam et al, 2012; Syed et al, 2016; Wassum et al, 2012; Wheeler 
et al, 2015; Wightman et al, 2007). To investigate connectivity between hemispheres, 
we measured dopamine transients bilaterally in the NAc of freely moving rats. We 
recorded from dual carbon-fiber electrodes, as previously employed in anesthetized 
animals (Park et al, 2011). We targeted guide cannulas over the NAc (Fig 5.1a) and 
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optimized recording locations for spontaneous dopamine release (Fig 5.1c-d). We found 
dopamine transients of similar magnitudes (L: 92.1 ± 5.23 nM, R: 96.4 ± 5.92 nM, Fig 
5.1e) and frequency (L: 8.5 ± 1.6, R: 7.7 ± 0.6, transients min-1, Fig 5.1f) in both 
hemispheres. Interestingly, 74 ± 5.3 % of dopamine transients occurred simultaneously 
between hemispheres in animals at rest (Fig 5.1g). We next administered d-
amphetamine (AMPH, 2.5 mg/kg, i.p.) and transient magnitude increased in both 
hemispheres (L: 157.2 ± 30.6 nM, R 184.3 ± 39.2 nM, 2-way RM ANOVA, effect of 
AMPH, F(1,4)=11.3, P<0.05, Fig 5.1e). Following AMPH, all dopamine transients 
synchronized and increased in frequency (15.9 ± 2.0 transients min-1, 2-way RM 
ANOVA, effect of AMPH, F(1,4)=13.7, P<0.05, Fig 5.1f-g). When animals were 
anesthetized and the VTA stimulated unilaterally, we measured dopamine at both 
electrodes (Fig 5.1b). 
Stimulation of dopamine neurons elicits release in the contralateral hemisphere.  
Given that electrical stimulation of the VTA resulted in dopamine in both 
hemispheres, we characterized contralaterally evoked release to ascertain if it was 
restricted to the NAc and if it contributed to coupled dopamine transients. We implanted 
a carbon-fiber electrode into either the NAc or DMS (schematics in Fig 5.2a,d) of 
anesthetized rats and lowered it ventrally through the striatum with the stimulating 
electrode in the contralateral VTA (8.8 mm DV) or substantia nigra (SN, 7.6 mm DV). 
We found multiple locations that supported release (examples in Fig 5.2b,e). In the NAc, 
contralateral dopamine release peaked (DA]con/[DAcon-max) in the core (6.4 mm DV) and 
in the shell (7.4 mm DV, Fig 5.2c). In the DMS, maximal dopamine release elicited by 
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contralateral SN stimulations was restricted to a smaller range (6.2-6.4 mm, DV, Fig 
5.2f).  
We examined interhemispheric differences using within-animal comparisons of 
dopamine evoked contralateral vs. ipsilateral to the stimulation site (schematic in Fig 
5.3a,c). With the recording electrode at a constant depth, (NAc: 7.4 mm DV, DMS: 6.2 
mm DV) maximal release was achieved by stimulating similar VTA or SN depths in both 
hemispheres. Notably, in the NAc, ipsilateral stimulation elicited ~20x more dopamine 
release than contralateral (8.8 mm DV, Fig 5.3a). In contrast, ipsilateral and 
contralateral SN stimulations evoked dopamine release of equal magnitude in the DMS 
(7.6 mm DV, Fig 5.3c). We obtained similar release in the DMS by stimulating 
contralateral and ipsilateral peduncolopontine tegmental nucleus (PPTg), an excitatory 
input to the SN (Fig 5.4). Recording in the dorsolateral striatum revealed equal release 
was unique to the DMS (Fig 5.5).Additionally, contralateral release was not due to 
electrical spread to the ipsilateral hemisphere, as lidocaine infusions in the ipsilateral 
SN/VTA did not affect release evoked by contralateral stimulation (Fig 5.6). 
We confirmed the origin of contralateral release using optogenetics to activate 
only dopaminergic neurons. We drove unilateral channelrhodopsin-2 (ChR2) expression 
in dopamine neurons using a tyrosine hydroxylase promoter (Bass et al, 2013; Gompf et 
al, 2015). Light stimulations of the VTA elicited dopamine release in the contralateral 
NAc roughly equivalent to electrical stimulations (Examples in Fig 5.3b). We found 
similar release in the DMS following stimulations of the contralateral SN (Examples in 
Fig 3d). ChR2 expression was confirmed in the contralateral striatum and was not due 
to viral spread between hemispheres (Fig 5.7, 5.8). 
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Contralateral dopamine release is differentially regulated  
To investigate the differences in dopamine released from contralateral and 
ipsilateral projections, we administered D2 antagonist raclopride (RAC; 2 mg/kg, i.p.) 
and dopamine transporter inhibitor GBR-12909 (GBR; 15 mg/kg, i.p.) and measured 
their effects on evoked dopamine.There were no differences in D2-like regulation 
between contralateral and ipsilateral projections to the DMS (Fig 5.9a). In contrast, D2 
autoreceptors in the NAc exerted more control over dopamine release from contralateral 
compared to ipsilateral projections, evidenced by a much larger RAC response on the 
contralateral side (525 ± 135.3% vs 204 ± 26.5%, n=7, respectively, F(3,22) =4.9, P<0.05, 
Fig 5.9b). Thus, enhanced regulation by D2 may account for the discrepancy in 
dopamine concentrations evoked in ipsilateral and contralateral NAc. We also found an 
increased response to GBR in the DMS following contralateral SN stimulation relative to 
ipsilateral (1260 ± 301% vs 694 ± 199%, n=7, respectively, F(3,26)=5.7, P<0.05), but not 
NAc (Fig 5.9a-b). To exclude the effects of supraphysiological stimulation frequency on 
dopamine release, we delivered 10 Hz stimulations to the contralateral VTA and SN, 
resulting in small, physiologically relevant concentrations (Fig 5.10). 
Contralateral release is not solely compensatory 
Parkinson’s disease is often modeled with unilateral 6-OHDA lesions. Although 
small dopamine concentrations remain in lesioned animals (Zigmond et al, 1992), the 
extent to which contralateral projections compensate for depletion is unknown. Since 
the DMS exhibited hemispherically equivalent release, we chose it as a site to monitor 
changes in contralateral dopamine release after depletion. We used unilateral 6-OHDA 
lesions of the SN and recorded dopamine in the lesioned hemisphere. Two-weeks after 
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treatment, we validated the lesion by measuring ipsilaterally biased rotations after 
AMPH (2.5 mg/kg, Fig 5b. RM 2-way ANOVA, effect of 6-OHDA treatment F(1,12)=38.32; 
effect of AMPH F(1,12)=49.55, P<0.001). After 3-days, animals were anesthetized and we 
recorded dopamine in the DMS ipsilateral to the lesion. Stimulations were delivered to 
ipsilateral (lesioned) and contralateral SN (Fig 5.11a, examples in Fig 5.11c). Ipsilateral 
dopamine efflux was ablated following lesioned SN stimulation relative to controls (0.03 
± 0.007 µM vs 0.15± 0.024 µM, n=7, respectively, F(3,24)=8.3, P<0.001, Fig 5.11d). 
Stimulation of the contralateral/untreated SN resulted in dopamine release in the same 
recording location (Fig 5.11d). Surprisingly, lesioned and control animals showed no 
differences in dopamine release following contralateral SN stimulation, suggesting that 
contralateral projections in 6-OHDA treated rats do not compensate via increased 
release (Fig 5d, 0.10 ± 0.01 µM vs. 0.12 ± 0.02 µM, n=7, respectively P>0.05, Fig 
5.11d).  
Dopamine denervation drives homeostatic changes in striatal signaling (Zigmond 
et al, 1990), such as increased D2 expression in indirect pathway neurons (Gerfen, 
2000). To test for D2-like adaptations in intact contralateral projections after unilateral 
dopamine depletion, we measured the effect of D2 antagonist RAC (2mg/kg i.p.) on 
release in the lesioned DMS. RAC produced a larger increase in contralaterally evoked 
dopamine in lesioned relative to control animals (674 ±98.3% vs 401±79.9%, n=7, 
respectively, t(13)=2.2, P<0.05), confirming adaptations after dopamine depletion.  
Finally, we measured spontaneous dopamine efflux in awake animals two-weeks 
after unilateral 6-OHDA. We found spontaneous dopamine transients in the DMS of 
sham-lesioned animals that increased following AMPH (Fig 5.11e) in agreement with 
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previous studies (Daberkow et al, 2013). In 6-OHDA lesioned animals, spontaneous 
dopamine transients in the DMS ipsilateral to the SN lesion were not present under 
vehicle, but elicited by AMPH (Fig 5.11f). Thus, AMPH-induced dopamine release 
appears to arise from intact contralateral projections in unilaterally lesioned animals.  
Discussion  
These studies reveal previously undescribed interhemispheric communication in 
the mesencephalic dopamine system of rats. First, we found that optogenetic and 
electrical stimulation of dopamine cells elicited physiologically relevant release in the 
contralateral striatum. Contralateral projections from the VTA released less dopamine in 
the NAc and were more tightly controlled by D2 autoreceptors compared to ipsilateral 
projections. In contrast, dopamine release in the DMS was equivalent following 
contralateral or ipsilateral SN stimulation and accompanied similar D2 control in both 
hemispheres. Next, we found that ~75% of spontaneous NAc dopamine transients 
synchronized between hemispheres in freely moving rats, which increased to 100% 
following amphetamine. Finally, we showed that contralateral projections from SN 
neurons are functional in the hemiparkinsonian state, but do not compensate with 
increased dopamine release. Instead, D2 control on contralateral projections is 
increased after unilateral 6-OHDA. Contralateral SN projections can be stimulated with 
AMPH to evoke dopamine transients in the lesioned striatum of awake animals. These 
results establish for the first time that transient dopamine concentrations are 
synchronous between hemispheres, and that the dopamine system has functional 
contralateral projections with implications for interhemispheric adaptations in 
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Parkinson’s disease. Furthermore, the data indicate that psychostimulants such as 
AMPH play a role in coupling dopamine transients between hemispheres. 
Anatomical studies describe ~5% of midbrain dopamine neurons as projecting 
contralaterally to their origin (Geisler et al, 2005; Jaeger et al, 1983). In agreement with 
this, we measured smaller dopamine concentrations in the NAc following contralateral 
VTA stimulation compared to ipsilateral (Fig 5.3a). Interestingly, dopamine release from 
contralateral VTA neurons was more regulated by D2 autoreceptors. Dopamine 
released from ipsilateral projections may occupy D2 receptors on terminals from the 
contralateral hemisphere, attenuating release from contralateral VTA. Under intense 
stimulation, or when regulation mechanisms are disrupted, dopamine can be released 
from these fibers. Consistent with this, dopamine receptor antagonism in the 
contralateral NAc suppressed intra-VTA self-stimulation in the ipsilateral hemisphere 
(Steinberg et al, 2014), corroborating cross-hemispheric functionality and providing 
behavioral significance.  
Surprisingly, when we placed our recording electrode in the DMS and stimulated 
contralateral or ipsilateral SN, we found similar release amplitudes regardless of 
stimulated hemisphere (Fig 5.3c). This property was unique to the DMS, as the evoked 
dopamine ratio in the dorsolateral striatum was more similar to the NAc (Fig 5.5). 
Similar D2 regulation in both hemispheres accompanied hemispherically equivalent 
release in the contralateral DMS, in contrast to D2 regulation of contralateral/ipsilateral 
VTA projections. Since our findings were confirmed using optogenetics, contralateral 
dopamine release is driven by dopamine neurons. However, optical activation does not 
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preclude the effects of glutamate co-release (Zhang et al, 2015), which may facilitate 
hemispherically equivalent release. 
Dopamine transients increase following administration of drugs of abuse (Cheer 
et al, 2007b), and this appears to mediate their reinforcing properties (Covey et al, 
2014). Dopamine transients have been studied extensively, (Cacciapaglia et al, 2011; 
Cheer et al, 2007b; Daberkow et al, 2013; Day et al, 2007; Hamid et al, 2016; Howe et 
al, 2013; Owesson-White et al, 2008; Phillips et al, 2003; Robinson et al, 2002; Roitman 
et al, 2004; Saddoris et al, 2015a; Sombers et al, 2009; Stuber et al, 2005; Sugam et al, 
2012; Syed et al, 2016; Wassum et al, 2012; Wheeler et al, 2015; Wightman et al, 
2007); however, previous measurements were restricted to a single hemisphere, 
including those using a MRI-compatible dopamine reporter (Lee et al, 2014), and few 
microdialysis experiments measure bilaterally (Buck and Ferger, 2008). In this work, we 
measured spontaneous dopamine efflux with millisecond time resolution in both 
hemispheres simultaneously and found synchronicity in release. In agreement with 
previous reports (Wightman et al, 2007), synchronized dopamine concentrations 
exhibited variability on a sub-minute timescale (Fig 5.1d), but on average, transient 
concentrations over 30 min were comparable between hemispheres (Fig 5.1e). The 
apparent bilateral synchrony in NAc dopamine release shows that although transients 
are heterogeneous within subregions (Wightman et al, 2007), their occurrence is 
coupled between hemispheres.  
Interestingly, after AMPH, all dopamine efflux became synchronized between 
hemispheres. Since NAc dopamine transients originate from VTA cell firing 
(Cacciapaglia et al, 2011; Sombers et al, 2009), and AMPH-induced dopamine release 
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occurs in an action-potential dependent manner (Covey et al, 2016), coupled dopamine 
transients reflect synchronicity within the VTA that could arise from several 
mechanisms. During psychostimulant-induced excitation, VTA cells display slow 
rhythmic oscillations (Shi et al, 2004). Oscillations enable neurons to become more 
sensitive to precise timing of synaptic inputs and aid in synchronizing patterns of 
neuronal activity (Volgushev et al, 1998). Thus, AMPH may synchronize firing in the 
VTA between hemispheres, or synchronize contralaterally and ipsilaterally projecting 
neurons within a hemisphere. Synchronicity in dopamine transients may result from 
neurotensin release in the VTA. Intra-VTA neurotensin activates dopamine neurons and 
contributes to behavioral sensitization after psychostimulants (Panayi et al, 2005). The 
parabrachial nucleus is one source of neurotensinergic projections to the VTA (Geisler 
and Zahm, 2006) and projects bilaterally to midbrain dopamine neurons (Watabe-
Uchida et al, 2012).  
Regardless of mechanism, the synchronicity in dopamine release between 
hemispheres uncovered here establishes that chemical signaling, like physiological 
activity (Shen et al, 2015), is tightly coupled across the brain. Since amphetamine-
induced dopamine transients remain in unilaterally lesioned animals, it is apparent that 
interhemispherical connectivity contributes to psychostimulant induced dopamine 
fluctuations. Dopamine transients, demonstrated to be important in drug abuse (Covey 
et al, 2014), clearly arise from bilateral interactions. Furthermore, AMPH is used to treat 
attention deficit hyperactivity disorder (ADHD), and ADHD patients have abnormal 
frontostriatal asymmetry (Silk et al, 2015). The observed synchronicity in dopamine 
signaling after AMPH may contribute to its therapeutic effects in individuals with ADHD. 
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While further research is needed to establish the mechanisms that coordinate dopamine 
transient coupling, the present work establishes that dopamine fluctuations display 
synchrony between hemispheres.  
Contralateral projections may balance dopamine concentrations between 
hemispheres after dopamine depletion. However, when the SN was 6-OHDA lesioned, 
we found dopamine release from the contralateral, unlesioned SN was equivalent in 
lesioned and control animals. This was surprising, because these projections are 
thought to compensate for depletion via increased release (Nieoullon et al, 1977). 
Instead, we found enhanced D2 control over release in the lesioned hemisphere, 
supporting prior findings of increased D2 expression after dopamine depletion (Gerfen, 
2000).  
When we extended our measurements into awake animals, we found 
spontaneous transients in the DMS of sham-lesioned animals that were not present in 
the 6-OHDA group. However, dopamine transients were elicited in the lesioned 
hemisphere with amphetamine. Since D2 receptors exerted more control over 
contralateral dopamine release in lesioned animals, and AMPH attenuates D2 function 
(Calipari et al, 2014b), we believe this release arises from intact contralateral 
projections. With the perturbation introduced by amphetamine, contralateral projections 
may release dopamine into the depleted hemisphere. Indeed, dopamine cell firing 
between hemispheres normalizes after activation of dopamine receptors in 6-OHDA 
lesioned animals (Chen et al, 2001). Previous work in primates (Salvatore et al, 2009) 
and rats (Yang et al, 2007) has alluded to interhemispheric adaptations following 
130 
 
nigrostriatal damage. The data presented here establish a functional role for 
interhemispheric dopamine projections after unilateral 6-OHDA treatment.  
In summary, this work demonstrates the functional significance of 
interhemispheric communication in dopaminergic signaling. Activation of midbrain 
dopamine neurons evokes physiologically relevant dopamine release in the 
contralateral striatum of rats that synchronizes between hemispheres. D2 autoreceptors 
from contralateral VTA projections exert more control over NAc dopamine release 
relative to the ipsilateral projections, in contrast to DMS release via SN stimulation. 
Selective activation confirmed that dopaminergic neurons drive contralateral release. 
Furthermore, we found contralateral release was not solely compensatory because 
similar amounts of dopamine were evoked after contralateral SN stimulations in 6-
OHDA treated and control rats. These data are the first to demonstrate the functional 
nature of cross-hemispheric dopamine projections and provide new context for plasticity 
of striatal synapses after unilateral manipulation. Crossing projections likely facilitate the 
observed coupling of dopamine transients. Moreover, our findings provide additional 
insight for recently reported receptor alterations (Capper-Loup et al, 2013; Day et al, 
2006; Fieblinger et al, 2014; Gerfen, 2000; Thiele et al, 2014) as the lesioned 
hemisphere is not completely dopamine-deprived. Small concentrations released from 
contralateral projections, such as those reported here after amphetamine, likely 
influence receptor sensitivity in the lesioned hemisphere, and should be accounted for 
in future studies. The previously unappreciated cross-hemispheric functionality revealed 
here may also be useful in devising new therapies for treating dysregulated dopamine 
signaling.  
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Figure 5.1: Spontaneous dopamine transients synchronize bilaterally in the nucleus 
accumbens. (a) Schematic of electrode implantation for simultaneous dopamine 
transient measurements. (b) Representative dopamine release in the right and left NAc 
following stimulation (red bar) of the right VTA with voltammograms inset. (c) 
Representative color plots demonstrating synchronous dopamine transients in both 
hemispheres with applied potential on the ordinate, recording time on the abscissa, and 
current encoded in false color. (d) Changes in dopamine concentration (asterisks) in 
both hemispheres extracted from (c) using principle component analysis. Gray lines 
indicate synchronized transients; asterisks alone indicate asynchronous dopamine 
release. (e) Average ± SEM dopamine transient concentration in left (L) and right (R) 
NAc after saline (VEH, green) and 2.5 mg/kg amphetamine (AMPH, yellow) (f) Average 
± SEM number of dopamine transients per min in L and R NAc after VEH and AMPH. 
(g) Within-animal comparison of % transient synchrony after VEH and AMPH. N=3 
animals.
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Figure 5.2: Stimulation of dopamine neurons produces localized release in the 
contralateral striatum. Electrode trajectories are shown superimposed on coronal 
sections in (a) and (d). Dopamine release at the terminals was dependent on recording 
electrode depth with example traces shown in (b) and (e).  Insets are the cyclic 
voltammograms recorded at maximum release. Dopamine response (DAcon) following 
electrical stimulations of the contralateral VTA (c) or SN (f), normalized to maximum 
dopamine release (DAcon-max) and plotted as a function of working electrode depth. N= 
10 animals per group, average ± SEM.  
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Figure 5.3: Stimulation of contralateral dopamine neurons produces variable dopamine 
release in the striatum.  Coronal section showing stimulating electrode tracts in the VTA 
(a) and SN (c), and within-animal comparison of NAc and DMS effluxes, respectively, 
resulting from ipsilateral stimulation (DAips) compared with contralateral stimulation 
(DAcon) at identical depths. N= 10 animals per group, average ± SEM. Representative 
dopamine response in the contralateral NAc (b) and DMS (d) to optogenetic (blue) and 
electrical (red) stimulation of VTA or SN.   
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Figure 5.4: Stimulation of the peduncolopontine tegmental nucleus elicits release in the 
contralateral DMS. (a) Coronal section showing stimulating electrode tracts in the PPTg, 
and (b) within-animal comparison of DMS effluxes resulting from ipsilateral (DAips) 
compared to contralateral stimulation (DAcon) at identical depths. N=5 animals, average 
± SEM.  
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Figure 5.5: 
Mapping 
contralaterally 
evoked dopamine 
release in 
dorsolateral 
striatum. (a) 
Electrode 
trajectories are 
shown 
superimposed on 
the coronal 
section. (b) 
Dopamine 
response (DAcon) 
following electrical 
stimulations of the 
contralateral SN 
normalized to 
maximum 
dopamine release 
(DAcon-max) and 
plotted as a 
function of working 
electrode depth. 
N= 5 animals, 
average ± SEM. 
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Figure 5.6: 
Contralateral 
dopamine 
release is not a 
result of 
electrical spread 
between 
hemispheres. 
Schematics of 
carbon-fiber 
electrode in the 
(a) NAc, or (c) 
DMS, with 
cannulated 
stimulating 
electrode in the 
ipsilateral 
VTA/SN for 
delivery of 
lidocaine, and 
stimulating 
electrode in the 
contralateral 
VTA/SN. 
Dopamine 
release as a 
percent of 
baseline in (b) 
the NAc, or (d) 
DMS, resulting 
from 
contralateral and 
ipsilateral 
stimulations of 
VTA/SN. 
Lidocaine (350 
nmol/0.5µL) 
delivery is 
indicated by the 
arrow. N=4 
animals per 
group, average 
± SEM 
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Figure 5.7: Channelrhodopsin-2 expression in the contralateral striatum. (a) Low 
magnification images of ChR2-eYFP expression in the striatum after 
immunohistochemistry with GFP antibody. High magnification images ChR2-eYFP 
expression in (b) contralateral and (c) ipsilateral striatum as highlighted in (a). Scale bar 
=80  m. 
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Figure 5.8: Channelrhodopsin-2 expression is restricted to one hemisphere in the 
midbrain. (a) Low magnification images of ChR2-eYFP expression at the level of the 
SN/VTA after immunohistochemistry with GFP antibody. Higher magnification images 
ChR2-eYFP expression in (b) contralateral and (c) ipsilateral midbrain as highlighted in 
(a). Scale bar = 200µm. 
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Figure 5.9: Contralateral dopamine release is differentially regulated in the dorsomedial 
striatum and nucleus accumbens. (a-b) Representative contralateral dopamine efflux in 
the DMS (a) and NAc (b) after administration of D2 antagonist raclopride (RAC, 2 
mg/kg, i.p., gray line) and subsequent transporter blockade (GBR-12909, 15 mg/kg, i.p., 
blue line) compared to baseline (black). (c-d) Average increase in contralaterally 
(gray/blue bars) or ipsilaterally (white bars) evoked dopamine after raclopride and GBR-
12909 administration as a percent of baseline. N=6-8 animals per group. Data are 
average ± SEM with individual experiments overlaid. ANOVA with Bonferonni post-hoc, 
*, P<0.05.  
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Figure 5.10: Effect of stimulation frequency on contralateral dopamine release. 
Representative traces with inset cyclic voltammograms in the NAc of a single animal 
following 5-second, 10 Hz stimulation (a) and 1-second, 60 Hz stimulation (b) of the 
contralateral VTA. Red bars denote stimulation duration. 
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Figure 5.12: Tyrosine hydroxylase immunoreactivity is reduced in the SN after unilateral 
infusion with 6-OHDA. Hashed lines show tract of cannulated stimulating electrode for 
6-OHDA infusion 
  
Figure 5.11: Activation of the 
contralateral substantia nigra evokes 
dopamine release in 6-
hydroxydopamine lesioned rats. (a) 
Schematic of 6-OHDA delivery 
through a cannulated stimulating 
electrode, recording locations in the 
ipsilateral DMS, and contralateral 
stimulating electrode placement. (b) 
Rotational behavior in sham and 6-
OHDA lesioned rats treated with 
saline (VEH) followed by 2.5 mg/kg d-
amphetamine (AMPH). Repeated-
measures 2-way ANOVA with 
Bonferroni post-hoc. ***,P<0.001 (c) 
Representative dopamine in the DMS 
following stimulation of the 6-OHDA 
treated SN (purple) and contralateral 
(black) SN. Red bar denotes 
stimulation duration with cyclic 
voltammograms inset. (d)  Average ± 
SEM maximal dopamine 
concentrations evoked from 
stimulating 6-OHDA treated and 
contralateral SN in lesioned and 
sham rats. N=7 per group, ANOVA 
with Bonferroni post-hoc, 
***,P<0.001.  Representative 
dopamine transients (asterisks) in the 
DMS in awake sham-lesioned (e, 
black line), or 6-OHDA treated (f, 
purple line) rats following vehicle and 
amphetamine. Inset cyclic 
voltammograms correspond to the 
dopamine transient marked with a 
circle. 
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CHAPTER 6: CROSS-HEMISPHERIC NOREPINEPHRINE RELEASE IN THE VBNST 
ARISES FROM THE NUCLEUS OF THE SOLITARY TRACT 
 
Introduction 
Norepinephrine signaling is important in mediating a variety of processes 
including learning and memory, drug reward and withdrawal, and the behavioral and 
physiological responses to stress (Berridge and Waterhouse, 2003; Cecchi et al, 2002; 
Delfs et al, 2000; Forray et al, 2004; Olson et al, 2006). Dysregulation of noradrenergic 
signaling is implicated in disorders ranging from drug addiction (Koob, 2009) to 
Alzheimer’s disease (Weinshenker, 2008), and the ventral bed nucleus of the stria 
terminalis (vBNST) is a site of some of the densest noradrenergic innervation in the 
brain (Kilts et al, 1986). Limbic, forebrain, and brainstem inputs converge in the BNST to 
relay information about stressors and generate an appropriate physiological response 
through regulation of the hypothalamic-pituitary adrenal axis (Forray et al, 2004). The 
BNST receives noradrenergic input primarily from medullary neurons (A1/A2) coursing 
through the ventral noradrenergic bundle (VNB) and, to a lesser extent, from the 
neurons of the locus coeruleus (LC) through the dorsal noradrenergic bundle (DNB) 
(Forray et al, 2004; Robertson et al, 2013).  Norepinephrine is released in the vBNST 
during presentation of an aversive tastant, omission of an expected reward, and delivery 
of a noxious stimulus (Park et al, 2015; Park et al, 2013; Park et al, 2012). Furthermore, 
the vBNST is an important structure in the mediation of the aversive components of 
drug-
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withdrawal (Aston-Jones et al., 1999; Delfs et al., 2000) and norepinephrine signaling in 
the vBNST undergoes robust plasticity following stress or drug-withdrawal in a strain-
dependent manner (Fox et al, 2015; McElligott et al, 2013). Regulation of 
norepinephrine in the vBNST is an important topic of investigation, since it integrates 
information about aversive and stressful stimuli to generate an appropriate physiological 
response. 
Like all monoamine neurons, norepinephrine neurons are thought to project 
solely to one hemisphere (Andén NE, 1966). However, we recently uncovered an 
unexpected population of dopamine neurons that cross the midline to release dopamine 
in the contralateral striatum (Fox et al, 2016a). Although norepinephrine and dopamine 
traditionally signal in opposition of each other (Park et al, 2013; Park et al, 2012), we 
hypothesized that some norepinephrine neurons might also project bilaterally and 
contribute to norepinephrine release. We used fast-scan cyclic voltammetry combined 
with retrograde tracing to identify functional cross-hemispheric norepinephrine 
projections. In this work we found that noradrenergic axon pathways can release 
norepinephrine in the vBNST contralateral to their origin. While characterizing the origin 
of contralateral release, we serendipitously discovered that LC and DNB stimulations 
produce norepinephrine overflow indirectly. Instead, the direct bilateral projections to the 
vBNST originate in the nucleus of the solitary tract.   
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Materials and Methods 
Volammetric Norepinephrine Measurements 
Norepinephrine release was measured in anesthetized animals as described 
previously (Fox et al, 2015). For bilateral norepinephrine measurements, rats were 
anesthetized with urethane (1.5 g/kg) and placed in a stereotaxic frame. Holes were 
drilled for the BNST (AP 0mm, ML +1.2mm), the D/VNB ( AP -5.2mm, ML +1.2mm), and 
the LC(AP -9.8mm, ML +1.3mm)  referenced from bregma and based on the atlas of 
Paxinos and Watson. A Ag/AgCl reference electrode was placed in the left hemisphere 
and secured with a jeweler’s screw. A carbon-fiber microelectrode (~100 µm active 
length) was lowered into the BNST (7-7.5mm DV) and the stimulating electrode was 
lowered ipsilaterally to the carbon-fiber electrode to the dorsal (-6.5mm DV) or ventral (-
8.0mm DV) noradrenergic bundle or LC (-7mm DV) until maximal NE release was 
attained. Both stimulating and carbon-fiber electrodes were subsequently secured with 
dental cement. A second carbon-fiber microelectrode was lowered into the ipsilateral 
BNST (7-7.5mm DV) until maximal norepinephrine was achieved.  A total of 10 animals 
were used for these studies. 
 For mapping experiments and stimulation duration studies, first a carbon-fiber 
electrode was lowered into the vBNST until maximal release with ipsilateral VNB 
stimulations was attained. Next, the stimulating electrode was raised to the DNB to 
determine maximum ipsilatateral release. Then, the stimulating electrode was lowered 
through the contralateral hemisphere in 200 µm increments to map the effect of 
contralateral stimulating electrode placement in the vBNST. 60 Hz stimulations of 
varying duration (20-120 pulses) were delivered at depths corresponding to maximal 
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release from contralateral DNB and VNB stimulations and plotted vs. stimulation 
duration. We compared maximal norepinephrine evoked by ipsilateral and contralateral 
DNB and VNB stimulations at the same recording electrode location. A total of 6 
animals were used for these experiments.  
DSP-4 treatment  
Adolescent rats (150 – 200 g) were administered DSP-4 (N-(2-chloroethyl)-N-
ethyl-2-bromobenzylamine) in two doses (0.5 mL, 50 mg/kg, i.p.) provided 3 days apart  
(Fox et al, 2015). Voltammetric (n=5 DSP-4, n=5 control) and tissue content (n=6 DSP-
4, n=5 control) experiments were conducted 10 to 15 days after the last dose.    
Tissue Content Analysis  
A separate group of rats were anesthetized with urethane (1.5 mg/kg) and  
decapitated, and their brains were rapidly removed and placed on ice. Coronal sections 
(300 µm thick) containing the BNST or AV were collected with a VF-200 Compresstome 
(Precisionary Instruments Greenville, NC) in ice cold artificial cerebral spinal fluid 
(aCSF).  The aCSF contained (in mM) 126 NaCl, 25 NaHCO3, 2.45 KCl, 12 NaH2PO4, 
1.2 MgCl2, 2.4 CaCl2, 20 HEPES, and 11 glucose, and was adjusted to pH 7.4 and 
saturated with 95% O2 /5% CO2.  Tissue containing the vBNST or AV was excised 
bilaterally with a 1 mm punch, and collected into pre-weighed tubes. The samples were 
mixed with 200 µL of 0.1 N HClO4 containing 1 µM hydroquinone, the internal standard, 
and subsequently homogenized using a sonic dismembrator (Fisher Scientific, Model 
60, Pittsburgh, PA).  The homogenate was spun down at 6000 rpm for 10 minutes, and 
the supernatant was removed and filtered using a 0.2 µm syringe filter.  High 
performance liquid chromatography was performed using the methods of Mefford and 
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Lähdesmäki et al (Lahdesmaki et al, 2002; Mefford, 1981).  Briefly, 20 µL injections 
were made onto a revered-phase column (5 µm, 4.6 x 5 mm, Waters Atlantis, Milford, 
MA, USA).  The mobile phase consisted of 0.1 M citric acid, 1 mM sodium hexylsulfate, 
0.1 mM EDTA (pH = 3), and 10% methanol organic modifier at a flow rate of  1.0 
mL/min.  Norepinephrine and dopamine were detected with a thin layer radial 
electrochemical cell (BASi, West Lafayette, IN, USA) at a potential of +800 mV vs 
Ag/AgCl.  Data were collected at 60 Hz using a LabVIEW stripchart recorder program 
(Jorgenson Lab, UNC) and custom-made electronics.  Concentration was determined 
by a ratio of analyte peak area to internal standard peak area, and normalized to wet 
tissue weight.    
6-hydroxydopamine lesions 
 Rats underwent stereotaxic surgery under isofluorane anesthesia, and an 
incision was made in the scalp to drill bilateral holes targeting the LC (AP -9.8mm, 
ML±1.4). An infusion cannula (Plastics One) was lowered to a depth of 7.0mm from 
brain surface, and 1µL of 10 mM 6-hydroxydopamine hydrobromide (6-OHDA)/ 0.01% 
w/v ascorbic acid (Sigma-Aldrich) in sterile saline (0.9%), or saline (sham-lesioned) was 
infused into each hemisphere with an infusion needle (33 ga, 10 mm, Plastics One) over 
5 min. The scalp was closed with Vet Bond (3M) and rats were allowed to recover for 2 
weeks before being anesthetized with urethane for voltammetric norepinephrine 
measurements.  
Knife-cut experiments 
 Rat were anesthetized with urethane (1.5 g/kg) and affixed in a stereotaxic 
frame. Holes were drilled for the vBNST, VNB, and LC as described above. Once 
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maximal release was attained with VNB stimulations, the stimulating electrode was 
moved to the LC and adjusted for maximal release. The stimulating electrode was 
subsequently removed, and a surgical blade was lowered 0.2mm past the depth of 
maximal LC release. The stimulating electrode was repositioned in the LC, and 
norepinephrine release was measured after subsequent LC stimulations. A total of 5 
animals were used for these experiments.   
FluoroGold Tracing 
Rats underwent stereotaxic surgery under isoflurane anesthesia (4% induction, 
1.5% maintenance).  A small incision was made in the scalp and a hole was drilled in 
the skull to target the BNST (AP 0.0mm, ML 1.2mm) and a 2 µL Hamilton syringe was 
lowered to a depth of 7.2 mm from brain surface. 200 nL of FluoroGold (4% w/v in 0.9% 
saline, Fluorochrome, Denver, CO) in was infused slowly over 5min using a 
microinjection unit (Model 500, Kopf, Tujunga, CA). The syringe was left in place for an 
additional 5 min to minimize spread up the tract. The scalp was closed with vet bond 
(3M, St Paul, MN) and rats were allowed to recover for 2 weeks. Rats were then 
anesthetized with urethane (1.5 g/kg) and transcardially perfused with 0.1M phosphate 
buffered saline (PBS, pH 7.4), followed by 4% paraformaldehyde dissolved in PBS. 
Brains were subsequently removed and post-fixed for >24 hr in 4% paraformaldehyde. 
The fixed tissue was cryoprotected for >24 hr in 30% sucrose before 30 µm sections 
were collected in PBS using a freezing microtome (Leica, Germany).  
Free-floating sections were incubated in 1%NaBH4/0.1M PBS for 15 min to 
quench endogenous fluorescence, and then rinsed in PBS 3x 15 min. Sections were 
blocked in 10% Normal Goat Serum (NGS)/ 0.3% Triton x-100 for 2 hr at RT. After 
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blocking, sections were incubated in 1:1000 Rabbit-anti-FluoroGold (Fluorochrome) in 
3% NGS 0.1%Triton x-100 overnight at 4ºC. Sections were washed in PBS before being 
incubated for 2 hr in 1:500 Goat anti Rabbit-FITC in 2% bovine serum albumin/0.1M 
PBS at RT. Sections were rinsed 3x in PBS, then mounted, dried, and coverslipped with 
fluoromount (Sigma Aldrich) for imaging on an Olympus FV1000 confocal microscope.  
Ibotenic Acid Infusion 
Electrical stimulation of the DNB was repeated every 3 min over a 1 h period to 
establish a baseline for norepinephrine release. Thereafter the stimulating electrode 
was removed and the tip of a 2 µL Hamilton syringe containing sterile saline was 
positioned 500 µm dorsal to the original stimulation depth. The saline was infused 
manually with a microinjection unit (Model 500, Kopf, Tujunga, CA, USA) over a 20 min 
period and the syringe was removed for reinsertion of the stimulating electrode. 
Stimulations commenced for another 1 h period before the infusion procedure was 
repeated with 2 µL ibotenic acid (130 mM in 2% Chicago Sky Blue prepared in sterile 
saline, Abcam, Cambridge, MA, USA). The last 15 min of data collected for baseline, 
post-saline and post-IBA were used in analysis 
Results 
Stimulation of noradrenergic axons elicits release in the contralateral vBNST 
To determine if norepinephrine in the vBNST could be elicited by contralateral 
stimulations, we lowered carbon-fiber electrodes bilaterally into the vBNST and a 
stimulating electrode into the VNB (Schematic in Fig 6.1A). Unilateral VNB stimulation 
produced norepinephrine release at both electrodes (Examples in Fig 6.1B).  We next 
mapped contralateral release by holding a carbon-fiber at a fixed depth in the vBNST (-
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7.2mm DV), and lowered the stimulating electrode ventrally in 200 µm increments 
through the contralateral hemisphere. Contralateral norepinephrine release was seen 
over a large dorsal-ventral range, but it peaked at locations corresponding to the DNB 
(6.4 mm DV) and VNB (8.0 mm DV Fig 6.1C). Norepinephrine release evoked by DNB 
and VNB stimulation was linear with increasing stimulation duration (DNB slope= 0.146 
± 0.007 r2=0.97; VNB slope=0.170 ± 0.005, r2=0.98; Fig 6.1D).  On average, maximal 
norepinephrine release in the vBNST was of similar magnitude following stimulations of 
the contralateral DNB or VNB (DNB: 0.214 ± 0.066 µM; VNB: 0.192 ± 0.038 µM, n=10, 
respectively), and ipsilateral DNB and VNB (DNB: 0.228 ± 0.063µM; VNB: 0.191 ± 
0.029 µM, n=10, respectively). In a subset of animals, we performed within-animal 
comparisons of ipsilateral vs contralateral release by lowering the stimulating electrode 
ventrally through the ipsilateral, then contralateral hemisphere. The ratio of ipsilateral to 
contralateral release was equal between hemispheres, regardless of DNB/VNB 
stimulation (Ipsi/Contra, VNB: 1.3± 0.20; DNB:1.0 ±0.08, n=6 animals, P>0.05, Fig 
6.1E).   
DSP-4 treatment does not attenuate vBNST norepinephrine release  
The DNB mainly contains axons originating from the LC, and the vBNST receives 
very little coerulean innervation. Since both DNB and VNB stimulations produced 
surprisingly similar release amplitudes, we next placed our stimulating electrode in the 
LC to ascertain its influence over contralateral release. Stimulations of the contralateral 
and ipsilateral LC produced norepinephrine release to an equal extent (Ipsi: 0.163 ± 
0.082 µM; Contra 0.250 ± 0.115µM, n=5, P>0.05). To examine the possibility that 
release was due to off-target effects we employed the selective neurotoxin DSP-4 to 
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lesion norepinephrine from the LC. Tissue content analysis revealed the treatment 
effectively eliminated some LC innervation, as concentrations were reduced in the 
anteroventral thalamus (AV), a brain region receiving exclusively coerulean input (Table 
6.1). Control values for the vBNST and the AV are similar to those previously reported 
from our lab (McElligott et al, 2013; Park et al, 2009) and others (Kilts et al, 1986; Oke 
et al, 1983). DSP-4 treatment significantly reduced norepinephrine and dopamine in the 
AV (unpaired student’s t-test, NE: t(9)=3.579, P=0.006; DA: t(9)=2.586, P=0.029), but 
did not exhibit an effect on the catecholamine content of the vBNST (NE: t(9)=0.959, 
P=0.363; DA: t(9)=0.371, P=0.719).   
DSP-4 treatment did not affect release with VNB stimulations, in agreement with 
our previous work (Fox et al, 2015) and tissue content analysis (Control vs. DSP-4, 
0.281± 0.046 vs 0.408 ±0 .104 µM, n=5 animals, respectively, Fig 6.2A). Surprisingly, 
DSP-4 treatment did not reduce norepinephrine evoked by DNB or LC stimulations 
(Control vs. DSP-4, DNB: 0.288 ± 0.046 vs 0.386±-0.154; LC 0.163 ± 0.032, 0.237± 
0.073 µM, n=5 animals, respectively, P>0.05 Fig 6.2A).  
Physical, but not 6-OHDA LC lesions attenuate vBNST norepinephrine release 
Since DSP-4 does not lesion the LC with 100% efficacy (Bortel, 2014), and its 
actions on the LC noradrenergic system have been called into question (Szot et al, 
2010) we next used bilateral 6-hydroxydopamine (6-OHDA) lesions targeted to the LC 
to corroborate the DSP-4 findings. 2-weeks after 6-OHDA treatment, we anesthetized 
animals and recorded norepinephrine evoked from electrical stimulations. Similar to 
DSP-4 treatment, 6-OHDA lesions of the LC had no measurable effect on vBNST 
norepinephrine release (Sham vs 6-OHDA; DNB: 0.364 ± 0.092 vs 0.342 ± 0.054 µM; 
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VNB: 0.339 ± 0.065 vs 0.457± 0.072 µM; LC 0.213 ± 0.082 vs 0.278± 0.060 µM, n=5 
animals, respectively, P>0.05 Fig 6.2B). Given that chemical ablations did not reduce 
norepinephrine release, we turned to a physical disconnection approach by performing 
a knife-cut at the level of the LC. Cutting the LC reduced LC-evoked norepinephrine 
release in the vBNST to ~10% of its original value (9.0 ±6.1%, n=5 animals). 
 A2, but not LC neurons project bilaterally to the vBNST 
Since a physical, but not chemical lesion of the LC reduced norepinephrine 
overflow, we asked if the LC was sending projections to the vBNST that might be 
spared by the chemical treatments. We unilaterally injected fluorogold into the vBNST, 
and looked for retrograde labeling in the LC and the nucleus of the solitary tract (A2) 
(schematic in Fig 6.3A, representative injection site Fig 6.3B). Even after signal 
amplification with an antibody against fluorogold, we did not find any retrogradely 
labeled cells in the LC (Fig 6.3C,D). Instead, we found bilateral fluorogold labeling in the 
A2 (Fig 6.3E-G). The number of labeled cells ipsilateral to the tracer infusion was 
greater than those in the contralateral hemisphere (27± 1.7 vs 5.3±1.2 cells, n=3 
animals).  
DNB stimulations produce vBNST norepinephrine indirectly 
The LC sends most of its forebrain projections through the DNB (Nakazato, 
1987; Ungerstedt, 1971). Since the LC was not labeled with fluorogold, we 
hypothesized that DNB stimulations produced norepinephrine release through an 
indirect mechanism. To test the possibility that another midbrain structure was 
mediating norepinephrine release, we delivered ibotenic acid (IBA) through a 
cannulated stimulating electrode targeted to the DNB (Schematic in Fig 6.4A). IBA is an 
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excitotoxic agent that causes cell loss within an area closely confined to the locus of its 
injection, but does not target afferent terminals or fibers of passage (Jarrard, 1989).  IBA 
infusions reduced vBNST norepinephrine release elicited by DNB stimulations 
compared with saline infusions (Saline: 77.9 ± 3.3% vs. IBA: 20.3 ±3.8 %, n=5 
respectively, 2-way RM ANOVA: Drug x region interaction F(2,16)=16.52, Effect of 
region F(2,16) =21.47, Effect of drug F(2,16) =46.67, Fig 6.4 B,C). IBA treatment did not 
reduce evoked norepinephrine in the AV, consistent with the lack of effect this toxin has 
on axons of passage (Saline:  68.0± 4.3% vs IBA: 70.8± 10.4%, n=5 animals, Fig 6.4 
B,C). Post hoc analysis revealed significant attenuation of vBNST, but not AV release 
compared with saline (Bonferroni, Saline vs IBA p<0.001). Thus, DNB evoked NE in the 
vBNST, but not AV, arose from an indirect mechanism 
Discussion 
In this study, we found norepinephrine release was elicited in the vBNST 
contralateral to the electrical stimulation location. Stimulations of the DNB, VNB, and LC 
evoked norepinephrine of equal magnitude in both hemispheres. Norepinephrine 
evoked from LC stimulations occurred via nonspecific activation, as only physical, but 
not selective chemical lesions of the LC attenuated release.  DNB stimulations also 
elicited norepinephrine in a non-specific way, since inactivation of cells proximal to the 
DNB reduced evoked vBNST norepinephrine.  Furthermore, fluorogold tracing revealed 
the A2, but not LC, sends bilateral projections to the vBNST. Taken together, these data 
show that although norepinephrine is released in both hemispheres with unilateral 
activation, only the projections from the A2 are directly responsible for cross-
hemispheric release in the vBNST.  
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Anatomical studies describe noradrenergic neurons as projecting primarily 
unilaterally (Andén NE, 1966; Ungerstedt, 1971). Recent reports have uncovered that a 
small percentage of dopamine neurons project contralateral to their origin (Geisler et al, 
2005; Jaeger et al, 1983) and support dopamine release in the striatum (Fox et al, 
2016a), however no studies have described cross-hemispheric noradrenergic 
projections originating in the A2. In this work we found norepinephrine was released in 
both hemispheres after VNB stimulations, supported by bilateral retrograde labeling in 
the A2. Surprisingly, release elicited by VNB stimulations was equivalent between 
hemispheres, despite the smaller number of projections originating in the contralateral 
A2. This equivalent release could arise from a number of mechanisms. First, 
norepinephrine concentrations are tightly regulated and require much longer stimulation 
trains compared with dopamine (Miles et al, 2002; Park et al, 2011). Since 
norepinephrine concentrations released from contralateral projections were linear with 
respect to stimulation duration, similar to ipsilaterally evoked concentrations (McElligott 
et al, 2013), this might indicate that norepinephrine release is “capped” from ipsilateral 
projections.  Although there are more ipsilateral than contralateral projections, 
regulation mechanisms may attenuate the amount of norepinephrine released from 
ipsilateral projections to create hemispherically equivalent release. Alternatively, 
norepinephrine neurons may co-release glutamate, which was recently demonstrated to 
occur from some dopamine terminals (Zhang et al, 2015).  Co-release of other 
neurotransmitters may depolarize norepinephrine terminals in the vBNST and partially 
explain the apparent hemispheric equivalence. Regardless, these data reveal that 
norepinephrine in the vBNST is similar to dopamine release in the dorsomedial striatum 
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(Fox et al, 2016a) in that it is of equivalent magnitude with ipsilateral or contralateral 
stimulations.  
The vBNST is thought to receive a small input from the LC (Forray et al, 2004; 
Robertson et al, 2013), and in a previous study, we characterized norepinephrine 
overflow with LC stimulations (Park et al, 2009). In this work, we found that stimulation 
of the LC and its projections through the DNB produced equivalent norepinephrine 
release in both hemispheres. However, this release arises from a non-coeruelan 
mechanism since selective chemical lesions of the LC did not attenuate norepinephrine 
release, and fluorogold was not retrogradely transported from the vBNST to the LC. In 
our initial characterization of LC-evoked norepinephrine, release was suppressed after 
delivery of lidocaine to the stimulation site (Park et al, 2009). Similar to lidocaine, we 
found a knife-cut of the LC drastically attenuated norepinephrine overflow in the BNST. 
This finding brings up two important points. First, selective chemical inactivation with 
DSP-4 and 6-OHDA strongly suggest that noradrenergic neurons of the LC are not 
responsible for release in the vBNST. However, both lidocaine and knife-cut would 
prevent the propogation of action potentials traveling down axons near the LC. It is 
therefore possible that projections from medullary noradrenergic neurons close to the 
LC are responsible for this release. Indeed, an anterograde tracing study revealed A2  
neurons innervate regions proximal to the LC (Geerling and Loewy, 2006). Second, the 
A2 projects to the nucleus paragigantocellularis (PGi) (Reyes and Van Bockstaele, 
2006), which in turn, sends projections to the LC (Ennis and Aston-Jones, 1988). 
Therefore, stimulating the LC may antidromically activate the PGi and subsequently the 
A2 to produce norepinephrine release. Cross-talk between noradrenergic cell groups is 
157 
 
supported by work demonstrating both coerulean and medullary norepinephrine 
contribute to opiate withdrawal syndrome (Delfs et al, 2000; Maldonado, 1997), and 
coerulean lesions produce adaptations in norepinephrine signaling originating from the 
A2 (Fox et al, 2015). Regardless of mechanism, the selective chemical lesions reveal 
that although the LC can produce release in both ipsilateral and contralateral vBNST, it 
does so indirectly.     
Stimulations of the DNB also produced release in the ipsilateral and contralateral 
vBNST, and when we infused IBA into the DNB we found blunted release in the vBNST. 
IBA is a glutamate analog that, through excitotoxicity, selectively inactivates cell bodies 
while leaving fibers of passage intact (Jarrard, 1989). Therefore its neurotoxicity is not 
expected to impact the axons of the DNB. In agreement with this, norepinephrine was 
not significantly altered in the AV, supporting that norepinephrine release in this region 
is mediated by direct activation of the DNB. However release was markedly attenuated 
in the vBNST after IBA treatment, suggesting other midbrain nuclei are mediating 
release. At the coordinates used in this study, the DNB courses by several structures 
including the periaqueductal gray (PAG). Fluorogold infusions into the ventrolateral 
portion of the PAG bilaterally labels neurons in the A2 region (Chang et al, 2012b). 
Thus, one possible explanation for contralateral norepinephrine release produced by 
DNB stimulations may be through a PAG mechanism. PAG stimulation may 
antidromically activate the A2 group to elicit vBNST release in both hemispheres and 
future efforts should address this possibility. Regardless, the results of the chemical 
lesions of both DNB and LC suggest that DNB-evoked norepinephrine release arises 
via an indirect mechanism.   
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 Unilateral  manipulation of catecholaminergic  neurons is often used to model 
neurodegenerative conditions such as Parkinson’s disease (Zigmond et al, 1990).  
Additionally, unilateral knife-cut of the DNB was used in a recent report to rule out 
contributions of  LC norepinephrine to measured catecholamine release in the medial 
prefrontal cortex (Shnitko et al, 2014b).  The cross-hemispheric projections found from 
the A2 call into question the nature of LC projections. Indeed, LC neurons project 
bilaterally to some regions (Simpson et al, 1997) and may release physiologically 
relevant concentrations in the contralateral hemisphere. It is clear from these findings 
that care must be taken when performing unilateral disconnection studies, since the 
unilateral monoamine projections originally described by Ungerstedt (Andén NE, 1966; 
Ungerstedt, 1971) are now being called into question.  
In summary, this work demonstrates that stimulation of noradrenergic pathways 
elicits release in the contralateral vBNST. These projections arise from the A2, and 
stimulations of the VNB produce hemispherically equivalent release. While projections 
from the LC also elicit norepinephrine release in the vBNST, they do so indirectly. This 
previously undescribed property or norepinephrine neurons should be taken into 
account when performing unilateral manipulations.  
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Figure 6.1. Stimulation of noradrenergic axon bundles produces hemispherically 
equivalent norepinephrine release in the vBNST. (A) Schematic of dual carbon-fiber 
electrodes in the vBNST with unilateral stimulating electrode in the VNB. (B) 
Representative color plots demonstrating norepinephrine release to a 1 s electrical 
stimulation (red bar) of the VNB, recording ipsilateral (Ipsi) and contralateral (Contra) to 
the stimulation. Applied potential is plotted on the absiscca, recording time on the 
ordinate, and current is encoded in false color. (C) Effect of stimulation electrode 
placement on contralateral norepinephrine release. Data are plotted as norepinephrine 
release [NE]con over maximal norepinephrine release [NE]con-max as elicited by 
contralateral stimulations and are presented as average±SEM. (D) Effect of stimulation 
duration on norepinephrine release evoked by contralateral DNB and VNB. 
Average±SEM (E) Within-animal comparison of norepinephrine release in the vBNST as 
elicited by ipsilateral and contralateral DNB and VNB stimulations. Average±SEM with 
individual experiments overlaid.   
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Figure 6.2: Chemical lesions of the LC do not impact vBNST norepinephrine release. 
(A) Maximal norepinephrine concentrations elicited by DNB, VNB, and LC stimulations 
in control (white, 5 animals) and DSP-4 treated rats (black, 5 animals). (B) Maximal 
norepinephrine concentrations elicited by DNB, VNB, and LC stimulations in sham 
(white, 5 animals), and 6-OHDA lesioned rats (black, 5 animals). Average±SEM with 
individual experiments overlaid. 
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Figure 6.3: Unilateral fluorogold tracing in the vBNST. (A-B) Schematic and 
representative infusion site of FG into the vBNST. (C-D) Apparent lack of FG-positive 
cells in the LC and atlas section corresponding to the photomicrograph. (E-F) FG-
positive cells in the A2 and atlas section corresponding to the photomicrograph. (G) 
Higher magnification image of FG-positive cells in the A2. Scale bars are 200µm. 
Abbreviations: vBNST, ventral bed nucleus of the stria terminalis; LC, locus coeruleus, 
cc, central canal; 4V, fourth ventricle. 
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Figure 6.4. Ibotenic acid infusions in the DNB attenuate norepinephrine release in the 
vBNST, but not AV. (A) Schematic of recording locations and infusion of IBA  in the 
DNB. (B) Effect of saline (white) and IBA (black) infusions on norepinephrine release in 
the vBNST and AV as a percent of baseline release (hashed line).***, P<0.01, 2-way 
RM ANOVA with Bonferroni post-hoc (C) Representative evoked norepinephrine in the 
vBNST and AV after saline and IBA infusions. Red bar denotes electrical stimulation.  
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Table 6.1. Catecholamine tissue content in target regions for untreated and DSP-4-
treated animals. Values are shown as mean ± SEM. *P < 0.05, **P < 0.01, compared to 
untreated values. Abbreviations: NE, norepinephrine; DA, dopamine. 
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CHAPTER 7: CONCLUSION 
 
Adaptations in in vivo norepinephrine regulation 
 The goal of this work was to measure functional adaptations to norepinephrine 
signaling in vivo.  Prior studies established that FSCV could be used to measure 
norepinephrine overflow and regulation in intact animals (Herr et al, 2012; Park et al, 
2009). With the careful pharmacological and histological verification described in 
Chapter 1, we were able to selectively monitor norepinephrine in the vBNST. Since 
noradrenergic signaling plays a key role in stress and aversion, and vBNST 
norepinephrine can activate the HPA axis (Forray et al, 2004), we first used animal 
models with divergent HPA axis function to examine how noradrenergic signaling may 
differ with varying stress-susceptibility. The results of these experiments are described 
in Chapters 2 and 3 (Fox et al, 2015; McElligott et al, 2013). In this work, we found a 
correlation between anxiety-like behavior and norepinephrine signaling in the vBNST. In 
the inbred Lewis rat, a model of PTSD, we found increased norepinephrine tissue 
content, a slow rate of norepinephrine clearance, and blunted α2 receptor control over 
norepinephrine release. In the inbred Wistar-Kyoto (WKY) rat, a model of depression, 
we found norepinephrine regulation mechanisms similar to those of the outbred 
Sprague-Dawley (SD) rat, with correspondingly low levels of anxiety-like behavior. 
When we subjected each rat strain to a host of stressors, adaptations in noradrenergic 
signaling varied dependent on HPA axis function. For example, morphine-dependent 
SD rats exhibited reduced α2 function, slowed norepinephrine clearance, and increased 
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anxiety-like behavior. In contrast, morphine-dependent Lewis rats did not become more 
anxious, nor were vBNST norepinephrine control mechanisms altered as compared with 
baseline.  WKY rats exhibited an intermediate phenotype with decreased α2 function 
and increased anxiety without an accompanying change in norepinephrine clearance 
rate. Following the stress of social-isolation, noradrenergic synaptic function in SD rats 
was similar to that of morphine-dependent SD, whereas WKY rats were unaffected by 
social isolation. Additionally, depletion of LC norepinephrine produced an 
anxious/morphine-dependent profile in SD rats without changing the behavior or 
noradrenergic regulation mechanisms in WKY rats. The findings detailed in Chapters 2 
and 3 demonstrate that noradrenergic signaling can undergo robust plasticity in 
response to different manipulations. The response of the noradrenergic system to stress 
and drug-exposure is dependent on genetic factors and correlated with anxiety-like 
behavior.  Furthermore, they suggest that genetic factors may interact with stress to 
predispose individuals to drug-addiction, since after stress, noradrenergic synaptic 
function resembles a drug-dependent phenotype.    
Real-time catecholamine overflow during drug-intoxication and withdrawal 
 Since vBNST norepinephrine regulation underwent robust plasticity after 
morphine-dependence, we measured neurochemical signaling in awake animals during 
a single-drug exposure and withdrawal episode to elucidate the mechanism.  We 
compared norepinephrine in the vBNST with dopamine in the NAc after morphine 
exposure and naloxone-precipitated withdrawal. The results of these experiments are 
described in Chapter 4. In the NAc, we found increased dopamine transients during 
drug exposure, in contrast to a lack of norepinephrine overflow in the vBNST. When the 
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animals underwent naloxone precipitated withdrawal, dopamine transients decreased in 
frequency and magnitude in the NAc, and we measured broad norepinephrine release 
events in the vBNST that occurred with somatic withdrawal behaviors. Norepinephrine 
and withdrawal behaviors were elicited in the absence of morphine by administering an 
α2 antagonist with naloxone. Remarkably, at the end of the treatment, norepinephrine 
concentrations were depleted in the vBNST, in agreement with the reduced 
norepinephrine tissue content in Chapter 2. This was in stark contrast to unchanged 
NAc dopamine after the treatment. These findings provide a real-time picture of how 
noradrenergic synaptic function becomes dysregulated in morphine dependent animals. 
During withdrawal, norepinephrine is released in the vBNST where it can bind α2 
receptors. The continued occupation of α2 receptors by norepinephrine can result in α2 
desensitization, which we describe in Chapters 2 and 3. This disruption in control over 
norepinephrine release by α2 autoreceptors likely facilitates the development of anxiety 
and the negative affect via exacerbated norepinephrine signaling. Additionally, 
dopamine concentrations decreased in the NAc during withdrawal. In the allostasis 
model, the transition to drug abuse is characterized by both deficits in dopaminergic 
signaling and enhanced noradrenergic signaling (Koob et al, 2010). How the opposing 
responses of these catecholamines develop longitudinally should be a topic of future 
investigation.  
Unexpected cross-hemispheric catecholamine projections 
 In characterizing aspects of catecholamine release and regulation, we 
serendipitously discovered an unexpected property of catecholamine neurons which is 
described in Chapters 5 and 6. Traditionally, catecholamine neurons were thought to 
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project solely unilateral to their origin (Andén NE, 1966). We found that stimulations of 
the VTA and SN elicited dopamine in the contralateral dorsal and ventral striatum. 
Transient dopamine concentrations were synchronized between hemispheres in the 
NAc, and D2 regulation of dopamine release was different between contralateral and 
VTA projections. Furthermore, in a hemiparkinsonian model, intact contralateral 
projections from the SN could be stimulated with amphetamine to restore dopamine 
transients in an otherwise depleted dorsomedial striatum. Similar to our findings with 
dopamine, stimulations of noradrenergic cell groups and their afferent projections also 
elicited release in the contralateral vBNST. Subsequent characterization revealed only 
those arising from the A2 group produced release directly. These findings highlight the 
importance of combining functional measurements with anatomical tracing. Our 
measurements provide new insight regarding the function of catecholamine neurons.  In 
the case of dopamine neurons, both nigrostriatal and mesolimbic groups directly 
produced contralateral release; in contrast, only norepinephrine neurons from the A2 
were directly responsible for cross-hemispheric norepinephrine in the vBNST.  
Future Directions 
 Over the last four decades, voltammetry has been used to characterize release 
and uptake of catecholamines. The technology has sufficiently advanced to allow for 
measurements in awake and behaving animals, and numerous works have focused on 
dopamine fluctuations during a variety of tasks. Yet it is only within the last ten years 
that FSCV has been used for norepinephrine measurements in awake animals. 
Although dopamine and norepinephrine appear to signal in opposition of each other, it is 
too soon to make sweeping generalizations about the function of dopamine vs. 
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norepinephrine in shaping action selection and behavior. For convenience we tend to 
think about patterns of signaling that arise after an animal is well trained. Dopamine is 
released during presentation of reward-predicting cues; norepinephrine is released 
during omission of a reward. Dopamine increases during a positive stimulus; 
norepinephrine increases during a negative stimulus. However, it is important to note 
that even within a rewarding-seeking paradigm there are aspects that might be aversive 
to rodents. Although an audiovisual cue may eventually predict reward and elicit 
dopamine, presentation of a noise and a light may initially be aversive to an animal. 
How does catecholamine signaling change during learning about rewards? How does it 
change while learning about avoiding negative stimuli? Are these patterns maintained in 
other catecholamine containing regions such as the prefrontal cortex? How do they 
change in individuals with Parkinson’s or Alzheimer’s disease?   Furthermore, the last 
several decades of work has focused on signaling in outbred rats, despite evidence that 
signaling exhibits incredible variability in diverse genetic models. Dopamine transients 
are heterogeneous in outbred SD rats (Wightman et al, 2007), however this may not 
hold true in other strains.  Additionally, most measurements have been restricted to 
male animals, even though sex plays a role in the development of drug addiction 
(Becker and Koob, 2016). Great strides have been made in understanding the dynamic 
processes controlling release and uptake of catecholamines, but there are many 
unresolved questions with respect to their function in shaping behavior.   
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